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University of Connecticut, 2018 
In the last few decades, the pharmaceutical industry has employed a quality by design (QbD) 
approach for conventional drug product development to minimize errors in product optimization 
and validation. Lately, this has been extended to novel pharmaceutical drug products (such as 
nanocrystalline and nanoamorphous drug products). The present research emphasizes the design 
and development of stable nanocrystalline and nanoamorphous formulations of BCS class II and 
II/IV drugs via a comprehensive QbD approach.  This approach was used to identify, optimize, 
validate and control different critical process parameters and critical formulation parameters of 
solid nano-formulations. The objectives of this research were to: (1) investigate any correlation 
between critical process parameters and critical formulation parameters as well as critical quality 
attributes using a comprehensive QbD approach; (2) investigate the effect of temperature and 
relative humidity during accelerated and/or long term stability studies; and (3) investigate drug-
stabilizer interaction mechanisms.  
Based on proof-of-concept studies, BCS class II and II/IV drugs with different physicochemical 
properties were utilized for the successful development of stable and robust nanocrystalline and 
nanoamorphous formulations. Different top-down and bottom-up manufacturing techniques: wet 
media milling (nanocrystalline formulations); and sonoprecipitation (nanoamorphous 
formulations) followed by spray drying were used to prepare the solid nanoformulations. Based 
on the pre-formulation studies, drug-stabilizer interaction mechanisms were investigated via 
different solid-state tools (DSC, FTIR and PXRD). The DSC data was used to determine whether 
drug-stabilizer interactions occurred and the type of interaction was investigated using FTIR.  
PXRD was used to detect the solid-state form and any polymorphic transition in the drug-stabilizer 
complexes. Low and intermediate molecular weight polymers, high glass transition (Tg) sugars 
and anionic surfactants were determined to be the strong stabilizers during processing and storage 
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stability of the solid nanoformulations. A quality by design approach was used to establish a 
correlation between critical process parameters, critical formulation parameters and critical quality 
attributes for the development of the robust solid nanoformulations. Critical process parameters 
related to manufacturing techniques: wet media milling (milling speed, milling time, pump speed); 
sonoprecipitation (ultra-sonication speed, time); and spray drying (inlet temperature, aspirator rate, 
feed flow rate) were investigated. Critical formulation parameters: drug and stabilizer 
concentrations were investigated. The process speed, time, inlet temperature, flow rates, drug 
concentrations and stabilizer concentration significantly affected the particle size and total product 
yield of the solid nanoformulations. Following the DoE studies, validation was performed to 
ensure reproducibility and robustness of different CQAs (particle size, total product yield, drug 
loading, moisture content and zeta potential) of solid nanoformulations prepared using the 
optimized and predicted process and formulation parameters. Stability studies were performed at 
three different conditions: 4C, 25C/60% RH and 40C/75% RH for different time-points (1, 3, 
6 and 12 month/s) to investigate the effect of temperature and relative humidity on the 
nanoamorphous and nanocrystalline formulations. Stability studies revealed the following trend: 
4C (most stable) > 25C/60% RH > 40C/75% RH (least stable) for the optimized spray-dried 
nanocrystalline and nanoamorphous formulations in terms of physicochemical attributes, 
crystallinity and in vitro dissolution testing. An array of orthogonal solid-state tools (DSC, ATR-
FTIR, PLM, PXRD and AFM) were utilized to characterize the solid-state form (crystalline, 
amorphous, semi-crystalline and semi-amorphous) and polymorphic transitions in the freshly 
prepared solid nanoformulations and those stored at different stability conditions. Particle size 
distribution and moisture content analysis were performed via Zetasizer (ZS90) and Karl fisher 
titration, respectively. RP-HPLC was used to detect drug loading in the solid nanoformulations. 
The solid nano-formulations prepared via the comprehensive QbD approach resulted in a 
remarkably high total product yield (~70-80% w/w) with small, uniform and homogenous particle 
size (200-300 nm, 0.05-0.2 PDI). In vitro dissolution testing were performed to investigate the 
effect of pH, solid-state form, particle size, temperature and relative humidity on drug release from 
the solid nano-formulations. USP apparatus I and II were utilized to study and differentiate the 
drug release from the nanoamorphous and nanocrystalline formulations based on their solid-state 
form and particle size. Drug release from the solid nanoformulations followed a particle size 
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dependent dissolution trend. Nanoamorphous and nanocrystalline formulations showed a high 
dissolution rate/kinetic solubility compared to the macro-sized formulations.  
To sum up, the comprehensive QbD approach performed in the present research delineates an 
important and time-saving strategy to develop successful, robust and stable solid nanoamorphous 
and nanocrystalline formulations with the desired physicochemical attributes/CQAs, solid-state 
form and in vitro and/or in vivo performance.  
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Chapter 1 
 
Introduction, Objectives, and Specific Aims  
 2 
1.1. Introduction  
There has been an incredible increase in the identification of potential drug candidates based 
on the application of high throughput screening techniques, genomics, combinatorial 
chemistry and in-silico computational approaches [1-6]. Out of these potential drug 
candidates, about 70% do not have “drug-like” properties, such as good aqueous solubility 
and/or dissolution rates [6-9]. There are a number of approaches that are utilized to increase 
the dissolution rate and/or solubility and thus oral bioavailability of poorly soluble drugs. 
Traditional approaches to improve drug dissolution rate and/or solubility include: salt 
formation, as well as the use of solubilizing excipients and complexation agents. However, 
the success of these traditional approaches has been limited due to the taxing process of 
selection of highly soluble salts, as well as the requirement for large quantities of 
solubilizing excipients and complexation agents [10].  
Crystalline or amorphous nanoparticles are an attractive alternative approach to enhance the 
rate of dissolution and/or the solubility of poorly soluble drugs. Discrete drug particles in 
the range of 100–1000 nm are defined as pharmaceutical nano-particles [11]. An increase 
in the exposed surface area (or surface area-to-volume ratio) by particle size reduction 
causes an increase in the dissolution rate and thus the oral bioavailability [12, 13]. In 
addition, according to the Kelvin equation, saturation solubility (in terms of vapor pressure) 
of the drug is dependent on the drug particle size (which translates to the curvature effect). 
Theoretically, reduction in particle size will cause an increase in drug solubility [14]. 
However, the actual increase in saturation solubility for “nanocrystalline suspensions” 
(colloidal size range 100–1000 nm) is marginal, approximately 2 - 10% compared to un-
milled particles. Thus, nano-sized crystalline powders may not be a useful approach for 
solubility-limited drugs (i.e. solubility is rate limiting for oral bioavailability) [15]. In the 
case of amorphous formulations, the solubility of the drug is increased over the crystalline 
form due to its high-energy state (higher Gibbs’ free energy) [16-18]. However, amorphous 
formulations are unstable and will convert to the stable crystalline form over 
pharmaceutically relevant timescales [19]. Generally, amorphous drugs have been 
formulated as micro-sized solid dispersions prepared using techniques such as spray drying 
and hot melt extrusion. For both of these techniques the drug is stabilized in a polymer 
matrix with a higher glass transition temperature than the neat polymer. Recently, nano-
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sized amorphous formulations, namely “nano-amorphous” have been utilized to enhance 
the dissolution rates and solubilities of poorly soluble drugs. Theoretically, combining 
nanotechnology and amorphization approaches may offer absolute or synergistic effects in 
terms of solubility and dissolution rates. The advantage of amorphous versus crystalline 
nanoparticles is the considerably higher kinetic solubility of amorphous nanoparticles, 
which can be as much as 10 to 1600 fold.  Although, a significant amount of research has 
been carried out on amorphous nanoparticles, there are no marketed drug products available, 
till date. The major formulation challenge associated with amorphous nanoparticles is their 
stability, which depends on: API properties such as the melting temperature (Tm), Tm/Tg 
ratio, and the properties of the polymer or stabilizer utilized [20-24]. Amorphous systems 
have higher free volume or enthalpy as well as high Gibbs-free energy. Accordingly, these 
systems are unstable and tend to crystallize to a stable polymorph of the drug, which 
typically would have lower solubility. The crystallization time of an amorphous drug is a 
kinetically controlled process (which can vary from seconds to years) and depends on 
several factors such as, storage temperature and moisture content. Various approaches have 
been used to stabilize the amorphous form of drugs. For example, crystallization inhibitors 
(high Tg polymers/sugars) can be added and/or the formulation may be stored at low 
temperature (50°C below the drug Tg) and at low moisture/humidity conditions [17].  
Broadly, there are two basic methods to manufacture nanoparticles; (i) a “top-down 
approach” (i.e. milling/grinding of the particles to achieve the required size) and (ii) a 
“bottom-up approach” (i.e. precipitation of drug from a solvent to an anti-solvent system) 
[12]. The top-down approach is very time consuming and usually leads to crystalline 
particles whereas the bottom-up approach is less time consuming and usually leads to 
amorphous particles due to fast evaporation of the solvent and thus precipitation of the API 
as amorphous particles.  
The mechanism by which nanoparticles improve the dissolution rate and bioavailability of 
poorly water-soluble active pharmaceutical ingredients (APIs) [BCS class II and II/IV] is 
the enhanced surface area to volume ratio as described by the Noyes-Whitney equation [25]. 
According to the Noyes-Whitney equation the dissolution rate J is given by the following 
equation; 
𝐽 =
𝐷𝐴
ℎ
 (𝐶𝑠 − 𝐶) 
 4 
[J = dissolution rate, D = diffusion coefficient of drug, A = surface area of the dissolving 
solid, h = thickness of the diffusion layer, Cs = saturation solubility of the compound in the 
dissolution medium, C = concentration of the drug in the medium at different time points 
during dissolution] 
Increase in the surface-to-volume ratio and thus the dissolution rate of nanoparticles 
improves their pharmacokinetic properties in terms of: increased rate and extent of release 
and absorption; rapid onset of action; reduced side effects and improved clinical 
performance [12, 25, 26]. Concurrently, the drug saturation solubility is increased as 
theoretically predicted by the Ostwald–Freundlich equation as below;  
𝑙𝑛
𝐶𝑠,𝑟
𝐶𝑠,
=  
2𝑉𝑚
𝑟𝑅𝑇
 
[Cs,r and Cs, (g/L) = solubility of drug particles with radii r and r = (m), respectively, c  = 
interfacial tension between the drug particles and the medium (N/m), Vm = drug molar 
volume (m3/mol), R = gas constant (8.314 J/ mol K), T = absolute temperature (K)] 
The importance of crystalline nanosuspensions to the pharmaceutical industry can be judged 
by the fact that seventeen formulations are already on the market and approximately 10 - 15 
are in different stages of clinical trials [27]. However, one of the major concerns with 
nanosuspension formulations is the preservation of their physical and chemical stability in 
aqueous medium [28, 29]. Experimental and computational approaches to estimate 
solubility and permeability in drug discovery and development settings are being 
investigated. Being a liquid dosage form, nanosuspensions are more susceptible to both 
physical instability (due to crystal growth and agglomeration) and to chemical instability 
(due to degradation of the active pharmaceutical ingredient(s)), when compared to solid 
dosage forms. In fact, of all the marketed formulations, only Megace ES is in the suspension 
form (nano-particulate suspension of megesterol acetate). All others are prepared as 
nanosuspension-based solid dosage forms, as a way to overcome instability problems. 
Liquid nanosuspensions can be converted into solid dosage forms by drying to obtain a 
powder of nano-sized drug particles, which can be processed into conventional dosage 
forms such as tablets or capsules. Spray and freeze-drying are the most common methods 
of removing water from aqueous systems [28, 29].  
In this proposed research, different processes (wet media milling, sonoprecipitation and 
spray drying) were used to prepare robust and stable nanoamorphous and nanocrystalline 
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formulations (BCS class II and II/IV drugs) via a comprehensive QbD approach. Multiple 
linear regression and statistical ANOVA studies were applied to establish whether 
correlations exists between the different critical process parameters, critical formulation 
parameters and critical quality attributes. Several QbD approaches have been applied to 
conventional drug products (tablet, capsule, etc.), however, no comprehensive QbD has 
been reported till date to understand novel drug product development (such as amorphous 
and crystalline nanoparticles). There are individual process and formulation QbD studies 
reported in literature but comprehensive QbD including multiple manufacturing process 
optimization in combination with formulation QbD has not been reported for solid nano-
formulations.  
1.2. Objectives 
The objectives of this research are to: (1) investigate whether correlations can be established 
between critical process parameters (wet media milling – speed, time; sonoprecipitation – 
speed, time; spray drying – inlet temperature, aspirator rate, feed flow rate) and critical 
formulation parameters (drug and stabilizer concentrations) as well as critical quality 
attributes (particle size, total product yield, moisture content, drug loading) using a 
comprehensive QbD approach; (2) investigate the effect of temperature and relative 
humidity (4C, 25C/60% RH and 40C/75% RH) during accelerated and/or long term 
stability studies (1, 3, 6, and 12 month/s); and (3) investigate the drug-stabilizer interaction 
mechanism via an array of orthogonal solid-state tools (DSC, ATR-FTIR and PXRD). This 
information will aid in developing robust and stable nanoamorphous/nanocrystalline drug 
products with an improved shelf-life. This research will further help in minimizing the risks 
of product failure in terms of physicochemical attributes governing the therapeutic efficacy 
of poorly soluble compounds.  
1.3. Specific Aims 
The following specific aims were developed to achieve the objectives mentioned above: 
Specific Aim I: (Chapter 2) 
Solid state drug-polymer miscibility studies using the model drug ABT-102 
Specific Aim II: (Chapter 3) 
Formulation design and evaluation of amorphous ABT-102 nanoparticles  
Specific Aim III: (Chapter 4) 
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Comprehensive quality by design approach for stable nanocrystalline drug products 
Specific Aim IV: (Chapter 5) 
Nanoamorphous drug products – design and development  
*The stability studies were performed based on the ICH Q1A(R2) guidelines. The measured 
relative humidity at 4C was 6-6.5%.  
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Chapter 2 
Solid-State Drug-Polymer Miscibility Studies Using the Model Drug ABT-102 
ABSTRACT  
Amorphous solid dispersions typically suffer storage stability issues due to: their amorphous 
nature, high drug loading, uneven drug:stabilizer ratio and plasticization effects as a result 
of hygroscopic excipients. An extensive solid state miscibility study was conducted to aid 
in understanding the mechanisms involved in drug/stabilizer interactions. ABT-102 (model 
drug) and nine different polymers with different molecular weights and viscosities were 
selected to investigate drug/polymer miscibility. Three different polymer:drug ratios (1:3, 
1:1 and 3:1, w/w) were analyzed using: DSC, FTIR and PXRD.  Three different techniques 
were used to prepare the amorphous solid dispersions: serial dilution, solvent evaporation 
and spray drying. Spray drying was the best method to obtain amorphous solid dispersions. 
However, under certain conditions amorphous formulations could be obtained using solvent 
evaporation. Melting point depression was used to calculate interaction parameters and free 
energy of mixing for the various drug polymer mixtures. The spray dried solid dispersions 
yielded a negative free energy of mixing which indicated strong drug-polymer miscibility 
compared to the solvent evaporation and serial dilution method. Soluplus was the best 
stabilizer compared to PVP and HPMC, which is probably a consequence of strong 
hydrogen bonding between the two C=O moieties of soluplus and the drug N-H moieities.  
2.1. INTRODUCTION 
Drug dissolution and gastrointestinal permeability are the important factors controlling the 
rate and extent of drug absorption. This forms the basis of the biopharmaceutics drug 
classification scheme (BCS class I, II, III and IV), which correlates in vitro drug product 
dissolution and in vivo bioavailability [1]. Dissolution is the rate-limiting step for 
gastrointestinal absorption for most BCS class II drugs [2]. There are different approaches 
(solid dispersion, solid lipid nanoparticles, crystalline nanoparticles, liposomes, 
cyclodextrin complexes, etc.) in the pharmaceutical world to enhance the dissolution rate 
and increase the oral bioavailability of these poorly soluble drugs.  Solid dispersion 
technology is a well-established method to prepare the most stable solid formulations [3, 4].  
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Solid dispersion incorporate one or more crystalline or amorphous active ingredient in a 
solid matrix provided by an inert carrier [5]. These formulations increase the dissolution 
rate and oral bioavailability of poorly soluble drugs, with an added advantage of high drug 
loading [6]. Commercially, three different methods are used to prepare solid dispersions 
(i.e. spray drying, hot melt extrusion and co-precipitation) [7-9]. Additionally, solid 
dispersions can be prepared using solvent evaporation and fusion techniques [10, 11]. 
Generally, all these methods result in the production of amorphous solid dispersions 
(ASDs), which significantly enhance the solubility and bioavailability compared to the 
crystalline form of the drug [12]. Additionally, these methods might also result in formation 
of semi-crystalline or crystalline systems. The amorphous form of drug has drawn 
considerable attention, as theoretically it represents the most energetic solid state, and may 
provide the advantages in terms of solubility and bioavailability [13]. Recently, amorphous 
solid dispersions have been successfully developed to thermodynamically or kinetically 
stabilize the amorphous form of drugs and yield drug products with enhanced bioavailability 
[14-16]. Among the various techniques for preparing solid dispersions, hot-melt extrusion 
(HME) has stood out with obvious advantages due to its single-step, simple and organic 
solvent-free preparation process, and gained increasing popularity [6, 17]. However, the 
elevated processing temperature has certainly limited the application of HME for heat-
sensitive drugs, and so far only a few number of studies focused on this problem [18-20]. 
Furthermore, amorphous solid dispersions have associated physical and chemical instability 
issues which become particularly apparent on scale up [21]. Selection of the best excipient 
at the formulation development stage may prevent the risk associated with these 
instabilities.  Hence, it is very important to study drug stabilizer interactions (strong/weak) 
at the molecular level to predict the stability/miscibility of the drug in a given polymer 
matrix. Such understanding would allow a significant improvement over the conventional 
trial and error strategies for stabilizer selection. 
Interactions between different stabilizers and poorly soluble drugs, has been reported in the 
literature for amorphous solid dispersions. Different solid state analytical tools such as DSC, 
FTIR and PXRD have been used to characterize both strong and weak interactions [22-27].  
In the present study the effect of the molecular weight of three different polymers (PVP, 
HPMC and soluplus) on interaction with the drug – ABT-102 (BCS class II) were 
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investigated. Nine different polymers (PVP K-17, PVP K-25, PVP K-30, PVP K-90, HPMC 
E3, HPMC E5, HPMC E15, HPMC E50 and soluplus) with different molecular weights and 
viscosities were selected to investigate drug-polymer miscibility. Three different ratios of 
drug:polymer (1:3, 1:1 and 3:1, w/w) were studied using solid state characterization tools 
(DSC, FTIR and PXRD).  
2.2. MATERIALS  
Poly (1-vinyl-2-pyrrolidone) (PVP) – K17 and K90 were gifted by Sigma Chemicals. Poly 
(1-vinyl-2-pyrrolidone) (PVP) – K25, K30 (USP, JP, EP) and soluplus (polyvinyl 
caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer) were gifted by BASF. 
Hydroxy propyl methyl cellulose (Methocel premium LV) – E3, E5, E15 and E50 were 
donated by the Dow Chemical Company. The chemical structures of the polymers and drug 
are shown in Table 2.1. Methanol HPLC grade was purchased from Fisher Scientific. ABT-
102 was provided by AbbVie Pte. Ltd. The molecular weights and viscosities of the different 
polymers are shown in Table 2.2. 
2.3. METHODS 
2.3.1. Method of preparation of the solid dispersions 
Nine different polymers (i.e. PVP K-17, PVP K-25, PVP K-30, PVP K-90, HPMC E3, 
HPMC E5, HPMC E15, HPMC E50 and soluplus) were selected to investigate drug-
polymer miscibility. Based on the knowledge that polymers with carbonyl groups have a 
strong interaction ability with drugs containing amine groups, polymers containing carbonyl 
groups (PVPs) were selected. Additionally, polymers devoid of carbonyl groups (HPMCs) 
were selected to facilitate understanding of drug-polymer interactions. Furthermore, a 
polymer containing two carbonyl groups (soluplus) was also selected to investigate whether 
a better drug-polymer interaction may occur with additional carbonyl moieties. A wide 
range of PVPs and HPMCs (different molecular weights of both polymers) were selected 
for this study to compare the interaction of low, intermediate and high molecular weight 
polymers with the drug. The model drug selected for the study was ABT-102 which contains 
three –NH groups.   
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2.3.1.1. Spray drying 
The polymer and drug were accurately weighed using an analytical balance. The mixtures 
were transferred into 250 mL Schott glass bottles. 37.5 mL, 25 mL and 12.5 mL of methanol 
were added to the polymer:drug ratios 1:3, 1:1 and 3:1, w/w, respectively to completely 
dissolve the mixtures. The solutions were spray dried using a Buchi B-290, bench-top spray 
dryer to prepare the amorphous solid dispersions. Briefly, the spray drier was equilibrated 
using 100% methanol. Once equilibrated, the solutions were pumped into the drying 
chamber using a peristaltic pump (feed rate about 20 mL/min). All the samples were spray 
dried at inlet and outlet temperatures of 75°C and 55°C, respectively. Gas flow (atomizing 
air) was kept constant at 40 mm Hg (air flow approximately 600 L/h) for all the samples. 
The dried samples were immediately transferred from the collection chamber and analyzed 
using solid state characterization tools (DSC, FTIR and PXRD). All samples were prepared 
in triplicate. Additionally, the standards of neat polymers and neat drug were also dissolved 
in appropriate volumes of methanol and these were spray dried to obtain standards for spray 
dried neat polymers and drug. 
2.3.1.2. Solvent evaporation 
The polymer and drug were accurately weighed using an analytical balance. The mixtures 
were transferred into uncapped glass tubes. A fixed volume of methanol was added to the 
polymer:drug mixtures as follows: 3.75 mL, 2.5 mL and 1.25 mL of methanol were added 
to the polymer:drug ratios 1:3, 1:1 and 3:1, w/w, respectively to completely dissolve the 
mixtures. The tubes were placed in a nitrogen evaporator assembly for approximately 2-3 h 
to remove the solvent. After complete solvent removal, the dry films were analyzed using 
the solid state characterization tools (DSC, FTIR and PXRD). All samples were prepared in 
triplicate. The samples were vacuum dried for 12 h and stored in uncapped glass tubes at 
40°C for 12 h. Additionally, standards of neat polymers and drug were also dissolved in 
appropriate volumes of methanol and post solvent removal, the samples were vacuum dried 
for 12 h and stored in uncapped glass tubes at 40°C for 12 h. 
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2.3.1.3. Physical mixtures 
The polymer and drug were accurately weighed using an analytical balance and mixed 
homogeneously via serial dilution. The mixture was transferred into uncapped glass tubes. 
For each polymer, three different polymer to drug ratios were mixed; 1:3, 1:1 and 3:1, w/w. 
The powder mixtures were vacuum dried for 12 h and following that stored in uncapped 
glass tubes at 40°C for a further 12 h. The samples were analyzed using the solid state 
characterization tools (DSC, FTIR and PXRD). All samples were prepared in triplicate. 
Additionally, standards of neat polymers and drug were similarly vacuum dried for 12 h and 
stored in uncapped glass tubes at 40°C for 12 h. 
2.3.2. Characterization  
2.3.2.1. Differential scanning calorimetry 
DSC was performed using a TA Q1000 calorimeter (TA instruments, New Castle, DE, 
USA) equipped with a refrigerated cooling accessory. The instrument was calibrated for 
enthalpy and heat capacity using indium and sapphire, respectively. A constant weight of 
10 mg of the samples were sealed in non-hermetic pans and analyzed. The heating rate was 
maintained at 10 °C/min from 0°C to 235 °C. Nitrogen gas was used for purging at a flow 
rate of 50 mL/min. Data were analyzed using TA universal analysis software. 
2.3.2.2. Fourier transform infrared spectroscopy 
IR spectroscopy was performed using a Nicolet FTIR (iS5 FTIR, Thermo Scientific) 
spectrometer attached with an attenuated total reflectance (ATR) accessory. The samples 
were placed on the crystal window (Germanium) and compressed lightly using the pressure 
clamp. Spectra were recorded over a range of 400–4000 cm−1 with a resolution of 4 cm−1, 
for 128 parallel scans. Data analysis was performed using Omnic 6.0a software (Thermo 
Nicolet Corporation). 
2.3.2.3. Powder X-ray diffraction 
PXRD (wide-angle X-ray scattering) was used to study the presence of crystallinity in the 
samples prepared using the above three methods. X-ray diffraction patterns were obtained 
using an X-ray diffractometer (Model D5005, Bruker AXS Inc., Madison, WI) with Cu-kα 
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radiation, a voltage of 40 kV, and a current of 40 mA. All the scans were performed with a 
scanning rate of 2°/minute from 5° to 40° at 2θ ranges.  
2.4. RESULTS & DISCUSSIONS 
The polymer:drug physical mixtures were easily retrieved for solid state analysis. However, 
the neat polymers and polymer:drug ratio of 3:1, w/w (exception - soluplus:drug) were 
difficult to retrieve post solvent evaporation due to the formation of a rigid glassy structure 
on the walls of the glass tubes, thus solid state analysis for these samples could not be 
performed. All physical mixtures showed drug in the crystalline form, dispersed in the 
polymer matrix. Samples prepared by solvent evaporation showed drug in crystalline form, 
dispersed in the polymer matrix at a higher drug:polymer ratio (3:1, w/w). However, all 
spray dried samples resulted in molecular level amorphous dispersions. Solid state analysis 
of the other samples were performed using DSC, FTIR and PXRD.  
2.4.1. Differential scanning calorimetry 
When the chemical potential of the pure crystalline drug is equal to the chemical potential 
of the molten drug, an endothermic event (the melting point) is observed in the DSC 
thermogram [30]. It has been established that strong interactions produce large melting point 
depressions while weak interactions, result in smaller melting point depressions [31]. 
However, if the drug-polymer mixtures are immiscible, the chemical potential of the molten 
drug remains unchanged in the presence of polymer, resulting in no melting point 
depression.  
2.4.1.1. PVP 
PVP is a carbonyl group containing polymer. The melting point depression of polymer-drug 
mixtures using three different manufacturing methods (serial dilution, solvent evaporation 
and spray drying) and three different PVPs:drug ratios are shown in figure 2.1. Lower 
molecular weight PVP (PVP K17) resulted in a significant shift (lowering) in the melting 
point peak (229.81±0.19°C) compared to the higher molecular weight PVP (PVP K90), for 
all three polymer:drug ratios (1:3, 1:1 and 3:1, w/w). Furthermore, the intermediate 
molecular weight PVP’s (PVP K25 and PVP K30) also resulted in melting point depression, 
indicating possible interaction between the polymer and the drug. It was observed that for 
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polymer:drug mixtures prepared using all three methods (spray drying, solvent evaporation 
and physical mixture), the lower molecular weight PVP’s showed a greater ability to interact 
with the drug compared to the higher molecular weight PVP. The presence of the carbonyl 
group (C=O) in PVP (PVP K17, K25 and K30) enhances interaction with drugs containing 
N-H groups, resulting in strong hydrogen bonding. In the case of the high molecular weight 
PVP (PVP K90), the high viscosity of this polymer is probably an inhibiting factor, limiting 
drug-polymer interaction. For the spray drying experiments, the DSC thermograms showed 
the absence of melting endotherms for polymer to drug ratios of 1:3 and 1:1, w/w. Similarly, 
for the solvent evaporation experiment, the DSC thermograms showed the absence of 
melting endotherms for the polymer to drug ratio of 3:1, w/w. This indicates a complete 
conversion from the crystalline to the amorphous form.  
2.4.1.2. HPMC  
HPMC is devoid of carbonyl groups. The melting point depression using three different 
manufacturing methods (serial dilution, solvent evaporation and spray drying) and three 
different HPMCs:drug ratios are shown in figure 2.2. For the physical mixtures, lower 
molecular weight HPMC’s (HPMC E3 and E5) resulted in a minor shift (224-227°C) in 
the drug melting peak (229.81±0.19°C) compared to the higher molecular weight HPMC’s 
(HPMC E15 and E50)  which showed no melting peak shift (228-230°C), for two 
polymer:drug ratios (1:3 and 1:1, w/w). The minor shifts in the drug melting peak in the 
presence of low molecular weight HPMCs may be due to weak hydrogen bonding 
interactions between the OH group of the polymer and NH group of the drug. However, at 
the polymer:drug ratio of 3:1, w/w the drug melting peak shift was significant ( 10°C lower 
than the drug melting point) for the lower molecular weight HPMC’s (HPMC E3 and E5) 
indicating a strong interaction between the polymer and the drug. In addition, a minor shift 
in the melting peak was observed for the higher molecular weight HPMC’s (HPMC E15 
and E50) (224°C). For the solvent evaporation experiment, the melting endotherm of the 
polymer:drug mixture (3:1, w/w) resulted in a significant shift in the drug melting 
endotherm for the lower molecular weight HPMC’s (HPMC E3 and E5) (216°C) 
indicating a strong interaction between the polymer and the drug. Again the high molecular 
weight HPMC’s (HPMC E15 and E50) resulted in a minor shift in the melting peak 
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(223°C). The 1:3 and 1:1, w/w drug:polymer ratios showed a minor shift (224°C) for the 
lower molecular weight HPMC’s (HPMC E3 and E5) and no shift (227°C) for the higher 
molecular weight HPMC’s (HPMC E15 and E50). For the spray dried samples, it was 
observed that the polymer:drug ratio of 3:1, w/w resulted in a significant shift in the drug 
melting endotherm for all molecular weight HPMC’s. Again, the interaction appeared to be 
stronger for the low molecular weight HPMCs with melting point depressions of ~15-20°C 
compared to the high molecular weight HPMCs (~10°C). The polymer:drug ratio of 1:3, 
w/w did not show any significant change in the melting point for lower and higher molecular 
weight HPMCs. However, for the polymer:drug ratio of 1:1, w/w, HPMC E3 showed the 
strongest interaction with the drug, reducing the melting point to 212C. HPMC E5 and 
E50 also shifted the drug melting to 215C. HPMC E15 resulted in the weakest interaction 
with the drug at the polymer:drug ratio of 1:1, w/w, shifting the melting to 217C.  
2.4.1.3 Soluplus 
Soluplus contains two carbonyl moieities. The melting point depression observed for the 
three different manufacturing methods (serial dilution, solvent evaporation and spray 
drying) and the three different soluplus:drug ratios are shown in figure 2.3. No interactions 
were observed in the polymer:drug physical mixtures. This was confirmed by no change in 
the melting endotherms 227-229°C for the three polymer:drug ratios of; 3:1, 1:1 and 1:3, 
w/w, compared to the neat drug melting endotherm (229.81°C). In the case of 
polymer:drug samples prepared via solvent evaporation interactions were observed. 
However, these were significantly less compared to those observed between the drug and 
the HPMCs for soluplus:drug ratios of 1:1 and 1:3, w/w. The polymer:drug ratio of 3:1, w/w 
resulted in the strongest interaction as observed by a greater shift in the melting endotherm 
(to 216°C) compared to the 1:3 and 1:1, w/w ratios (222-223°C).  The polymer-drug 
interactions appeared to be strongest in the case of solid dispersions prepared using spray 
drying for all three polymer:drug ratios. However, for the polymer:drug ratio of 3:1, w/w a 
melting endotherm was not observed, indicating that the polymer:drug mixture completely 
converted from the crystalline to the amorphous form at this ratio. The melting peak shifted 
to  207 and  216°C for polymer:drug ratios of 1:1 and 1:3, w/w, respectively. These were 
the strongest interactions observed between the drug and soluplus. The presence of two 
 17 
carbonyl groups (C=O) in soluplus may result in a strong interaction with the multiple N-H 
moieities present in the drug, allowing for strong hydrogen bonding.  
2.4.2 Thermodynamics of mixing 
In amorphous solid dispersions containing a drug-polymer system, miscibility is defined as 
formation of the single phase amorphous system through drug-polymer mixing. A totally 
miscible system will achieve molecular level mixing of the drug and the polymer leading to 
a significant increase in the physical stability of the drug. Such molecular level mixing of 
the drug and the polymer will decrease the chemical potential of the drug, thus 
minimizing/preventing the thermodynamic driving force for crystallization [32-34].  
2.4.2.1 Melting Point Depression Approach 
The Flory-Huggins equations for polymer-solvent system interaction can be extended to 
drug-polymer systems, in order to calculate the polymer-drug interaction parameter from 
the melting point depression of the drug by the polymer [35]. Equation 1 represents the 
relationship between melting point depression of drug and the polymer-drug interaction 
parameter.  
 (1) 
where, TmixM is the melting temperature of the drug in the presence of the polymer, TpureM 
is the melting temperature of the drug in the absence of the polymer, Hfus is the heat of 
fusion of the pure drug, and m is the ratio of the volume of the polymer to that of the lattice 
site (volume of the drug),  is the interaction parameter (unit less), drug and polymer are the 
volume fractions of the drug and polymer, respectively.  has an enthalpy component 
(defining the relative strength of adhesive and cohesive interactions) and an entropic 
component (which varies with composition and temperature) [30, 36, 37]. 
The equation for the free energy of mixing (Gm in joules) for an API-polymer system can 
be described according to equation 2, on adding the Flory-Huggins interaction parameter,  
to account for the enthalpy of mixing. The Flory-Huggins interaction parameter was 
estimated using the melting point depression method. 
 (2) 
= + 
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where, ndrug is the number of moles of drug, npolymer is the number of moles of polymer, 
drug is the volume fraction of the drug, polymer is the volume fraction of the polymer,  is 
the interaction parameter, R is the gas constant, and T is the absolute temperature.  
The interaction parameters and free energy of mixing for the different polymer-drug 
mixtures prepared via spray drying, solvent evaporation and serial dilution were calculated 
as follows; 
2.4.2.1.1 Spray drying 
The drug-polymer systems which exhibits a negative interaction parameter value, indicates 
strong miscibility. Furthermore, the free energy of mixing is positive for large positive 
interaction parameters indicating immiscibility, whereas the free energy of mixing is 
negative for small values of the interaction parameter, indicating miscibility [38]. As 
observed from figure 2.4(a), the low (PVP K17) and intermediate (PVP K25 and K30) 
molecular weight PVPs, all four grades of HPMCs and soluplus resulted in negative 
interaction parameter values, indicating strong miscibility with ABT-102 at polymer:drug 
ratio of 1:3, w/w. This result is reflected in the free energy of mixing data (figure 2.4(b)), as 
negative free energy of mixing was observed for drug-polymer mixtures that exhibited small 
interaction parameter values. The blends of ABT-102 and PVP K90 showed a positive 
interaction parameter value and a positive free energy of mixing predicting immiscibility. 
A plot of interaction parameter vs. the volume fraction of the polymers, as shown in figure 
2.4c, yielded a linear relationship at low polymer weight fractions for low and intermediate 
molecular weight PVPs and soluplus, with a slope equal to . However, for all four HPMC 
grades and for the high molecular weight PVP, a non-linear relationship was observed with 
increase in the volume fraction of polymer. The non-linearity over the entire concentration 
range indicates escalating unfavorable kinetics of drug-polymer interaction and that the 
interaction parameter is composition dependent [30].  
2.4.2.1.2 Solvent evaporation 
As observed in Figure 2.5(a and b), samples prepared via solvent evaporation using PVP 
K17 and soluplus at a polymer:drug ratio of 1:3, w/w showed a negative interaction 
parameter and a negative free energy of mixing indicating strong miscibility of ABT-102 
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with the two polymers (PVP K17 and soluplus). The plot of interaction parameter vs. 
volume fraction of polymers (figure 2.5c) resulted in a non-linear relationship with increase 
in the volume fraction of the polymers.  
2.4.2.1.3 Physical mixture 
As observed in Figure 2.6(a and b), the samples prepared via serial dilution using PVP K17 
at a polymer:drug ratio of 1:3, w/w showed a negative interaction parameter and a negative  
free energy of mixing indicating strong miscibility of ABT-102 with the two polymers (PVP 
K17 and soluplus). This indicates that even in the physical mixture for low molecular weight 
PVP, a strong interaction is observed. This result was different from the other polymers used 
to prepare the physical mixture samples via serial dilution. The other polymers resulted in 
a higher interaction parameter value and a positive free energy of mixing indicating weak 
miscibility or absence of miscibility. The plot of interaction parameter vs. volume fraction 
of polymers (figure 2.6c) resulted in a non-linear relationship with increase in the volume 
fraction of the polymers.  
2.4.3. Fourier transform infrared spectroscopy 
FTIR has been extensively used to study polymer-drug miscibility. Any change in the 
absorbance (shift in the wavenumber or change in the intensity) observed in the formulations 
compared to the neat drug or drug-polymer physical mixtures provides information that 
there is interaction between the drug and the polymer. These interactions can be of various 
types: hydrogen bonding, covalent bonding, ionic interaction, etc. The presence of hydrogen 
bonding in solid dispersions can be confirmed using FTIR by comparing the FTIR spectra 
of solid dispersions (formulations) with those of the neat drug and polymers.  Polymer-drug 
miscibility was studied for the nine different polymers as described in section 2.3.1. The 
characteristic FTIR absorbance bands for ABT-102, PVP, soluplus and HPMC are listed in 
Table 2.3. Figure 2.7, 2.8, 2.9, 2.10, 2.11, 2.12, 2.13, 2.14 and 2.15 are shown in 
supplementary material.  
2.4.3.1. Spray drying 
The miscibility of the polymer:drug samples prepared using spray drying were superior 
compared to those prepared using the serial dilution and solvent evaporation techniques. 
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The polymer and drug in solution form precipitate together to form a solid powder with 
superior homogeneity due to rapidity of the spray drying process, compared to the solvent 
evaporation and serial dilution methods. In spray drying, the organic solvent containing the 
polymer:drug mixture (in dissolved state) is sprayed into fine droplets. The consequent 
evaporation of the organic solvent from the dispersed droplets, results in the conversion of 
the crystalline drug to mostly amorphous solid dispersions, due to the rapid precipitation. 
As a result of the higher free energy and higher molecular mobility of amorphous systems, 
interaction between the drug and the polymer is enhanced. The type of polymer and the 
polymer:drug ratio play an important role in maximizing stability. Different types of 
molecular level interactions such as hydrogen bonding and other weak hydrophobic 
interactions have been reported in the literature for spray dried solid dispersions [33, 43].  
2.4.3.1.1. PVP 
From figure 2.7, it can be observed that, with increase in the PVP:drug ratio from 1:3 to 3:1, 
w/w, band broadening was observed between 3700-3100 cm-1 compared to the sharp peak 
associated with the neat drug. This band broadening may be a result of: 1) the high level of 
interaction obtained in the drug:polymer solid dispersion; and/or 2) masking of the drug 
peak by the high concentration of the polymer. This interaction appears to be H-bonding, 
since N-H stretching and O-H stretching are observed in the drug and PVP, respectively. 
Additionally, with increase in the PVP:drug ratio from 1:3 to 3:1, w/w, there was a decrease 
in the absorption intensity between: 1600-1500 cm-1 (due to C-C stretching – aromatic); 
1400-1200 cm-1 (due to C-H bending); and 1100-600 cm-1 (due to C-H aromatic out of plane 
bending and C-C stretching). These reductions in the absorption intensities indicate the 
presence of weak hydrophobic interactions between the drug and PVP. The spray dried 
PVP:drug mixtures showed similar FTIR spectra for all four grades of PVP, due to the high 
level of interaction between the drug and the polymer in these solid dispersion formulations. 
Additionally, the FTIR data is supportive of the DSC thermograms observed for the 
amorphous solid dispersions in the previous section. 
2.4.3.1.2. Soluplus 
As shown in figure 2.8, band broadening was observed between 3700-3000 cm-1 (due to N-
H stretching in the drug and O-H stretching in soluplus), compared to the sharp peak 
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observed for the neat drug. The band broadening became more pronounced with increase in 
the soluplus:drug ratio from 1:3 to 3:1, w/w. Additionally, a decrease in the absorption 
intensity between 1700-1500 cm-1 was observed with increase in the polymer concentration, 
due to C-C aromatic stretching in the drug and C=O stretching (amide group) in soluplus. 
These observations suggest that there is strong hydrogen bonding between the drug and 
soluplus. Moreover, the decrease observed in the absorption intensity between 1000-600 
cm-1 (C-H aromatic out of the plane bending) with the increase in polymer concentration 
indicated that there was weak hydrophobic interactions between the drug and polymer.  
2.4.3.1.3. HPMC 
According to Figure 2.9, for the spray dried dispersions prepared using HPMC as the 
stabilizer, all the different molecular weight HPMCs showed similar FTIR spectra. This 
indicated that there was strong miscibility between the drug and the HPMCs in the spray 
dried dispersions. With increase in the HPMC:drug ratio from 1:3 to 3:1, w/w, band 
broadening was observed between: 3680-3100 cm-1 (O-H stretching); and 3000-2800 cm-1 
(C-H aliphatic stretch) compared to the neat drug. This indicates that there is intermolecular 
hydrogen bonding between the drug and all grades of HPMC. Additionally, with the 
increase in the HPMC concentration from 1:3 to 3:1, w/w (HPMC:drug), there was a 
decrease in the absorption intensity between: 1700-1500 cm-1 (C-C aromatic stretching); 
1400-1200 cm-1 (symmetric bending of OCH3 and C-O-C stretching); and band broadening 
was observed between 1000-600 cm-1 (C-H aromatic out of plane bending), compared with 
the neat drug. Moreover, with the increase in the HPMC concentration from 1:3 to 3:1, w/w 
(HPMC:drug), there was increase in the absorption intensity between 1200-1000 cm-1, 
mainly due to C-O-C stretching, for all four different molecular weights of HPMC. These 
observations suggests hydrogen bonding and hydrophobic interactions between the drug 
and polymer.  
2.4.3.2. Solvent evaporation 
The FTIR spectra indicated that the samples prepared via solvent evaporation were more 
homogenous compared to the physical mixtures. However, the spray dried solid dispersions 
showed superior miscibility between the drug and polymer compared to the solvent 
evaporation and serial dilution methods. Hydrogen bonding and other types of interactions 
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are more likely to occur in samples prepared via spray drying, followed by intermediate 
interactions observed in samples prepared via solvent evaporation and minimal/no 
interactions in the samples prepared via serial dilution. Since the solvent evaporation 
method is a slow drying process, one of the components (the drug or the polymer), 
precipitates before the other, resulting in a less homogeneous mixture compared to the spray 
drying process. 
2.4.3.2.1. PVP 
With increase in the PVP:drug ratio from 1:3 to 3:1, w/w, band broadening was observed 
between 3625-3150 cm-1 (figure 2.10) for the low and intermediate molecular weight PVPs. 
The broadening at 3600-3450 cm-1 is characteristic of O-H stretching (polymer, PVP) and 
N-H stretching (drug). Therefore, the observed broadening indicates hydrogen bonding 
between the aromatic group of the drug and the hydroxyl group of the low and intermediate 
PVPs. Additionally, with increase in the PVP:drug ratio from 1:3 to 3:1, w/w, there was a 
decrease in the absorbance intensity between 1600-1500 cm-1 and a broadening of the 
absorbance band between 1700-1600 cm-1 for the samples prepared using low and 
intermediate PVP’s. This indicates that the low and intermediate molecular weight PVPs 
have strong miscibility with the drug due to the observed C-C stretching (aromatic moiety) 
and C=O stretching. The low and intermediate PVP’s showed a characteristic decrease in 
the absorbance intensity form 1000-500 cm-1, indicating C-H aromatic out of the plane 
bending and C-C stretching, which points to possible weak hydrophobic interactions 
between the drug and PVP. For the low and intermediate PVPs, with increase in the polymer 
concentration, there is strong hydrogen bonding and hydrophobic interactions. However, 
the high molecular weight PVP (PVP K-90) had a similar absorbance band as the neat drug 
for all polymer:drug ratios, indicating that the high molecular weight PVP was immiscible 
and lacked interaction with the drug. 
2.4.3.2.2. Soluplus 
According to Figure 2.11, the soluplus:drug 3:1, w/w, ratio showed band broadening 
between 3625-3150 cm-1 (due to N-H stretching in the drug and O-H stretching in the 
soluplus). For all polymer:drug ratios, a decrease in the absorbance band intensity was 
observed between 1700-1500 cm-1 (due to C=O stretching in the soluplus and C-C aromatic 
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stretching in the drug). Additionally, all three polymer:drug ratios showed an increase in the 
absorbance band intensity between 1300-1200 cm-1 and a decrease between 1000-500 cm-
1. These two effects indicate an interaction between the drug and the polymer due to C-H 
aromatic out of plane bending in the drug and C-C stretching in soluplus. Accordingly, there 
appears to be strong hydrogen bonding between the drug and soluplus at the polymer:drug 
ratio of 3:1, w/w, whereas, there appears to be weak hydrophobic interactions in the 
polymer:drug 1:1 and 1:3, w/w ratios. 
2.4.3.2.3. HPMC 
According to Figure 2.12(A), with increase in the HPMC:drug ratio from 1:3 to 3:1, w/w, 
band broadening was observed between: 3680-3100 cm-1 (O-H stretching) and 3000-2800 
cm-1 (C-H aliphatic stretch) compared to the neat drug. These changes were observed mainly 
with HPMC E3 and not with the intermediate molecular weight HPMC’s (HPMC E5 and 
E15) and high molecular weight HPMC’s (HPMC E50). This indicates that there is 
intermolecular hydrogen bonding between the drug and HPMC E3 (lower molecular weight 
HPMC), which was absent in the other HPMCs used in this study (HPMC E5, E15 and 
E50). Specifically, for the low molecular weight HPMC (E3), there was a decrease in the 
absorption intensity between: 1700-1500 cm-1 (C-C aromatic stretching); 1300-1200 cm-1 
(C-O-C stretching); and 800-700 cm-1 (C-H aromatic out of plane bending), with increase 
in the HPMC:drug ratio from 1:3 to 3:1, w/w, indicating a hydrophobic interaction between 
the drug and the polymer. Moreover, for HPMC E3, E15 and E50, an increase in the 
absorption intensity between 1100-1000 cm-1 (ethereal C-O-C stretching) was observed 
with the increase in the HPMC:drug ratio from 1:3 to 3:1, w/w.  
2.4.3.3. Physical mixture 
It was difficult to interpret any interaction between the drug and polymer in samples 
prepared via serial dilution into physical mixtures. However, weak interactions in the 
polymer-drug physical mixtures were observed for all three polymers at the high 
polymer:drug ratio (3:1, w/w). The samples prepared via serial dilution were controls for 
the other two methods (spray drying and solvent evaporation), due to minimal interactions 
between the drug and polymers. 
2.4.3.3.1. PVP  
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As observed in figure 2.13, the FTIR spectra of the 1:1 and 1:3 PVP:drug physical mixtures, 
did not show any significant change in comparison to the neat drug and neat polymer, 
indicating insufficient miscibility to allow interaction. However, in the case of the 3:1, w/w 
PVP:drug physical mixture, a slight decrease in the absorbance intensity was observed 
between 1500-1600 cm-1. This corresponds to a C-C stretch for aromatic molecules, 
indicating that a weak hydrophobic interaction between drug and PVP may have occurred.  
2.4.3.3.2. Soluplus 
According to figure 2.14, the intensity of the absorbance band corresponding to C=O 
stretching (1700-1800 cm-1) was reduced for all soluplus:drug physical mixtures compared 
to the neat soluplus. This indicates that there may be weak interactions between the drug 
and soluplus. However, no other significant changes (such as wavenumber shift or 
absorbance intensity change) were observed.  
2.4.3.3.3. HPMC 
As observed in figure 2.15, the intensity of the absorbance band corresponding to ethereal 
C-O-C stretching (1100-1000 cm-1) increased when the HPMC:drug ratio increased from 
1:3 to 3:1, w/w, indicating a weak hydrophobic interaction between the drug and the HPMC 
physical mixtures. However, no other significant changes were observed for all four HPMC 
grades.  
2.4.4. Powder X-ray diffraction 
Powder X-ray diffraction (PXRD) is an important solid state tool to identify the crystallinity 
present in solid dispersions. Minimal or absence of crystallinity in the finished formulation 
has a great impact in improving the dissolution characteristics of many poorly soluble drugs. 
Crystalline drugs or their formulations are characterized by sharp diffraction peaks, however 
amorphous drug or their formulations are represented by a halo pattern (absence of sharp 
diffraction peaks) in the PXRD profile. The conversion of a mixture of crystalline drug and 
amorphous/crystalline polymer into a completely amorphous solid dispersion indicates that 
there is a strong miscibility between the drug and polymer, since amorphization leads to an 
increase in the molecular mobility of both the drug and the polymer. Additionally, PXRD 
has a limitation in the detection of small crystals (< 5%), which do not show strong 
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diffraction peaks. In this study, PXRD was used to characterize the amorphous formulations 
and understand the effect of increase in polymer concentration (different molecular weights) 
on the drug-polymer mixtures. Figure 2.16, 2.17 and 2.18 are shown in supplementary 
material. 
2.4.4.1. PVP 
The characteristic diffraction peaks of neat crystalline ABT-102 are 6.3, 9.2, 12, 14.7, 
16.3, 18.2, 19.9, 22.8, 24.9 and 26.8. According to figure 2.16A, it was observed that, 
after serial dilution of drug and PVP K17, all the PVP K17:drug physical mixtures were 
crystalline. However, in the formulations prepared via solvent evaporation, it was observed 
that with increase in the polymer concentration from 1:3 to 3:1, w/w (polymer:drug), there 
was complete transformation from crystalline to amorphous form. The crystalline 
diffraction peaks were only observed in the PVP K17:drug physical mixture 1:3 and 1:1, 
w/w, which transformed into the amorphous form for the 3:1, w/w PVP K17:drug physical 
mixtures.  
According to figure 2.16 B,C,D, it was observed that all physical mixtures of PVP K25:drug, 
PVP K-30:drug and PVP K-90:drug showed characteristic crystalline diffraction peaks, 
similar to the neat crystalline drug.  Additionally, for the formulation prepared using solvent 
evaporation, the halo pattern was only observed at the 3:1, w/w polymer:drug ratio. 
However, the other two polymer:drug ratios i.e. 1:1 and 1:3, w/w, showed the presence of 
diffraction peaks with less intensity, indicating low crystallinity. These observations were 
evident for all drug:PVP mixtures (intermediate and high molecular weight; PVP K25, PVP 
K30 and PVP K90), indicating that the 3:1, polymer:drug ratio resulted in completely 
amorphous material.  
In the case of spray dried formulations, a halo pattern was observed for all three ratios of 
PVP:drug, indicating complete amorphization of the drug. The halo pattern was observed 
for low, intermediate and high molecular weight PVPs (PVP K17, PVP K25, PVP K30 and 
PVP K90), confirming their amorphous nature. Thus, spray drying was the best method to 
formulate amorphous dispersions, wherein the drug:polymer miscibility at all ratios was 
strong, compared to formulations prepared via the other methods. 
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2.4.4.2. Soluplus 
According to figure 2.17, it was observed that for the physical mixtures prepared via serial 
dilution of drug and soluplus, all formulations were crystalline under PXRD, indicating 
minimal interaction between the drug and the polymer. For the formulations prepared using 
the solvent evaporation technique, the soluplus:drug ratio of 3:1, w/w showed a halo pattern 
in the PXRD, indicating its amorphous nature compared to the sharp crystalline peaks 
observed in the 1:1 and 1:3, w/w soluplus:drug mixtures. For the formulations prepared 
using spray drying, a halo pattern was observed for all three soluplus:drug ratios, indicating 
that the spray dried solid dispersions were amorphous.  
2.4.4.3. HPMC 
According to figure 2.18, formulations prepared via serial dilution showed sharp diffraction 
peaks under PXRD, indicating their crystalline nature. Amongst, the formulations prepared 
using solvent evaporation, the HPMC:drug ratios of 1:1 and 1:3, w/w, for the low molecular 
weight HPMCs (E3 and E5) showed less intense crystalline peaks, whereas, the 3:1, w/w 
was completely amorphous. However, for the high molecular weight HPMCs; E15 and E50, 
all polymer:drug ratios showed less intense crystalline peaks under PXRD. In the case of 
the spray dried solid dispersions, it was observed that all ratios of the HPMC:drug (all grades 
of HPMC) showed a halo pattern in the PXRD, confirming their amorphous nature. Thus, 
the spray drying method was the best method to formulate amorphous dispersions, since the 
interaction between the drug and the polymer is strong in these molecular dispersion.  
2.5. CONCLUSIONS 
Spray drying was determined to be the best method out of those investigated (spray drying, 
solvent evaporation and serial dilution) to formulate amorphous solid dispersions. This is 
due to the formation of solid state molecular dispersions during the rapid precipitation of 
the drug and the polymer in the spray drying process. In this study, nine different polymers 
(PVP K17, PVP K25, PVP K30, PVP K90, soluplus, HPMC E3, HPMC E5, HPMC E15 
and HPMC E50) were used to investigate drug-polymer interactions. Soluplus, low 
molecular weight PVP K17, and HPMC E3 resulted in the best interactions with ABT-102, 
compared to the other polymers. Amongst these three polymers, soluplus showed the 
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strongest interaction due to the presence of two carbonyl groups on soluplus which were 
able to interact with the three N-H groups of ABT-102. PVP K17 showed the second best 
interaction with the N-H groups of ABT-102, due to its low viscosity and single C=O 
stretching, followed by HPMC E3, which interacted with the drug through multiple O-H 
stretching. It is important to characterize solid dispersions using a combination of solid state 
tools including; DSC, FTIR and PXRD. These different analytical techniques provide 
diverse information on drug-polymer interactions. The melting point depression observed 
in the DSC thermograms, along with the change in the intensity or shift in the absorbance 
bands (FTIR) and the absence of crystalline diffraction peaks (PXRD) are suggestive of 
drug-polymer interactions. DSC and PXRD only provide information on the presence of 
strong/weak interactions, whereas the type of interactions (hydrogen bonding, hydrophobic 
interactions) are provided via the supportive FTIR results. Hence, a combination of these 
three methods is necessary to understand the level and type of interactions between the drug 
and the polymer in amorphous solid dispersions as described here. A mechanistic approach 
was utilized to understand the drug-polymer interactions. The interaction parameters and 
free energy of mixing obtained using the Flory Huggins principle and the melting point 
depression approach confirmed that the solid dispersions prepared via spray drying resulted 
in the strongest miscibility between ABT-102 and the polymers compared to the solvent 
evaporation and serial dilution method. The present research describes the detailed 
mechanisms involved in the interactions between the drug ABT-102 and polymeric 
stabilizers. This study will aid pre-formulation scientists in screening stabilizers for 
formulation development of similar solid dispersion formulations compared to the 
conventional trial and error methods.  
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2.6. Tables  
Table 2.1. Chemical structures of the active and excipients [28-30] 
 
Table 2.2. Average molecular weights and viscosities of the polymers [28, 29] 
Polymers Average Molecular weight (Dalton) Viscosity (mPa.s) 
PVP K-17 9200 1.5-3.5 
PVP K-25 26000 3.5-5.5 
PVP K-30 42000 5.5-8.5 
PVP K-90 1100000 300-700 
HPMC E3 18000 2.4-3.6 
HPMC E5 22000 4-6 
HPMC E15 52000 12-18 
HPMC E50 91300 40-60 
Soluplus 118000 125 
 
 
Polyvinyl pyrrolidone 
K17, K25, K30 and 
K90 
(Kollidon) 
 
Hydroxypropyl methyl 
cellulose 
E3, E5, E15 and E50 
(Methocel) 
 
Polyvinyl 
caprolactam-polyvinyl 
acetate-polyethylene 
glycol graft copolymer 
(Soluplus) 
 
 
ABT-102 
(drug) 
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Table 2.3. Characteristic FTIR absorbance bands 
 Characteristic FTIR absorbance bands (cm-1) Ref 
ABT-102 3300 (N-H stretch), 3000-2800 (C-H aliphatic stretch), 1625-
1575 (C-C stretch aromatic), 900-650 (C-H aromatic out of 
plane bend) 
[39] 
PVP 3469 (O-H stretching), 1698 (C=O stretching-pyrrolidone 
group), 2987 (C-H asymmetric stretching-CH2), 1427 (C-H 
bending), 1260 (C-N stretching), 931 (C-C stretching) 
[40] 
Soluplus 3448.72 (O-H stretching), 2927.98 (aromatic C-H stretching), 
1735.93 -OC(O)CH3 or ester group, 1635.23-C(O)N or amide 
group (C=O stretching), 1477.21 (C-O-C stretching) 
[41] 
HPMC 3500-3400 (intermolecular H-bonding), 2550-2500 
(intramolecular H-bonding) (O-H stretching), 2900 (C-H 
symmetric stretching), 1650-1600 (C-O stretching – 6 
membered cyclic ring), 1500-1450 (asymmetric bending – 
OCH3), 1400-1350 (symmetric bending – OCH3, C-O-C 
stretching – cyclic anhydride), 1300-1250 (C-O-C stretching – 
cyclic epoxide), 1100-1000 (ethereal C-O-C stretching), 1000-
950 (asymmetrical stretching – pyranose), 850-800 (rocking 
CH2) 
[42] 
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2.7. Figures 
GRAPHICAL ABSTRACT: 
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Figure 2.1: Comparison of melting temperature vs. PVPs:drug ratio (four grades of PVP). 
Samples were prepared using three different methods: (a) spray drying, (b) solvent 
evaporation and (c) physical mixture. 
Figure 2.2: Comparison of melting temperature vs. HPMCs:drug ratio (four grades of 
HPMC). Samples were prepared using three different methods; (a) spray drying, (b) 
solvent evaporation and (c) physical mixture. 
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Figure 2.3: Comparison of melting temperature vs. soluplus:drug ratios. Samples were 
prepared using three different methods; (a) spray drying, (b) solvent evaporation and (c) 
physical mixture. 
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Figure 2.4: (a) interaction parameter; (b) free energy of mixing; and (c) interaction 
parameter vs. volume fraction of the nine different polymers along with the ABT-102 in the 
spray dried solid dispersions. 
 
 
Figure 2.5: (a) interaction parameter; (b) free energy of mixing; and (c) interaction 
parameter vs. volume fraction of nine different polymers with ABT-102 for samples 
prepared using solvent evaporation. 
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Figure 2.6: (a) interaction parameter; (b) free energy of mixing; and (c) interaction 
parameter vs. volume fraction of the nine different polymers with ABT-102 in samples 
prepared using serial dilution. 
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Figure 2.7: FTIR spectra of: (A) neat drug, neat PVP K17 and the 1:3, 1:1 and 3:1, w/w 
ratios of PVP K17:drug; (B) neat drug, neat PVP K25 and the 1:3, 1:1 and 3:1, w/w ratios 
of PVP K25:drug; (C) neat drug, neat PVP K30 and the 1:3, 1:1 and 3:1, w/w ratios of PVP 
K30:drug; and (D) neat drug, neat PVP K90 and the 1:3, 1:1 and 3:1, w/w ratios of PVP 
K90:drug. 
 
Figure 2.8: FTIR spectra showing; neat drug, neat soluplus and the 1:3, 1:1 and 3:1, w/w 
ratios of soluplus:drug. 
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Figure 2.9: FTIR spectra of: (A) neat drug, neat HPMC E3 and the 1:3, 1:1 and 3:1, w/w 
ratios of HPMC E3:drug; (B) neat drug, neat HPMC E5 and the 1:3, 1:1 and 3:1, w/w ratios 
of HPMC E5:drug; (C) neat drug, neat HPMC E15 and the 1:3, 1:1 and 3:1, w/w ratios of 
HPMC E15:drug; and (D) neat drug, neat HPMC E50 and the 1:3, 1:1 and 3:1, w/w ratios 
of HPMC E50:drug.  
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Figure 2.10: FTIR spectra of: (A) neat drug, neat PVP K17 and the 1:3, 1:1 and 3:1, w/w 
ratios of PVP K17:drug; (B) neat drug, neat PVP K25 and the 1:3, 1:1 and 3:1, w/w ratios 
of PVP K25:drug; (C) neat drug, neat PVP K30 and the 1:3, 1:1 and 3:1, w/w ratios of PVP 
K30:drug; and (D) neat drug, neat PVP K90 and the 1:3, 1:1 and 3:1, w/w ratios of PVP 
K90:drug. 
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Figure 2.11: FTIR spectra showing; neat drug, neat soluplus and the 1:3, 1:1 and 3:1, w/w 
ratios of soluplus:drug. 
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Figure 2.12: FTIR spectra of: (A) neat drug, neat HPMC E3 and the 1:3, 1:1 and 3:1, w/w 
ratios of HPMC E3:drug; (B) neat drug, neat HPMC E5 and the 1:3, 1:1 and 3:1, w/w ratios 
of HPMC E5:drug; (C) neat drug, neat HPMC E15 and the 1:3, 1:1 and 3:1, w/w ratios of 
HPMC E15:drug; and (D) neat drug, neat HPMC E50 and the 1:3, 1:1 and 3:1, w/w ratios 
of HPMC E50:drug. 
 
Figure 2.13: FTIR spectra of: (A) neat drug, neat PVP K17 and the 1:3, 1:1 and 3:1, w/w 
ratios of PVP K17:drug; (B) neat drug, neat PVP K25 and the 1:3, 1:1 and 3:1, w/w ratios 
of PVP K25:drug; (C) neat drug, neat PVP K30 and the 1:3, 1:1 and 3:1, w/w ratios of PVP 
K30:drug; and (D) neat drug, neat PVP K90 and the 1:3, 1:1 and 3:1, w/w ratios of PVP 
K90:drug. 
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Figure 2.14: FTIR spectra showing; neat drug, neat soluplus and the 1:3, 1:1 and 3:1, w/w 
ratios of soluplus:drug. 
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Figure 2.15: FTIR spectra of: (A) neat drug, neat HPMC E3 and the 1:3, 1:1 and 3:1, w/w 
ratios of HPMC E3:drug; (B)  neat drug, neat HPMC E5 and the 1:3, 1:1 and 3:1, w/w ratios 
of HPMC E5:drug; (C) neat drug, neat HPMC E15 and the 1:3, 1:1 and 3:1, w/w ratios of 
HPMC E15:drug; and (D) neat drug, neat HPMC E50 and the 1:3, 1:1 and 3:1, w/w ratios 
of HPMC E50:drug 
(A) PVP K17
(B) PVP K25
(C) PVP K30 
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(D) PVP K-90 
 
Figure 2.16: PXRD diffractograms showing: (A) PVP K17 (B) PVP K25 (C) PVP K30 and 
(D) PVP K90; neat amorphous drug (black), neat polymer (orange), drug:polymer mixtures 
1:3 (purple), 1:1 (yellow) and 3:1 (blue), w/w and neat crystalline drug (green), 
(formulations are prepared using three different methods: (1) physical mixtures by serial 
dilution; (2) solvent evaporation; and (3) spray drying). 
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Figure 2.17: PXRD diffractograms showing: neat amorphous drug (black), neat soluplus 
(orange), drug:polymer mixtures 1:3 (purple), 1:1 (yellow) and 3:1 (blue), w/w and neat 
crystalline drug (green), (formulations were prepared using three different methods: (1) 
physical mixtures by serial dilution; (2) solvent evaporation; and (3) spray drying). 
(A) HPMC E3 
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(B) HPMC E5 
(C) HPMC E15 
(D) HPMC E50 
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Figure 2.18: PXRD diffractograms showing: (A) HPMC E3 (B) HPMC E5 (C) HPMC E15 
(D) HPMC E50; neat amorphous drug (black), neat polymer (orange), drug:polymer 
mixtures 1:3 (purple), 1:1 (yellow) and 3:1 (blue), w/w and neat crystalline drug (green), 
(formulations were prepared using three different methods: (1) physical mixtures by serial 
dilution; (2) solvent evaporation; and (3) spray drying).  
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Chapter 3 
Formulation Design and Evaluation of Amorphous ABT-102 Nanoparticles 
ABSTRACT  
Amorphous nanoparticles are able to enhance the kinetic solubility and concomitant 
dissolution rates of BCS class II and BCS class II/IV molecules due to their characteristic 
increased supersaturation levels, smaller particle size and greater surface area. A DoE 
approach was applied to investigate formulation and spray drying process parameters for 
the preparation of spray dried amorphous ABT-102 nanoparticles. Stability studies were 
performed on the optimized formulations to monitor physical and chemical changes under 
different temperature and humidity conditions. SLS/soluplus and SLS/PVP K25 were the 
best stabilizer combinations. Trehalose was used to prevent nanoparticle aggregation during 
spray drying. Particle size distribution, moisture content, PXRD, PLM, FTIR and in vitro 
dissolution were utilized to characterize the spray dried nanoparticle formulations. The 
formulations prepared using soluplus showed enhanced dissolution rate compared to those 
prepared using PVP K25. Following three months storage, it was observed that the 
formulations stored at 4°C were stable in terms of particle size distribution, moisture 
content, and crystallinity, whereas those stored at 25°C/60%RH and 40°C/75%RH were 
unstable. A predictive model to prepare stable solid spray dried amorphous ABT-102 
nanoparticles, incorporating both formulation and process parameters, was successfully 
developed using multiple linear regression analysis.  
3.1. INTRODUCTION 
There has been a tremendous revolution in the field of nanotechnology, resulting in nano-
medicines for diagnosis and therapy [1]. One application of nano-medicines is to improve 
drug dissolution and bioavailability. Such systems are of importance since most of the recent 
drug molecules coming out of the drug discovery pipeline are water insoluble and may pose 
bioavailability challenges[2]. Drug nanoparticles (amorphous and crystalline) are one of the 
novel nano-medicine tools to resolve the issues of solubility and bioavailability, associated 
with brick-like BCS class II and II/IV molecules [3]. Two basic methods to manufacture 
such nanoparticles: (i) a “top-down approach” (i.e. milling/grinding of the particles to 
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achieve the required size) and (ii) a “bottom-up approach” (i.e. precipitation of solubilized 
drug by adding an anti-solvent system) are commonly utilized [4]. The top-down approach 
is very time consuming and usually leads to crystalline particles whereas the bottom-up 
approach is less time consuming and usually leads to amorphous particles due to fast solvent 
evaporation and thus precipitation of the API as amorphous particles [5].   
Amorphous drug nanoparticles are sub-micron colloidal dispersions of discrete drug 
particles, stabilized with polymers, surfactants or a mixture of both polymers and surfactant 
[6-8]. Amorphous nanoparticles through their combined mechanisms of enhancing  
dissolution rates (due to nano-size range and amorphous solid state form) and increasing 
supersaturation levels (due to amorphous solid state form) can significantly enhance 
solubility and bioavailability of poorly water-soluble active pharmaceutical ingredients 
(APIs) [BCS class II and II/IV] [9-15]. Amorphous nanoparticles of itraconazole have been 
shown to have improved dissolution and enhanced bioavailability compared to crystalline 
nanoparticles and amorphous macroparticles. For example, Kumar et. al. have reported that 
nano-amorphous itraconazole resulted in a 2.5-fold and 18-fold  increase in bioavailability 
compared to macro-amorphous (melt quench)  and macro-crystalline formulations 
respectively [16]. Similarly in another study, Dhumal et. al. showed that nano-amorphous 
cefuroxime resulted in a 2-fold increase in bioavailability compared to a macro-crystalline 
formulation [17]. However, until now, only a few nano-crystalline products have been 
successfully marketed for improved drug bioavailability [18]. Additionally, the technology 
to manufacture amorphous nanoparticles has been limited to only the nutraceutical and 
cosmetic industries [19]. Accordingly, it is important to optimize formulation and process 
parameters to achieve stable amorphous nanoparticles with desired properties of enhanced 
dissolution and bioavailability.  
In the current study, we have prepared stable spray dried amorphous nanoparticles of ABT-
102 (log P-5.2, aqueous solubility ~ 0.05 µg/mL in buffer [20]), a hydrophobic BCS class 
II molecule. A DoE approach was applied to investigate the spray drying process and 
formulation parameters. A three month stability study (40C/75%RH, 25C/60%RH and 
4C) was conducted to monitor the stability of the amorphous nanoparticles in terms of 
particle size distribution, in vitro dissolution and crystallinity. Based on the DoE approach 
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and stability studies, a predictive model to prepare stable solid spray dried ABT-102 
amorphous nanoparticles, incorporating both formulation and process parameters, was 
successfully developed using multiple linear regression analysis.  
3.2. MATERIALS  
Crystalline ABT-102 (greater than 99% purity) was provided by AbbVie Pte. Ltd., 
Singapore. Soluplus, PVP K-25 (polyvinyl pyrrolidone Kollidon®-25) and HPMC 
(hydroxy propyl methyl cellulose) were gifted by Dow Chemical Company. Sodium lauryl 
sulfate was purchased from Sigma Aldrich. Trehalose was gifted by Gattefose. The 
chemical structures are shown in Table 3.1. HPLC (high pressure liquid chromatography) 
grade solvents were purchased from Fisher Scientific. Inspire C18 column (4.6 mm x 100 
mm, 5μm) was gifted by Dikma Technologies Inc.  
3.3. METHODS 
3.3.1. Sonoprecipitation of ABT-102 
Amorphous nanoparticles were prepared using the sonoprecipitation approach. Briefly, 400 
mg of the ABT-102 was completely dissolved in a 25 mL of methanol (16 mg/mL). Drug 
solution in methanol was injected (using a syringe with a 22.1G needle) into an aqueous 
phase (275 mL) containing stabilizers (soluplus+SLS and PVP K-25+SLS) at a rate of 10 
mL/min under probe sonication. A sonic dismembrator (Fisher scientific model 550) using 
a probe tip diameter of 13 mm at a frequency of 20 KHz was used. The probe tip was 
immersed a distance of 5 mm into the antisolvent solution and sonication was carried out 
for the optimized time of 4 minutes. The entire process was conducted at 2-8°C to prevent 
any drug degradation due to thermal stress. The resultant nanosuspensions were kept under 
magnetic stirring until further use. 
3.3.2 Design of Experiments 
Two different polymers (soluplus and PVP K-25) in combination with SLS were evaluated 
for stabilization of the ABT-102 amorphous nanoparticles, based on results of screening 
studies for different stabilizers and the preliminary probe sonication studies. Two different 
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DoE design templates were drawn and studied for optimization of the formulation and spray 
drying process parameters. 
3.3.2.1 Formulation parameters  
Optimization of different formulation parameters [e.g. concentration of polymer (soluplus 
and PVP K-25), surfactant (SLS) and sugar (trehalose)] for the preparation of amorphous 
ABT-102 nanoparticles was performed using a central composite design. Three critical 
factors that may affect the preparation of spray-dried formulations were selected 
(concentration of polymer, concentration of surfactant and amount of sugar). Six different 
responses were monitored namely: particle size, PDI, drug loading, yield of spray-dried 
powder, moisture content and zeta potential. The data obtained were evaluated using Design 
Expert statistical software version 9 (Stat-ease, Minneapolis, USA). For the polymer 
concentration, the minimum and maximum levels (concentrations) were 0.3 %w/v and 0.7 
%w/v, respectively with 0.5 %w/v as the center point and 0.16 %w/v and 0.84 %w/v were 
the star or alpha points. For the surfactant concentration, the minimum and maximum levels 
(concentrations) were 0.03 %w/v and 0.07 %w/v, respectively with 0.05 %w/v as the center 
point and 0.016 %w/v and 0.084 %w/v were the star or alpha points. For the amount of 
sugar, the minimum and maximum levels were 600 mg and 1000 mg, respectively with 800 
mg as the center point and 464 mg and 1136 mg were the star or alpha points. The critical 
quality attributes were total yield and particle size distribution of the spray dried product. A 
DoE for formulation parameters was carried out using soluplus soluplus (table 3.2) and 
PVP K-25 (table 3.3) as the stabilizers. A total of 20 spray drying experiments post 
sonoprecipitation were performed.  
3.3.2.2 Spray drying process parameters  
Optimization of different spray-drying process parameters (e.g. temperature, aspirator 
setting, and feed rate) for the preparation of amorphous ABT-102 nanoparticles was 
performed using a central composite design. Three critical factors that may affect the 
preparation of spray-dried formulations were selected, namely the inlet temperature, 
aspirator rate and feed flow rate. Six different responses were monitored: outlet temperature 
(temperature at the connection between the spray drying chamber and cyclone); drug 
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loading; yield of spray-dried powder; particle size; PDI; and moisture content. The data 
obtained was evaluated using Design Expert statistical software version 9 (Stat-ease, 
Minneapolis, USA). For the inlet temperature, the minimum and maximum levels 
(temperatures) were 95C and 130C, respectively with 110C as the center point and 83C 
and 142C were the star or alpha points. For the aspirator rate, the minimum and maximum 
levels (rate of dry air flow) were 55% and 75%, respectively with 65% as the center point 
and 48% and 82% were the star or alpha points. For the feed flow rate, the minimum and 
maximum levels (rate of feed flow) were 15% and 25%, respectively with 20% as the center 
point and 12% and 28% were the star or alpha points. The critical quality attributes were 
total yield and particle size distribution of the spray dried product. A DoE for the spray 
drying process parameters was carried out using soluplus as the stabilizer (Table 3.4). A 
total of 20 spray drying experiments post sonoprecipitation were performed. 
Based on the above DoE studies, for the spray drying process and formulation parameters, 
optimized formulations (n=3) were prepared and stored at three different storage conditions 
(4C, 25C/60%RH and 40C/75%RH) for stability testing of the amorphous ABT-102 
nanoparticles for 1 and 3 month/s. 
3.3.3 Spray drying  
The liquid ABT-102 nanosuspensions were converted to solid ABT-102 amorphous 
nanoparticles using a Buchi B-290 spray dryer (Buchi Labortechhnik AG, Switzerland). 
The spray drier was equilibrated using distilled water at the following conditions (inlet 
temperature 110°C, feed rate 5 ml/min and aspiration rate -30 mbar). The outlet temperature 
was approximately 75°C. The inlet temperature of 110°C was selected based on a proof of 
concept study to ensure maximum dry gas for the efficient removal of solvent at high 
evaporation rates without affecting the nanoparticle integrity, therefore minimizing the 
moisture content in the final product. Upon equilibration of the spray dryer, the distilled 
water was replaced with nanosuspension formulation. In order to prevent nanoparticles from 
aggregating, drug:trehalose (1:2, w/w) was added to each formulation before spray drying. 
The final products, in the form of spray-dried powders, were collected from the collection 
chamber and immediately analyzed for particle size and crystallinity. 
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3.3.4. Particle size measurement 
Particle size measurements were performed using a Zetasizer Nano ZS90 (Malvern 
Instruments, UK). Briefly, the liquid or spray-dried samples were suspended in a saturated 
and filtered (0.2 μm PVDF membrane filter) solution of ABT-102 in 30% glycerin solution 
to avoid any discrepancy resulting from dissolution of the nano-particles during 
measurement. The viscosity of this dispersant solution was measured via a Brookfield 
viscometer (Model DV-III) and used to calculate the particle size of the re-dispersed and 
liquid nano-crystalline suspensions. All samples were analyzed in triplicate. 
3.3.5. Powder X-Ray Diffraction (PXRD) 
PXRD was utilized to determine the crystallinity of the spray-dried samples. X-ray 
diffraction patterns were obtained using an X-ray diffractometer (Model D5005, Bruker 
AXS Inc., Madison, WI) with Cu-kα radiation, a voltage of 40 kV, and a current of 40 mA. 
All the scans were performed with a scanning rate of 2°/minute with steps of 0.02° from 5° 
to 40° at 2θ ranges.  
3.3.6. HPLC analytical method 
The quantification of ABT-102 was conducted using a Perkin Elmer-HPLC system (USA) 
with a UV detector. The absorbance wavelength was set at 267 nm. The mobile phase was 
a mixture of 0.1% trifluoro acetic acid in water and acetonitrile at a isocratic 50:50 %v/v 
ratio. A C18 Inspire 5μ analytical column (4.6 mm × 100 mm) was used with a flow rate of 
1 ml/min.  
3.3.7 Transmission electron microscopy (TEM) 
The morphology of the amorphous ABT-102 nanoparticles were observed using TEM. TEM 
images were obtained using FEI Tecnai G2 Spirit BioTWIN Lab6 20-120 kV TEM, with a 
4 megapixel AMT 2k XR40 CCD camera (Oregon, USA). The samples were negatively 
stained using Uranyl acetate. One drop of the sample was transferred onto a copper TEM 
grid and dried under vacuum. The samples on the TEM grid were analyzed at 80 kV.  
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3.3.8 Attenuated Total Reflectance - Fourier Transform Infrared Spectroscopy (ATR-
FTIR) 
IR spectroscopy was performed using a Nicolet FTIR (iS5 FTIR, Thermo Scientific, USA) 
spectrometer with an attenuated total reflectance (ATR) accessory. Spray-dried powders 
were placed on the crystal window (Germanium) and compressed lightly using a pressure 
clamp. Spectra were recorded over a range of 400–4000 cm−1 with a resolution of 4 cm−1, 
for 128 parallel scans. Data analysis was performed on Omnic® 6.0a software (Thermo 
Nicolet Corporation, USA). 
3.3.9 Polarized Light Microscopy (PLM) 
The spray-dried samples were dispersed in the immersion oil and placed on microscope 
slides. The samples were analyzed using an Olympus BH2 polarized microscope, USA with 
a Q-imaging camera, accessories and software. All the pictures were obtained at 10X 
resolution. 
3.3.10. Stability 
All the spray-dried powder formulations were stored at three different storage conditions 
i.e. 4°C, 25°C/60%RH and 40°C/75%RH for 3 months. Samples were withdrawn at 1 and 
3 month/s and analyzed for particle size distribution, zeta potential, moisture content and 
crystallinity.  
3.3.11. In vitro dissolution testing 
USP apparatus I (basket apparatus) (Distek Inc. 2100C, NJ, USA) was utilized for the in 
vitro dissolution experiments. In the case of spray-dried powders, the samples were filled 
into hard gelatin capsules (size 000, Torpac) for in vitro dissolution studies. All the 
dissolution experiments were conducted at 37°C in 900 ml (sink conditions and non-sink 
conditions) of 0.1 N HCl and 0.025 %w/w Tween 80 (pH 1.2) at a speed of 100 rpm. At 
each time point, 2 ml samples were withdrawn from the dissolution chamber and replaced 
with fresh dissolution media. The samples were filtered using 0.1 μm PVDF filters to avoid 
any erroneous results from un-dissolved nano-particulates. All samples were analyzed using 
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the HPLC method as described above. The samples were analyzed initially and after storing 
for one month storage at three different conditions 4C, 25C/60%RH and 40C/75%RH.  
3.4. RESULTS & DISCUSSION 
3.4.1. Selection of stabilizer/s 
3.4.1.1 Selection of polymers and surfactants 
Different polymers and surfactants were screened for the preparation of spray dried 
amorphous ABT-102 nanoparticles. The polymers investigated were PVP 40, PVP K-15/17, 
PVP K-25, PVP K-30, PVP K-90, HPMC E3, HPMC E5, HPMC E15, HPMC E50 and 
soluplus. The surfactants investigated were Dowfax2A1, SLS, Triton X and Pluronic 
F127. None of the above polymers and surfactants were able to stabilize the amorphous 
nanoparticles, both before and after spray drying, when used individually. The instabilities 
observed were both particle aggregation and change from the amorphous to the crystalline 
state. However, combinations of polymers and surfactants were able to stabilize the 
amorphous ABT-102 nanoparticles. Based on a preliminary study, PVP K-25 or soluplus 
in combination with SLS were the best combinations of stabilizers (data not shown). 
Accordingly, these combinations were selected for the DoE study. The concentration ranges 
for the design study (0.3 – 0.7 %w/v for PVP K-25/soluplus and 0.03 – 0.07 %w/v for 
SLS) were also based on the preliminary stabilization data. 
3.4.1.2 Selection of solvents 
The solubility of ABT-102 in different solvents (chloroform, hexane, PEG 400, tetra butyl 
methyl ether, ethyl ether, acetone, acetic acid, dichloromethane, methanol and acetonitrile) 
was investigated at room temperature. ABT-102 was insoluble in chloroform, hexane, PEG 
400, tetra butyl methyl ether, ethyl ether, acetone, and acetic acid. The solubility of ABT-
102 in dichloromethane and acetonitrile was below 1 mg/mL and that in methanol and 
ethanol it was around 16 mg/mL (data not shown). However, the yield of the spray dried 
powder when using ethanol as the solvent was significantly lower (10 %w/w) compared to 
that when using methanol (70 %w/w) as the solvent. Ethanol increases the hygroscopicity 
and therefore caused sticking of the nanoparticles to the walls of the spray dryer chamber. 
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Accordingly, methanol was selected as the solvent for the preparation of the amorphous 
nanoparticles.  
3.4.1.3 Selection of sugars 
Five different sugar molecules namely: mannitol, sucrose, lactose, trehalose and maltose 
were screened. For the selection of sugars, one polymer must be selected, which stabilizes 
the spray dried formulation. It has been previously reported that both PVP and HPMC are 
crystallization inhibitors and have been used for the preparation of amorphous solid 
dispersions [21]. In particular, PVP K-25 is a well-known crystallization inhibitor [22]. 
Accordingly, the PVP K-25/SLS stabilizer combination was used in the sugar screening 
study.  As shown in Table 3, formulations containing higher concentrations of PVP K-25 
(0.5%, w/v) appeared to be more stable before and after spray drying, compared to 
formulations containing lower concentrations of PVP K-25 (0.05%, w/v). Only trehalose 
and lactose were able to prevent nanoparticle aggregation during the spray drying process. 
Due to its high Tg (106°C), trehalose was selected for further investigation. The high Tg of 
trehalose, indicates less hygroscopicity as well as the absence of internal hydrogen bonding 
[23]. Accordingly, trehalose should be able to readily hydrogen bond with the nanoparticles 
during the spray drying process.  In addition, these hydrogen bonds will facilitate removal 
of trehalose from nanoparticle surfaces when exposed to aqueous environment in vivo and 
during drug dissolution testing in vitro [24].  
3.4.2. Design of Experiments  
According to the results from the spray drying process DoE studies,  as shown in Table 3.2, 
it was determined that certain responses (i.e. moisture content and drug loading) were not 
significantly affected by the spray drying process parameters investigated. However, other 
responses such as outlet temperature, yield, particle size and homogeneity of the spray-dried 
amorphous nanoparticles were significantly affected by the spray drying process 
parameters. Moreover, according to the results from the formulation DoE studies as shown 
in the Table 3.3, it was determined that certain responses (i.e. zeta potential and drug 
loading) were not significantly affected by the formulation parameters investigated. 
However, other responses (i.e. particle size, PDI, yield, and moisture content) were 
significantly affected by the formulation parameters investigated.  
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3.4.2.1 Optimization of formulation parameters of spray dried amorphous ABT-102 
nanoparticles using soluplus 
1) Particle size 
As observed from Table 3.5, it was evident that the surface cubic model was significant 
indicating that the model obtained (Table 3.6) was significant for the response (i.e. particle 
size of the spray-dried powder). The final equation, based on the three factors and the 
interaction terms for the prediction of the particle size of the spray-dried powder, is shown 
in Table 3.6. According to the contour plots (Figures 3.1(a) and 3.1(b)), it was observed that 
high polymer concentration and high amounts of sugar can prevent particle aggregation 
during the drying process, thus the particle size did not increase. However, the surfactant 
concentration had minimal effect on the particle size. The particle size was smaller (<200 
nm) when the polymer concentration was >0.55% and the sugar amount was >800 mg.  
2) Yield of the spray-dried powder 
As observed from the Table 3.7, it was evident that the surface cubic model was significant 
indicating that the model (Table 3.8) was significant for the response (i.e. the yield of the 
spray-dried powder). The final equation, based on the three factors and the interaction terms 
for the prediction of the yield of the spray-dried powder, is shown in Table 3.8. According 
to the contour plots (Figure 3.2(a)), it was observed that the yield of the spray-dried powder 
increased with increase in the polymer and surfactant concentrations. Furthermore, it was 
observed that the yield of the spray-dried powder decreased with increase in the amount of 
sugar (Figure 3.2(b)). This may be due to the sticky nature of sugar in the presence of 
residual moisture resulting in more particle adhesion to the walls of the cyclone separator. 
As shown in Tables 3.7 and 3.8, as well as Figure 3.2, the yield was >70% when the polymer 
concentration was >0.5% and the surfactant concentration was >0.048%. However, the 
amount of sugar used had a significant effect on the yield of the spray-dried formulations. 
Based on the DoE study for optimizing the formulation parameters, the statistical software 
recommended the optimized formulation parameters as shown in Table 3.15.  
3.4.2.2 Optimization of formulation parameters of spray dried amorphous ABT-102 
nanoparticles using PVP K25 
1) Particle size 
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As observed from Table 3.9, it was evident that the surface cubic model was significant 
indicating that the model obtained (Table 3.10) was significant for the response (i.e. particle 
size of the spray-dried powder). The final equation, based on the three factors and the 
interaction terms for the prediction of the particle size of the spray-dried powder, is shown 
in Table 3.10. According to the contour plots (Figures 3.3), it was observed that the particle 
size of the spray-dried powder decreased with increase in the polymer concentration and the 
amount of sugar. However, the surfactant concentration had a minimal effect on the particle 
size. Increased polymer concentration and sugar amount can prevent particle aggregation 
during the drying process, thus the particle size did not increase. The particle size was 
smaller (<170 nm) when the polymer concentration was >0.5% and the sugar amount was 
>750 mg.  
2) Yield of the spray-dried powder 
As observed from the Table 3.11, it was evident that the surface cubic model was significant 
indicating that the model (Table 3.12) was significant for the response (i.e. the yield of the 
spray-dried powder). The final equation, based on the three factors and the interaction terms 
for the prediction of the yield of the spray-dried powder, is shown in Table 3.12. According 
to the contour plots (Figure 3.4(a)), it was observed that the yield of the spray-dried powder 
increased with increase in the polymer concentration, however the surfactant concentration 
had minimal effect on the yield of the spray dried powder. Furthermore, it was observed 
that the yield of the spray-dried powder decreased with increase in the amount of sugar 
(Figure 3.4(b)). This may be due to the sticky nature of sugar in the presence of the residual 
moisture resulting in more particle adhesion on the walls of the cyclone separator. As shown 
in Tables 3.11 and 3.12, as well as Figure 3.4, the yield was 80 % w/w when the polymer 
concentration and amount of sugar was >0.5% w/v and 800-900 mg respectively. However, 
the surfactant concentration had a minimum effect on the yield of the spray-dried 
formulations. Based on the DoE study for optimizing the formulation parameters, the 
statistical software recommended the optimized formulation parameters as shown in Table 
3.15. 
3.4.2.2 Optimization of spray drying process parameters 
1) Particle size  
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As shown in Table 3.13, it was evident that the surface cubic model was significant 
indicating that the model was significant for the responses (i.e. particle size of the spray-
dried powder). The final equation based on the three factors and the interaction terms for 
the prediction of the particle size of the spray dried powder is given in Table 3.14. As shown 
in Figure 3.5(a), the particle size of the spray-dried powder decreased with increase in the 
inlet temperature. However, the effect of aspirator rate on the particle size was minimal. 
Furthermore, it was observed that the particle size of the spray-dried powder decreased with 
decrease in the feed flow rate and increase in the inlet temperature (Figure 3.5(b)). Increased 
inlet temperature can increase the evaporation rate of the solvent from the nanosuspension 
droplets, which can reduce the particle size and consequently the homogeneity. In addition, 
a higher feed flow rate means that less liquid is evaporated from the nanoparticle surfaces, 
which in turn decreased the outlet temperature and both these factors resulted in particle 
aggregation. Based on the spray drying process parameter DoE, the particle aggregation was 
prevented when the inlet temperature and the aspirator rate were maintained above 115°C 
and 65%, respectively, while maintaining a low flow rate (<19%). Similarly total product 
yield was optimized for the spray drying process.  
Based on the spray drying process parameter DoE study, the statistical software 
recommended the optimized process parameters (Table 3.15). These optimized process 
parameters were implemented in the DoE study for optimizing the formulation parameters.  
3.4.3. Spray drying  
The ABT-102 nanosuspensions were spray dried as mentioned in the methods section using 
trehalose as an ancillary excipient. All DoE formulations (spray drying process parameters 
and formulation parameters) were evaluated for drug loading, total spray dried powder 
yield, particle size and zeta potential. The optimized spray drying process parameters (inlet 
temperature: 110°C, aspirator rate: 80 and feed flow rate: 20), were used to perform the DoE 
studies for the formulation parameters of the ABT-102 spray dried powder prepared using 
the stabilizer combinations (PVP K25+SLS and soluplus+SLS). The contour plots of the 
amorphous spray dried nanoparticles are shown in section 4.2. No polymorphic changes 
were observed for any of the DoE formulations as determined by PXRD (data not shown). 
Based on the formulation parameters DoE, a combination of 0.6% w/v soluplus, 0.05% 
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w/v SLS and ~ 860 mg of trehalose was selected for the amorphous ABT-102 nanoparticle 
formulation. Additionally, based on the formulation parameters DoE, a combination of 
0.3% w/v PVP K25, 0.07% w/v SLS and ~ 1000 mg of trehalose was selected for the 
amorphous ABT-102 nanoparticle formulation. 
3.4.4. Stability studies 
The optimized formulations prepared based on the parameters obtained from the 
formulation parameter DoE studies were stored at three different stability conditions; 4C, 
25C/60%RH and 40C/75%RH for one and three months. After one and three months, the 
formulations were analyzed for particle size distribution, moisture content and zeta 
potential. Additionally, the formulations were also analyzed using PXRD (to monitor any 
polymorphic transformation i.e. conversion of amorphous to crystalline form), ATR-FTIR 
(for interaction between drug and polymer), PLM (to monitor any generation of 
crystallinity) and in vitro dissolution testing (to observe the effect of temperature and 
humidity on drug release). 
3.4.4.1 Particle size distribution  
As shown in Table 3.16 (a and b) and  Figure 3.6, the particle size and PDI of the prepared 
spray-dried nanosuspensions increased following one and three month/s storage under 
40°C/75%RH conditions. On the other hand, the optimized formulation stored at 4°C and 
25°C/75%RH were determined to be stable in terms of particle size distribution and zeta 
potential over the three month study period. 
3.4.4.2 Moisture content 
As observed in Figure 3.7, the moisture content increased for the formulations stored at 
40°C/75%RH compared to those stored at 4°C and 25°C/60%RH. The formulations stored 
at 4°C and 25°C/60%RH were determined to be stable even after 3 months. It was also 
observed that the moisture content for the optimized formulation prepared using PVP K25 
was higher compared to those prepared using soluplus for all storage conditions, except at 
4C. The higher moisture content of the optimized formulation prepared using PVP K25 
can be attributed to the low viscosity (hydrophilic nature) of PVP K25, which results in 
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water entrapment into the formulations.  This can be compared to the high viscosity 
(combined hydrophilic and lipophilic nature) of soluplus, which limits water entrapment. 
3.4.4.3 Powder X-ray diffraction 
The characteristic diffraction peaks of neat crystalline ABT-102 are 6.3, 9.2, 12, 14.7, 
16.3, 18.2, 19.9, 22.8, 24.9 and 26.8. As shown in Figure 3.8 (a and b), the optimized 
formulation prepared using soluplus and PVP K25 showed a distinct halo pattern in PXRD 
after one and three month/s exposure at 4°C, 25°C/60%RH and 40°C/75%RH, indicating 
the amorphous nature of the formulations. However, the physical mixture containing the 
drug and polymer (soluplus or PVP K25) resulted in distinct diffraction peaks, indicating 
the crystalline nature of the drug. 
3.4.4.4 Attenuated total reflectance – Fourier transform infrared spectroscopy 
According to Figure 3.9 (a and b), there was a band broadening between 3000-3500 cm-1 in 
the FTIR spectra for the spray-dried amorphous nanoparticles stored for one and three 
month/s under all conditions (i.e. 4C, 25C/60%RH, and 40C/75%RH).  However, there 
was no band broadening in the case of the crystalline raw drug and the physical mixture of 
the drug-polymer when stored under similar conditions.  It was hypothesized that there may 
be hydrogen bonding between the N-H moiety of ABT-102 and the C=O group of the 
polymer (i.e. soluplus or PVP K25). In case of the physical mixture of the drug and the 
polymer, a sharp peak was observed at 3380 cm-1, indicating the absence of hydrogen 
bonding in the physical mixture.  
3.4.4.5 Polarized light microscopy 
As observed in Figure 3.10, there was no birefringence observed for the optimized 
formulation stored at 25°C/60%RH and 4°C after three months. However, those stored at 
40°C/75%RH for three months showed extensive birefringence. The amorphous 
nanoparticles will absorb moisture under accelerated stress at 40°C/75%RH which in turn 
causes plasticization and consequent recrystallization. However, the PXRD diffractograms 
for the optimized formulations stored under all three stability conditions showed a halo 
pattern (Figure 3.10), indicating PXRD was not able to detect this phase transformation due 
to limitations in the sensitivity of this instrument (<= 5% of crystallinity). Additionally, it 
was observed that the optimized formulation prepared using soluplus crystallized after only 
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one month storage at 40°C/75%RH, indicating that PVP K25 is a better crystallization 
inhibitor for this drug.  
3.4.4.6 Transmission electron microscopy 
As observed in Figure 3.11, the TEM images of the spray dried amorphous ABT-102 
nanoparticles prepared using soluplus showed the presence of the hydrophilic PEG chains 
of soluplus extending from the particle surfaces. However, the TEM images of the spray 
dried amorphous ABT-102 nanoparticles prepared using PVP K25 did not show any tail 
like moieities on the exterior, instead the PVP appeared to be in a globular form on the 
surface of the drug particles.  
3.4.5. In vitro dissolution testing 
All the dissolution experiments were conducted as described in the methods section, under 
non sink conditions (20 times the sink condition). As observed from Figure 3.12, the spray 
dried amorphous ABT-102 nanoparticles prepared using soluplus showed a four times 
increase in drug solubility (8-9 µg/mL) and were able to maintain supersaturation levels for 
5 hours. The optimized formulations prepared using PVP K25 increased the drug solubility 
by three fold (6 µg/mL) and also maintained supersaturation levels for 5 hours after which 
the drug crystallized out.  
The mechanism behind the enhanced solubility of amorphous ABT-102 nanoparticles 
compared to the macro-crystalline dug could be attributed to the better dispersibility of drug 
nanoparticles in soluplus, due to the proper miscibility of the drug with the 
polycaprolactam moieties (hydrophobic region) of soluplus. When the amorphous 
nanoparticles are exposed to the aqueous dissolution media, the polyethylene glycol 
moieties (hydrophilic region) undergoes rapid hydration into the aqueous solution, 
ultimately leading to enhanced solubility of the dispersed amorphous ABT-102 
nanoparticles [25, 26]. The physical mixture of drug and polymer have slightly higher 
solubility compared to the macro-crystalline drug, due to the formation of a viscose gel of 
soluplus around drug particles, which results in low miscibility between drug and the 
polymer, and ultimately increases the solubility of the physical mixture compared to the 
macro-crystalline drug. Similarly, the enhanced wettability of the drug nanoparticles in PVP 
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K25, resulted in increased solubility of the amorphous ABT-102 nanoparticles compared to 
the macro-crystalline drug. Although, PVP K25 is a strong crystallization inhibitor, the 
polymer was not as good as stabilizer for the amorphous ABT-102 nanoparticles, resulting 
in crashing out of the drug (recrystallization) after five hours of in vitro dissolution.  
3.5. CONCLUSIONS 
A novel sonoprecipitation method (a combination of ultrasonication and solvent-antisolvent 
precipitation) followed by spray drying for the preparation of the stable amorphous ABT-
102 nanoparticles was developed. Based on the spray drying process and formulation DoE 
studies, two responses (particle size and total yield of spray dried amorphous ABT-102 
nanoparticles) were significant, while the other responses (moisture content and drug 
loading) were not significant. Two polymers, PVP K25 and soluplus were effective 
stabilizers for the preparation of the amorphous ABT-102 nanoparticles. FTIR data showed 
that the C=O moieities of these polymers interacted with the N-H moiety of the drug via 
hydrogen bonding to facilitate nanoparticle stabilization. Soluplus possesses two carbonyl 
groups and therefore is able to form stronger hydrogen bonds with the drug. In addition, the 
lipophilic PVC region of soluplus is able to interact with the drug, while the hydrophilic 
PEG region resulted in enhanced wettability of the amorphous nanoparticles, thus increasing 
the dissolution rate and maintaining higher supersaturation levels (four fold) compared to 
PVP K25 (three fold).  PLM was a better solid state characterization tool compared to PXRD 
for the analysis of the amorphous ABT-102 nanoparticles stability. The stability studies 
carried out in the present study indicated that the storage conditions for the amorphous ABT-
102 nanoparticles should be 4C for long term stability. This study shows that amorphous 
nanoparticles prepared using sonoprecipitation followed by spray drying have an enhanced 
dissolution rate and may enhance bioavailability compared to macro-crystalline drug. 
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3.6. Tables 
Table 3.1. Chemical structures of the active pharmaceutical ingredient and excipients 
Materials Chemical structures 
ABT-102 
 
Soluplus 
(polyvinyl caprolactam-polyvinyl 
acetate-polyethylene glycol graft 
copolymer) 
 
Polyvinyl pyrrolidone K25 (PVP K25 - 
Kollidon®) 
 
Sodium lauryl sulfate (SLS) 
 
Trehalose 
 
Table 3.2. Design space for the optimization of formulation parameters for the preparation 
of stable spray dried amorphous ABT-102 nanoparticles using soluplus (3 Factors x 6 
Responses). 
No. 
Factors Responses 
Polymer 
concentration 
Surfactant 
concentrat
ion 
Sugar 
Particle 
size 
PDI 
Drug 
loading 
Yield 
Moisture 
content 
Zeta 
potential 
% % mg 
nm - % % % mV 
- 0.3-0.7 0.03-0.07 
600-
1000 
1 0.7 0.07 1200 159.3 0.186 11.76 75.63 2.566 -55.2 
2 0.5 0.05 800 202.9 0.191 13.93 76.04 2.539 -61.6 
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3 0.5 0.05 800 194.6 0.187 13.91 71.09 2.256 -67.7 
4 0.3 0.07 400 273.5 0.326 12.24 63.35 2.074 -75.7 
5 0.5 0.05 800 190.7 0.172 13.95 70.81 2.279 -60.7 
6 0.7 0.03 1200 191 0.216 12.84 74.22 2.676 -48.8 
7 0.5 0.05 800 175.5 0.196 13.97 73.26 2.459 -57.5 
8 0.5 0.05 800 202.9 0.178 13.8 69.16 2.382 -63 
9 0.5 0.05 800 208.5 0.165 13.86 72.77 2.522 -59.6 
10 0.5 0.08 800 211.9 0.225 13.93 68.18 2.418 -68.5 
11 0.5 0.05 1473 202.5 0.136 13.75 69.15 3.093 -63.6 
12 0.3 0.07 1200 214.2 0.3 13.91 52.69 3.113 -87.4 
13 0.7 0.07 400 223 0.244 13.92 49.77 2.059 -71.7 
14 0.3 0.03 400 537.4 0.488 12.39 67.49 2.507 -62.5 
15 0.7 0.03 400 153.9 0.205 13.57 66.02 2.519 -39.9 
16 0.84 0.05 800 193.4 0.11 11.85 64.15 2.535 -69.7 
17 0.5 0.05 127 312.5 0.402 13.88 58.97 1.915 -69.2 
18 0.16 0.05 800 261.4 0.415 13.38 42.91 4.008 -85.2 
19 0.5 0.02 800 231.8 0.263 13.2 53.95 2.926 -61.8 
20 0.3 0.03 1200 78.57 0.208 13.91 32.63 3.69 -79.3 
Table 3.3. Design space for the optimization of formulation parameters for the preparation 
of stable spray dried amorphous ABT-102 nanoparticles using PVP K25 (3 Factors x 6 
Responses). 
No. 
Factors Responses 
Polymer 
concentration 
Surfactant 
concentration 
Sugar 
Particle 
size 
PDI 
Drug 
loading 
Yield 
Moisture 
content 
Zeta 
potential 
% % mg 
nm - % % % mV 
- 0.3-0.7 0.03-0.07 
600-
1000 
1 0.5 0.084 800 153.2 0.171 8.820 72.72 4.133 -72.6 
2 0.5 0.05 800 162.1 0.177 10.430 79.06 2.053 -85.9 
3 0.3 0.03 1000 161.8 0.168 11.730 81.86 2.801 -84.6 
4 0.5 0.05 800 166.2 0.131 10.490 75.88 2.108 -66.9 
5 0.5 0.05 800 162.6 0.183 10.670 80.12 4.663 -76.6 
6 0.84 0.05 800 179.8 0.163 7.710 78.95 4.698 -62.0 
7 0.5 0.05 800 165.0 0.142 9.840 74.24 4.289 -80.7 
8 0.16 0.05 800 185.1 0.266 13.660 84.32 2.284 -84.6 
9 0.5 0.05 800 159.4 0.155 10.660 76.73 3.408 -79.1 
10 0.5 0.05 464 165.2 0.146 12.200 68.79 4.451 -76.4 
11 0.5 0.016 800 170.5 0.112 10.750 78.80 3.634 -89.2 
12 0.3 0.03 600 172.7 0.194 13.960 62.33 3.497 -81.1 
13 0.7 0.03 600 179.7 0.228 8.750 81.90 4.604 -61.9 
14 0.7 0.03 1000 169.2 0.142 8.380 76.83 3.865 -76.9 
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Table 3.4. Design space for optimization of the spray drying process parameters for the 
preparation of stable ABT-102 amorphous spray dried nanoparticles (3 factors x 6 
responses). 
No. 
Factors Responses 
Inlet 
temperature 
Aspirator 
Feed 
flow 
Outlet 
temperature 
Drug 
loading 
Yield 
Particle 
size 
Moisture 
content 
PDI 
°C % % 
°C 
% 
(w/w) 
% 
(w/w) 
nm % (w/w) - 
- 95-130 55-75 15-25 
1 110 65 20 43 13.4 59.33 202.8 2.653 0.271 
2 95 75 25 32 13.67 49.82 234.1 2.383 0.271 
3 110 65 20 44 13.6 61.49 225.2 2.556 0.231 
4 125 75 15 65 13.12 67.19 211.3 2.101 0.242 
5 95 75 15 46 12.32 69.33 191 2.666 0.203 
6 110 65 28 33 13.59 37.3 383.9 2.691 0.543 
7 95 55 25 29 14.04 23.75 330.6 1.971 0.663 
8 110 82 20 56 13.95 74.6 198.6 2.684 0.247 
9 125 55 25 42 13.19 37.89 244.1 2.204 0.304 
10 125 55 15 56 13.03 50.39 186.8 2.277 0.162 
11 110 65 20 43 13.28 58.19 214.7 2.481 0.263 
12 110 48 20 39 13.08 37.19 213 2.385 0.185 
13 85 65 20 29 14.14 38.21 386 2.48 0.643 
14 110 65 20 42 13.67 58.48 228.7 2.617 0.278 
15 110 65 20 44 13.44 59.71 216.4 2.462 0.253 
16 95 55 15 29 14.2 47.72 213.8 2.587 0.234 
17 110 65 12 56 13.1 67.02 180.4 1.964 0.156 
18 110 65 20 44 13.38 59.21 209.4 2.519 0.224 
19 135 65 20 56 13.98 59.37 155.1 2.186 0.248 
20 125 75 25 50 12.98 59.82 228.8 1.975 0.218 
Table 3.5. ANOVA response table for particle size of the spray-dried powder. 
ANOVA for response surface cubic model (Aliased) 
Analysis of variance table [partial sum of squares - Type III]  
Sum of 
 
Mean F p-value 
 
Source Squares df Square Value Prob > F 
 
Model 1.472E+005 13 11326.73 70.20 < 0.0001 significant 
15 0.5 0.05 1136 150.9 0.205 8.940 64.85 3.693 -62.9 
16 0.7 0.07 600 169.8 0.191 8.950 66.25 4.914 -73.3 
17 0.3 0.07 1000 151.0 0.166 11.530 69.29 2.988 -90.3 
18 0.7 0.07 1000 156.8 0.122 8.290 87.19 4.43 -79.2 
19 0.5 0.05 800 169.8 0.170 9.730 78.57 3.615 -84.7 
20 0.3 0.07 600 183.0 0.248 13.16 78.71 3.125 -87.4 
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A-Polymer 2312.00 1 2312.00 14.33 0.0091 
 
B-Surfactant 198.01 1 198.01 1.23 0.3104 
 
C-Sugar 6050.00 1 6050.00 37.49 0.0009 
 
Lack of Fit 266.50 1 266.50 1.90 0.2267 not significant 
R-squared – 0.9935, Adjusted R-squared – 0.9793 
Table 3.6. Final equation to predict the response: particle size of the spray-dried powder. 
Final equation in terms of coded factors: 
Particle size = 
+196.14 
 
-20.22 * A 
-5.92 * B 
-32.70 * C 
+20.71 * AB 
+61.44 * AC 
+37.34 * BC 
+9.23 * A^2 
+7.26 * B^2 
+19.87 * C^2 
-62.54 * ABC 
-5.44 * A^2B 
-35.39 * A^2C 
-26.84 * AB^2 
A – concentration of polymer, B – concentration of 
surfactant, C – amount of sugar  
Table 3.7. ANOVA response table for total yield of the spray-dried powder. 
ANOVA for response surface cubic model (Aliased) 
Analysis of variance table [partial sum of squares - Type III]  
Sum of 
 
Mean F p-value 
 
Source Squares df Square Value Prob > F 
 
Model 2578.49 13 198.35 33.79 0.0002 significant 
A-Polymer 225.43 1 225.43 38.40 0.0008 
 
B-Surfactant 101.29 1 101.29 17.26 0.0060 
 
C-Sugar 51.80 1 51.80 8.82 0.0249 
 
Lack of Fit 6.62 1 6.62 1.16 0.3310 not significant 
R-squared – 0.9865, Adjusted R-squared – 0.9573 
Table 3.8. Final equation to predict the response: total yield of the spray-dried powder. 
Final equation in terms of coded factors: 
Yield = 
+72.14 
 
+6.31 * A 
+4.23 * B 
+3.03 * C 
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-3.85 * AB 
+9.95 * AC 
+5.23 * BC 
-6.29 * A^2 
-3.63 * B^2 
-2.57 * C^2 
-0.82 * ABC 
-4.10 * A^2B 
-4.46 * A^2C 
-0.13 * AB^2 
A – concentration of polymer, B – 
concentration of surfactant, C – amount of 
sugar  
Table 3.9. ANOVA response table for particle size of the spray-dried powder. 
ANOVA for response surface cubic model (Aliased) 
Analysis of variance table [partial sum of squares - Type III]  
Sum of 
 
Mean F p-value 
 
Source Squares df Square Value Prob > F 
 
Model 1851.57 13 142.43 12.96 0.0024 significant 
A-Polymer 13.87 1 13.87 1.26 0.3042 
 
B-Surfactant 150.80 1 150.80 13.72 0.0100 
 
C-Sugar 102.24 1 102.24 9.30 0.0225 
 
Lack of Fit 0.38 1 0.38 0.029 0.38 not significant 
R-squared – 0.9656, Adjusted R-squared – 0.8911 
Table 3.10. Final equation to predict the response: particle size of the spray-dried powder. 
Final equation in terms of coded factors: 
Particle size = 
+164.15 
 
-1.57 * A 
-5.16 * B 
-4.25 * C 
-2.73 * AB 
+2.41 * AC 
-2.94 * BC 
+6.53 * A^2 
-0.74 * B^2 
-2.09 * C^2 
+2.33 * ABC 
+2.32 * A^2B 
-4.05 * A^2C 
+2.45 * AB^2 
A – concentration of polymer, B – concentration of 
surfactant, C – amount of sugar  
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Table 3.11. ANOVA response table for total yield of the spray-dried powder. 
ANOVA for response surface cubic model (aliased) 
Analysis of variance table [partial sum of squares - Type III]  
Sum of 
 
Mean F p-value 
 
Source Squares df Square Value Prob > F 
 
Model 811.18 13 62.40 13.73 0.0021 significant 
A-Polymer 14.41 1 14.41 3.17 0.1252 
 
B-Surfactant 18.47 1 18.47 4.06 0.0904 
 
C-Sugar 7.76 1 7.76 1.71 0.2391 
 
Lack of Fit 3.01 1 3.01 0.62 0.4665 not significant 
R-squared – 0.9675, Adjusted R-squared – 0.8970 
Table 3.12. Final equation to predict the response: total yield of the spray-dried powder. 
Final equation in terms of coded factors: 
Yield = 
+77.40 
 
-1.60 * A 
-1.81 * B 
-1.17 * C 
-1.14 * AB 
+0.72 * AC 
-0.37 * BC 
+1.69 * A^2 
-0.39 * B^2 
-3.55 * C^2 
+6.87 * ABC 
+1.62 * A^2B 
+4.42 * A^2C 
+4.09 * AB^2 
A – concentration of polymer, B – 
concentration of surfactant, C – amount of 
sugar  
Table 3.13. ANOVA response table for particle size of the spray-dried powder. 
ANOVA for response surface cubic model (Aliased) 
Analysis of variance table [partial sum of squares - Type III]  
Sum of 
 
Mean F p-value 
 
Source Squares df Square Value Prob > 
F 
 
Model 1.477E-005 13 1.136E-006 25.55 0.0004 significant 
A-Inlet temperature 7.437E-006 1 7.437E-006 167.22 < 0.0001 
 
B-Aspirator 6.101E-011 1 6.101E-011 1.372E-003 0.9717 
 
C-Feed flow rate 2.751E-006 1 2.751E-006 61.85 0.0002 
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Lack of Fit 5.211E-008 1 5.211E-008 1.21 0.3209 not significant 
R-squared – 0.9823, Adjusted R-squared – 0.9438 
Table 3.14. Final equation to predict the response: particle size of the spray dried powder. 
Final equation in terms of coded factors: 
1/(Particle size ) = 
+4.629E-003 
 
+1.147E-003 * A 
+3.284E-006 * B 
-6.974E-004 * C 
-2.405E-004 * AB 
+1.532E-004 * AC 
+1.694E-004 * BC 
-1.335E-005 * A^2 
+5.075E-005 * B^2 
-2.755E-004 * C^2 
-2.703E-006 * ABC 
+2.075E-004 * A^2B 
+1.965E-004 * A^2C 
-1.007E-003 * AB^2 
A = Inlet temperature, B = Aspirator rate, C = Feed flow rate 
Table 3.15.  Statistically predicted factors and responses based on the DoE studies. 
DoE studies 
Inlet 
temperature 
(C) 
Aspirator 
rate (%) 
Feed 
flow 
rate 
(%) 
Outlet 
temperature 
(C) 
Yield 
(%) 
Particle 
size 
(nm) 
PDI Desirability 
Spray 
drying 
process 
parameters 
110 80 20 53.65 72.80 190.45 0.164 0.868 
Formulation 
parameters 
(using 
soluplus) 
Polymer 
concentration 
(% w/v) 
Surfactant 
concentration 
(% w/v) 
Amount 
of sugar 
(mg) 
Particle size 
(nm) 
PDI 
Drug 
loading 
(%) 
Yield 
(%) 
Moisture 
content 
(%) 
Zeta 
potential 
(mV) 
Desirability 
0.584 0.054 860 188.54 0.145 13.62 75.02 2.32 -61.16 0.86 
Formulation 
parameters 
(using PVP 
K25) 
0.3 0.069 1000 150.9 0.165 11.43 68.92 2.84 -84.6 0.823 
Table 3.16. Physicochemical properties of the optimized formulations prepared using: (a) 
soluplus; and (b) PVP K25. Following one and three month/s exposure under different 
storage conditions. 
(a) Nanoparticles prepared using soluplus 
No. 
Testing 
formulation 
Storage conditions 
Particle 
size 
(nm) 
PDI 
Moisture 
content 
(%) 
Zeta 
potential 
(mV) 
Predicted values 188.6 0.145 2.32 -61.2 
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Experimental values 
1 
Optimized 
spray dried 
nanoparticles 
prepared 
using 
soluplus 
Initial  189.3 0.197 1.81 -55.1 
2 
40°C/75%RH – 1 
month 
483.9 0.613 2.039 -67.8 
3 
25°C/60%RH – 1 
month 
196.8 0.177 2.225 -67.0 
4 4°C – 1 month 175.6 0.183 2.313 -66.4 
5 
40°C/75%RH – 3 
months 
386.2 0.319 4.712 -71.4 
6 
25°C/60%RH – 3 
months 
162.1 0.211 2.231 -65.4 
7 4°C – 3 months 186.5 0.222 2.197 -66.0 
 
(b) Nanoparticles prepared using PVP K-25 
No. 
Testing 
formulation 
Storage 
conditions 
Particle 
size 
(nm) 
PDI 
Moisture 
content 
(%) 
Zeta 
potential 
(mV) 
Predicted values 150.9 0.165 2.84 -84.6 
Experimental values 
1 
Optimized 
spray dried 
nanoparticles 
prepared 
using PVP 
K25 
Initial  148.9 0.15 2.27 -73.2 
4 
40°C/75%RH – 
1 month 
79.94 0.173 2.86 -58.3 
5 
25°C/60%RH – 
1 month 
148.4 0.127 2.33 -87.4 
6 4°C – 1 month 145.0 0.173 2.15 -84.9 
7 
40°C/75%RH – 
3 months 
307.2 0.489 4.42 -56.0 
8 
25°C/60%RH – 
3 months 
207.5 0.223 2.71 -76.3 
9 4°C – 3 months 152.8 0.15 2.20 -93.2 
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3.7. Figures 
GRAPHICAL ABSTRACT: 
 
 
Figure 3.1. Contour plots for response: particle size of the spray-dried powder. (a) The 
effect of polymer concentration and surfactant concentration on the particle size of the 
spray-dried powder. (b) The effect of polymer concentration and amount of sugar on the 
particle size of the spray-dried powder. (polymer – Soluplus, surfactant – SLS, sugar – 
trehalose) 
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Figure 3.2. Contour plots for response: the yield of the spray-dried powder. (a) The effect 
of polymer concentration and surfactant concentration on the yield of the spray-dried 
powder. (b) The effect of polymer concentration and amount of sugar on the yield of the 
spray-dried powder. (polymer – Soluplus, surfactant – SLS, sugar – trehalose) 
 
Figure 3.3. Contour plots for response: particle size of the spray-dried powder. (a) The 
effect of polymer concentration and surfactant concentration on the particle size of the 
spray-dried powder. (b) The effect of polymer concentration and amount of sugar on the 
particle size of the spray-dried powder. (polymer – PVP K25, surfactant – SLS, sugar – 
trehalose) 
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Figure 3.4. Contour plots for response: the yield of the spray-dried powder. (a) The effect 
of polymer concentration and surfactant concentration on the yield of the spray-dried 
powder. (b) The effect of polymer concentration and amount of sugar on the yield of the 
spray-dried powder. (polymer – PVP K25, surfactant – SLS, sugar – trehalose) 
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Figure 3.5. Contour plots for response: particle size of the spray-dried powder. (a) The 
effect of inlet temperature and aspirator rate on the particle size and total yield of the spray-
dried powder. (b) The effect of inlet temperature and feed flow rate on the particle size and 
total yield of the spray-dried powder. (polymer – Soluplus, surfactant – SLS, sugar – 
trehalose)
 
Figure 3.6. Particle size distribution of the optimized spray dried amorphous nanoparticle 
formulation prepared using soluplus and PVP K25 stored for 1 and 3 month/s at (a) 4°C 
(b) 25°C/60%RH (c) 40°C/75%RH compared with zero day formulations. 
 
Figure 3.7. Moisture content of the optimized spray dried amorphous nanoparticle 
formulation prepared using soluplus and PVP K25 stored for 1 and 3 month/s at (a) 4°C 
(b) 25°C/60%RH (c) 40°C/75%RH compared with the initial formulations. 
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Figure 3.8 (a). PXRD diffraction profiles of the ABT-102 std (raw crystalline drug), 
physical mixture (PM) of the drug and the polymer (soluplus) and the optimized 
formulation stored for 1 (1M) and 3 month/s (3M) at (a) 4°C (b) 25°C/60%RH and (c) 
40°C/75%RH 
 
Figure 3.8 (b). PXRD diffraction profiles of the ABT-102 std (raw crystalline drug), 
physical mixture (PM) of the drug and the polymer (PVP K25) and the optimized 
formulation stored for 1 (1M) and 3 month/s (3M) at (a) 4°C (b) 25°C/60%RH and (c) 
40°C/75%RH  
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Figure 3.9 (a). FTIR spectra of the ABT-102 neat (raw crystalline drug),  soluplus neat 
(polymer), physical mixture (PM) of the drug and the polymer (soluplus) and the optimized 
formulation stored for 1 month and 3 months at (a) 4°C (b) 25°C/60%RH and (c) 
40°C/75%RH. 
 
Figure 3.9 (b). FTIR spectra of the ABT-102 neat (raw crystalline drug),  PVP K25 neat 
(polymer), physical mixture (PM) of the drug and the polymer (PVP K25) and the optimized 
formulation stored for 1 month and 3 months at (a) 4°C (b) 25°C/60%RH and (c) 
40°C/75%RH. 
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Figure 3.10. PLM images of ABT-102 crystalline drug, ABT-102 amorphous drug, day 
zero optimized formulations prior to accelerated stability tests (initial), physical mixture of 
drug and polymer (PM), optimized formulations stored at 4°C, 25°C/60%RH and 
40°C/75%RH for one and three month/s (1M & 3M). 
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Figure 3.11. TEM images of the spray dried amorphous ABT-102 nanoparticles prepared 
using: (a) PVP K25 and (b) soluplus  
 
Figure 3.12. In vitro dissolution testing profiles (amount of drug release (ng/mL) vs. time 
(h)) of the ABT-102 crystalline drug, physical mixture of drug and polymer (PM), optimized 
spray-dried nanoparticle formulations prepared using: (a) soluplus and (b) PVP K25. The 
formulations were filled into hard gelatin capsules and stored under 4°C, 25°C/60%RH and 
40°C/75%RH for one month. 
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Chapter 4 
Comprehensive Quality by Design Approach for Stable Nanocrystalline Drug 
Products 
ABSTRACT  
The novelty of the present research is application of a comprehensive quality by design 
(QbD) approach to minimize errors in product optimization and validation for the 
development of a stable nanocrystalline zileuton (BCS class II drug) formulation. A QbD 
approach was used to identify, optimize and validate the critical processes parameters (wet 
media milling and spray drying) and critical formulation parameters (drug and excipient 
concentrations). The milling time, milling speed, inlet temperature, aspirator rate, feed flow 
rate and drug concentration had a significant influence on the particle size and total product 
yield of the nanocrystalline zileuton. Trehalose compared to mannitol was determined to be 
a better stabilizer during spray drying processing. Stability studies revealed the following 
trend after 12 months: 4C (most stable) > 25C/60% RH > 40C/75% RH (least stable) for 
the optimized spray-dried nanocrystalline zileuton in terms of physicochemical attributes, 
crystallinity and in vitro dissolution testing. Based on the comprehensive QbD approach, 
stable spray-dried nanocrystalline zileuton was obtained with exceptionally high total 
product yield (~80% w/w) and small particle size (276.427.54 nm) with low PDI 
(0.1090.056 units). Drug release from the formulations followed a particle size dependent 
dissolution trend. Additionally, pH switch dissolution testing indicated that complete drug 
release from the nanoformulations was observed at intestinal pH (pH 6.8) within 1-2 h of 
the shift from the stomach pH (pH 1.2).  
4.1. INTRODUCTION 
The pharmaceutical world has undergone an unprecedented transformation in the last two 
decades in terms of novel strategies for drug product development [1-3]. Conventional drug 
product development involving high levels of resources (people, time, money and energy) 
is being replaced by cutting-edge and modern tools and technology that minimize the usage 
of resources and maximize the quality of the final drug product [4-8]. A QbD (quality by 
design) approach expedites product and process understanding and thereby can achieve high 
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quality and economical drug products [9-11]. QbD has replaced the traditional approach of 
“one factor/variable at a time” optimization of drug product development and 
manufacturing by screening and analyzing “multiple factors/variables at a time”. Thus 
providing a scientific understanding of the entire design space in the drug product 
development cycle [12-17].  
According to the International Conference on Harmonization (ICH) Q8 guideline 
(Pharmaceutical Development), QbD is defined as “a systematic approach to development 
that begins with predefined objectives and emphasizes on product and process 
understanding and process control, based on sound science and quality risk management” 
[18-21]. The important components of QbD include understanding and identification of the 
quality target product profile (QTPP) in order to define the precise design space for the 
identification of critical process parameters (CPPs), critical material attributes (CMAs), 
critical formulation parameters (CFPs), critical quality attributes (CQAs) and sources of 
variability (Figure 4.1) [22, 23]. The concept of QbD has been applied to diverse drug 
products ranging from conventional (tablets, capsules, injections) [24-26] to novel drug 
delivery systems (nanoparticles, liposomes) [27-32].  
The majority of drug products are solid oral dosage forms due to their straightforward 
manufacturability, ease of administration and patient acceptability [33]. Oral nanoparticles 
are an important class of drug products which involve critical manufacturing processes and 
complex compositions [17]. Therefore, it is important to optimize the drug product 
constituents and manufacturing processes utilized in developing quality and robust nano-
oral drug products, which can be achieved via a comprehensive QbD approach. Crystalline 
nanoparticles have significant advantages over other nano-oral dosage forms one of which 
is the enhancement in the rate of dissolution/kinetic solubility and the concurrent 
improvement in oral bioavailability of poorly soluble drugs (BCS class II and II/IV) (Figure 
4.2) [29-31, 34-38]. Predominantly, drug nanocrystals are manufactured by two techniques: 
(1) top down approach (i.e. milling/grinding of the drug macrocrystals to microcrystals and 
further to nanocrystals) and; (2) bottom-up approach (solvent-antisolvent precipitation 
technique) [39, 40]. These techniques are followed by a suitable drying step (spray drying, 
freeze-drying, solvent evaporation, etc.) to develop a solid nanocrystalline drug product. 
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Drug nanocrystals are stabilized using functional excipients: polymers; surfactants; sugars; 
or a combination of these. Particle size reduction of macro-crystalline to nanocrystalline 
drug results in increase in the exposed surface area (or surface area-to-volume ratio), leading 
to increase in the drug dissolution rate/solubility and hence concomitant improvement in the 
oral bioavailability of poorly soluble drugs [41]. Enhanced dissolution rate/solubility and 
improved oral bioavailability unequivocally translates to tremendous improvement in the 
biopharmaceutical properties of nanocrystals: increased rate and extent of release and 
absorption; rapid onset of action; reduced side effects and improved clinical performance 
(Figure 4.3) [39, 41-44]. It is important to establish a correlation between different critical 
process parameters, critical formulation parameters and CQAs to develop a robust and 
quality nanocrystalline drug product. A comprehensive QbD helps in identifying and 
defining the critical vs. non-critical parameters (product and process) influencing drug 
product critical quality attributes.  
Until now, individual DoEs (process or formulation) have been reported for nano-crystalline 
formulations [27, 30, 45-50]. Beg et. al. optimized the self-nanoemulsifying drug delivery 
system of lovastatin using only formulation DoE with amounts of lipid, surfactant and co-
surfactant as the critical material attributes without focusing on any critical process 
parameters involved in the manufacturing of nanoemulsions of lovastatin SNEDDS, which 
can significantly influence the CQAs (globule size, lipid liquefaction time and 
emulsification time) [46].Ghosh et. al. investigated only critical process parameters 
involved in the naproxen nanosuspension formulation development via wet media milling 
without focusing on any critical formulation parameters (drug or polymer concentration) or 
other critical process parameters (drying techniques and related parameters) [48]. Baldinger 
et. al. and Kumar et. al. studied only the critical process parameters of the spray drying 
process (inlet temperature, aspirator rate and feed flow rate) for excipients (mannitol and 
trehalose) and nanocrystalline indomethacin, respectively. They investigated the influence 
of these critical process parameters on the CQAs such as particle size, total yield, particle 
morphology and crystallinity of the spray-dried powder. The pre-processing step involved 
in the investigation of other critical process parameters related to the manufacturing of the 
nano-formulations (microfluidization) or the critical formulation parameters (drug and 
excipient concentrations) were not studied which may have significant influence on the 
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CQAs [27, 45].  There are many similar published literature reports wherein the authors 
have described to perform DoE leading to successful QbD, however all of them have 
performed either one or two process DoE studies and not a comprehensive multi-process 
and formulation DoE study [47, 49, 50]. This can lead to errors in optimization of critical 
process parameters and critical formulation parameters significantly affecting CQAs or an 
important CQA may be neglected. Whereas, a comprehensive QbD approach will minimize 
the errors in product optimization through investigation of the entire range of important 
CQAs (defining an explicit design space) involved in process and formulation DoE models. 
In the present research, a holistic QbD approach involving five DoE models (wet media 
milling, spray drying with sucrose, spray drying with trehalose, formulation post wet media 
milling and formulation post spray drying) was applied for the identification and 
optimization of the CQAs to achieve a stable spray-dried nanocrystalline zileuton 
formulation. Zileuton is an anti-asthmatic BCS class II drug (average molecular weight 
236.3 g/mol, log P-0.9, aqueous solubility ~ 0.1 mg/mL) [51]. It is a selective inhibitor of 
5-lipoxygenase, the enzyme that catalyzes the formation of leukotrienes from arachidonic 
acid in the eicosanoid synthesis pathway [52]. Multiple full factorial designs were applied 
to understand the critical process parameters [wet media milling (milling time, milling speed 
and pump speed) and spray drying (inlet temperature, aspirator rate and feed flow rate)] as 
well as the critical formulation parameters [drug and excipients (polymer – KollidonVA64 
fine, surfactant – dowfax2A1, sugar – trehalose) concentrations]. Additionally, the 
interactions between these critical parameters which significantly influence the CQAs 
(particle size distribution (as Z-average), total product yield, outlet temperature of spray 
dryer, drug loading, moisture content, PDI and zeta potential) were monitored. Furthermore, 
a response surface analysis was performed to design a predictive model for the particle size 
distribution, total product yield and nanocrystal agglomeration. Detailed data interpretation 
using ANOVA and multifactor analysis was performed to: (a) identify and optimize the 
most important critical process parameters and critical formulation parameters significantly 
affecting the CQAs; (b) elucidate the interactions between multiple critical process 
parameters and critical formulation parameters and their influence on the CQAs; (c) develop 
the rank order of multiple critical process parameters and critical formulation parameters; 
and (d) design a predictive model for development of stable spray-dried nanocrystalline 
 88 
zileuton.  Following the exhaustive QbD approach, validation and stability studies were 
performed for the optimized solid nanocrystalline formulations.  Stability studies 
(40C/75% RH, 25C/60% RH and 4C) were conducted for one year to monitor the 
stability of the crystalline nanoparticles in terms of particle size distribution, in vitro 
dissolution and crystallinity. Based on the comprehensive QbD approach and stability 
studies, a predictive model to prepare stable solid spray-dried nanocrystalline zileuton, 
incorporating both formulation and process parameters, was successfully developed using 
multiple linear regression analysis.  
4.2. MATERIALS  
Crystalline zileuton (greater than 99% purity) was purchased from Beijing Mesochem 
Technology Co. Ltd., China. Trehalose was gifted by Gattefose. Mannitol was procured 
from Fisher Scientific. SLS (sodium lauryl sulfate) was gifted by Sigma Aldrich. PVP (poly 
(1-vinyl-2-pyrrolidone) K17, PVP K25, PVP K30, PVP K90, soluplus (polyvinyl 
caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer), Kolliphor SLS fine, 
KollidonVA (vinyl acetate) 64, KollidonVA 64 fine and KollidonCLM were gifted by 
BASF. Dowfax 2A1, HPMC (hydroxy propyl methyl cellulose) E3, HPMC E5, HPMC E15, 
HPMC E50, HPMC K3, MC (methyl cellulose) A15 and EC (ethyl cellulose) 10 were gifted 
by Dow Chemical Company. Poloxamer P407 and Poloxamer 188 were purchased from 
Spectrum. The chemical structures of the ingredients used in the optimized spray-dried 
zileuton nanocrystalline formulation are shown in Table 4.1. HPLC grade solvents were 
purchased from Fisher Scientific. Inspire C18 column (4.6 mm x 100 mm, 5μm) was gifted 
by Dikma Technologies Inc.   
4.3. METHODS 
4.3.1. Solubility determination  
Equilibrium solubility was determined in different excipient solutions under continuous 
shaking for 48 h at 37 C. Briefly, 10 mg of the drug was added to each vial containing 10 
mL of the stabilizer/excipient solution (0.2% w/v solution). After 48 h, 1 mL samples were 
withdrawn from each vial, filtered through 0.22 µm PVDF (polyvinylidene fluoride) filters, 
and analyzed using the RP-HPLC method described below. 
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4.3.2 Wet media milling  
Nanocrystalline zileuton suspensions were manufactured using wet media milling. Three 
different design of experiments (DoEs) (process (wet media milling and spray drying) and 
formulation) were performed to investigate both critical process parameters (milling speed, 
milling time, pump speed, spray drying inlet temperature, aspirator rate, feed flow rate) and 
critical formulation parameters (drug concentration, polymer concentration, surfactant 
concentration and amount of sugar) affecting the critical quality attributes (CQAs) (particle 
size, zeta potential, drug loading and total yield). For wet media milling DoE: zileuton (1% 
w/v) was suspended in the distilled water containing stabilizers - KollidonVA64 (0.75% 
w/v) and Dowfax2A1 (0.05% w/v). The prepared suspensions were stirred for 30 min for 
complete wetting of the drug by the stabilizer solution. The micro-suspension (100 mL) was 
milled using a wet media mill (Microcer Netzsch) based on the DoE detailed in the section 
4.3.4.3.2. The temperature of the sample was maintained between 2 - 8 °C using two cooling 
bath re-circulators (one attached to the milling and the other to the suspension re-circulation 
chambers) (Figure 4.4) [53]. 
4.3.3 Spray drying  
Solid dry powders of nanocrystalline zileuton were prepared via spray drying. For spray 
drying DoE:  zileuton (1% w/v) was suspended in the aqueous stabilizer - KollidonVA64 
(0.75% w/v) and Dowfax 2A1 (0.05% w/v). The micro-suspension (100 mL) was milled to 
nanosuspension using a wet media mill (Microcer Netzsch) based on the optimized milling 
parameters from the wet media milling DoE detailed in section 4.3.4.3.2. The 
nanosuspension was spray-dried using a B-290 spray dryer (Buchi Labortechhnik AG) 
based on the DoE detailed in section 4.3.4.3.2. The spray dryer was equilibrated using 
distilled water. Once the spray dryer was equilibrated, distilled water was replaced with the 
nanosuspension formulations. Each formulation was spray-dried using trehalose as an 
excipient [drug–trehalose (1:1)] to prevent nanocrystal aggregation. Spray-dried powders 
were collected from the collection chamber and immediately analyzed for the CQAs 
(particle size, total yield and crystallinity) (Figure 4.5) [54]. 
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4.3.4 Quality by Design (QbD) 
The comprehensive QbD approach includes three important stages: (1) risk assessment; (2) 
design of experiments (process and formulation); and (3) process analytical tools (offline or 
inline). 
4.3.4.1 Risk assessment 
Risk identification, analysis and evaluation were performed for the different manufacturing 
process parameters (wet media milling and spray drying) and formulation parameters that 
can significantly influence the CQAs of zileuton nanocrystalline formulations. The process 
(wet media milling and spray drying) and formulation risk estimation matrix is summarized 
in Figure 4.6a. The risk estimation matrix were developed based on the preliminary results 
(data not shown) correlating different process and formulations parameters to different 
quality attributes of the nanocrystalline zileuton formulations in three major categories – 
high risk (red), medium risk (orange) and low risk (green). An Ishikawa diagram (fishbone 
diagram) shown in Figure 4.6b analyzes the risk associated with the preparation of stable 
nanocrystalline zileuton. 
4.3.4.2 Design of Experiments 
Three different design of experiments (DoEs) [process (wet media milling and spray drying) 
and formulation] were performed to investigate both critical formulation parameters (drug 
concentration, polymer concentration, surfactant concentration and amount of sugar) and 
critical process parameters (milling speed, milling time, pump speed, spray drying inlet 
temperature, aspirator rate and feed flow rate) affecting the critical quality attributes (CQAs) 
(particle size, polydispersity index, zeta potential, drug loading and total yield). 
Wet media milling DoE  
Three milling critical process parameters (milling speed, milling time, pump speed) were 
investigated against three different CQAs (particle size, PDI and zeta potential) monitored 
during the wet media milling DoE studies.  
Optimization of different wet media milling critical process parameters (e.g. milling speed, 
milling time and pump speed) for the preparation of nanocrystalline zileuton was performed 
 91 
using a central composite design. Three critical process parameters that may affect the 
preparation of milled formulations were selected, namely the milling speed, milling time 
and pump speed. Three different CQAs were monitored: particle size, PDI and zeta 
potential. The data obtained was evaluated using Design Expert 11.0 and Minitab 18.0 
statistical software. For the milling speed, the minimum and maximum levels (speed) were 
500 and 1500 rpm, respectively with 1000 rpm as the center point and 159 rpm and 1840 
rpm were the star or alpha points. For the milling time, the minimum and maximum levels 
(time) were 15 and 30 min, respectively with 22.5 min as the center point and 10 min and 
35 min were the star or alpha points. For the pump speed, the minimum and maximum levels 
(rpm) were 80 and 120 rpm, respectively with 100 rpm as the center point and 66 rpm and 
134 rpm were the star or alpha points. The CQAs were particle size, PDI and zeta potential 
of milled nanosuspension. A DoE for the wet media milling was performed using 
KollidonVA 64 fine and Dowfax2A1 as the stabilizers. A total of 20 wet media milling 
experiments were performed. (Table 4.2) 
Spray drying DoE  
Following the wet media milling DoE study, the optimized milling critical process 
parameters (milling speed 1200 rpm; milling time 30 min; and pump speed 92 rpm) were 
used to prepare the formulations for the spray drying DoE. Three spray drying critical 
process parameters (inlet temperature, aspirator rate and feed flow rate) were investigated 
against seven different CQAs (outlet temperature, particle size, PDI, zeta potential, drug 
loading, total yield and moisture content) monitored during the spray drying DoE studies. 
Two different sugars (mannitol and trehalose) were used at drug:sugar - 1:1, w/w as 
stabilizers during spray drying.  
Optimization of different spray drying critical process parameters (e.g. inlet temperature, 
aspirator rate and feed flow rate) for the preparation of nanocrystalline zileuton was 
performed using a central composite design. Three critical process parameters that may 
affect the preparation of spray-dried formulations were selected, namely inlet temperature, 
aspirator rate and feed flow rate. Seven different CQAs were monitored: outlet temperature, 
particle size, PDI, zeta potential, drug loading, total yield and moisture content. The data 
obtained was evaluated using Design Expert 11.0 and Minitab 18.0 statistical software. 
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For the inlet temperature during spray drying, the minimum and maximum levels (C) were 
105C and 125C, respectively with 115C as the center point and 98C and 132C were 
the star or alpha points. For the aspirator rate (rate of dry air flow), the minimum and 
maximum levels (%) were 70 and 90%, respectively with 80% as the center point and 63% 
and 97% were the star or alpha points. For the feed flow rate (rate at which the milled 
nanosuspension is flowing through the nozzle of the spray dryer), the minimum and 
maximum levels (%) were 10 and 25%, respectively with 17.5% as the center point and 5% 
and 30% were the star or alpha points. 
A DoE for the spray drying was performed using nanosuspension prepared using the 
optimized milling parameters in addition to two different sugar stabilizers (trehalose and 
mannitol) to prevent aggregation during spray drying. A total of 20 spray drying 
experiments were performed for each sugar (mannitol and trehalose). (Table 4.3a and 4.3b) 
Formulation DoE  
Following the wet media milling and spray drying DoE study, the optimized milling critical 
process parameters (milling speed 1200 rpm; milling time 30 min; and pump speed 92 rpm) 
and optimized spray drying critical process parameters (inlet temperature:125 C, aspirator 
rate:90 % and feed flow rate: 10 %) were used to prepare the solid nanocrystalline zileuton 
for the formulation DoE. Three critical formulation parameters (drug concentration, 
polymer concentration and surfactant concentration) were investigated against three 
different CQAs post wet media milling (particle size, PDI and zeta potential) and seven 
CQAs post spray drying (outlet temperature, particle size, PDI, zeta potential, drug loading, 
total yield and moisture content) monitored during the DoE studies. KollidonVA 64 fine 
and Dowfax2A1 were used as stabilizers during wet media milling. Trehalose was used at 
drug:sugar - 1:1, w/w as the stabilizer during spray drying.  
Optimization of critical formulation parameters [e.g. concentration of drug (zileuton), 
polymer (KollidonVA 64 fine), surfactant (Dowfax2A1) and sugar (trehalose)] for the 
preparation of nanocrystalline zileuton was performed using a central composite design. 
The data obtained were evaluated using Design Expert 11.0 and Minitab 18.0 statistical 
software. For the drug concentration, the minimum and maximum levels (concentrations) 
 93 
were 0.35% w/v and 1% w/v, respectively with 0.675% w/v as the center point and 0.025% 
w/v and 1.325% w/v were the star or alpha points. For polymer concentration, the minimum 
and maximum levels (concentrations) were 0.3% w/v and 0.8% w/v, respectively with 
0.55% w/v as the center point and 0.05% w/v and 1.05% w/v were the star or alpha points. 
For the surfactant concentration, the minimum and maximum levels (concentrations) were 
0.03% w/v and 0.08% w/v, respectively with 0.055% w/v as the center point and 0.005% 
w/v and 0.105% w/v were the star or alpha points. For the amount of sugar, the minimum 
and maximum levels were 850 mg and 2000 mg, respectively with 1425 mg as the center 
point and 275 mg and 2575 mg were the star or alpha points. The CQAs were particle size 
distribution (post wet media milling) and total yield (post spray drying). A DoE for 
formulation parameters was carried out using wet media milling (Table 4.4a) and spray 
drying (Table 4.4b) as the stabilizers. A total of 30 wet media milling and spray drying 
experiments were performed.  
Based on the above DoE studies, for the critical process parameters (wet media milling 
process and spray drying process parameters) and critical formulation parameters 
(formulation parameters), the process validation was performed. The process and product 
validation was performed via preparation of optimized formulations (n=3). These 
formulations were stored at three different storage conditions (4C, 25C/60% RH and 
40C/75% RH) for stability testing of the nanocrystalline zileuton for 1, 6 and 12 month/s. 
The controls (neat zileuton, physical mixture of drug and excipients) were also loaded for 
stability testing.  
4.3.4.3 Process Analytical Technology 
For the characterization of the nanocrystalline zileuton formulations, different offline 
process analytical tools were used including the analytical and solid-state tools. 
4.3.4.3.1 Particle size measurement 
Particle size measurements were performed using a Zetasizer Nano ZS90 (Malvern 
Instruments). Briefly, the liquid or spray-dried samples were suspended in a saturated and 
filtered (0.2 μm PVDF membrane filter) solution of zileuton in 30% glycerin solution to 
avoid any discrepancy resulting from dissolution of the nano-particles during measurement. 
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The viscosity of this dispersant solution was measured via a Brookfield viscometer (Model 
DV-III) and used to calculate the particle size of the re-dispersed and liquid nano-crystalline 
suspensions. All samples were analyzed in triplicate and reported as the standard deviation. 
4.3.4.3.2 Powder X-Ray Diffraction (PXRD) 
PXRD was utilized to determine the crystallinity of the spray-dried samples. X-ray 
diffraction patterns were obtained using an X-ray diffractometer (Model D5005, Bruker 
AXS Inc., Madison, WI) with Cu-kα radiation, a voltage of 40 kV, and a current of 40 mA. 
All the scans were performed with a scanning rate of 2°/minute with steps of 0.02° from 5° 
to 40° at 2θ ranges.  
4.3.4.3.3 HPLC analytical method 
The quantification of zileuton was conducted using a Shimadzu-HPLC system with a UV 
detector. The absorbance wavelength was set at 260 nm. The mobile phase was a mixture 
of 0.1% trifluoro acetic acid in water and acetonitrile at a 40:60% v/v ratio. A C18 Inspire 
5 μ analytical column (4.6 mm × 100 mm) was used with a flow rate of 1 mL/min and the 
column temperature was maintained at 40°C using a column heater. All samples were 
analyzed in triplicate and reported as the standard deviation. 
4.3.4.3.4 Attenuated Total Reflectance - Fourier Transform Infrared Spectroscopy 
(ATR-FTIR) 
IR spectroscopy was performed using a Nicolet FTIR (iS5 FTIR, Thermo Scientific) 
spectrometer with an attenuated total reflectance (ATR) accessory. Spray-dried powders 
were placed on the crystal window (Germanium) and compressed lightly using a pressure 
clamp. Spectra were recorded over a range of 400–4000 cm−1 with a resolution of 4 cm−1, 
for 128 parallel scans. Data analysis was performed on Omnic® 6.0a software (Thermo 
Nicolet Corporation). 
4.3.4.3.5 Polarized Light Microscopy (PLM) 
The spray-dried samples were dispersed in the immersion oil and placed on microscope 
slides. The samples were analyzed using an Olympus BH2 polarized microscope with a Q-
imaging camera, accessories and software. All the pictures were obtained at 10X resolution. 
All samples were analyzed in triplicate and reported as the standard deviation. 
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4.3.4.3.6 Differential Scanning Calorimetry 
Differential scanning calorimetry (DSC) was performed using a TA Q1000 (TA 
instruments) calorimeter and calibrated using indium and sapphire discs. Approximately 5–
10 mg of spray-dried formulations and neat drug (control) were sealed in hermetic pans and 
analyzed. The heating rate was maintained at 5 °C/min and the temperature was increased 
from room temperature to 190 °C. Nitrogen gas was used for purging at a flow rate of 50 
mL/min. The data were analyzed using TA universal analysis software. All samples were 
analyzed in triplicate and reported as the standard deviation. 
4.3.4.3.7 In vitro dissolution testing 
USP apparatus I (basket apparatus for spray-dried powders) and USP apparatus II (paddle 
apparatus for nanosuspensions) (AT7 smart, Sotax AG Switzerland) were utilized for the in 
vitro dissolution experiments. In the case of spray-dried powders, the samples were filled 
into hard gelatin capsules (size 0, Torpac) for in vitro dissolution studies. All the dissolution 
experiments were conducted at 37°C in 900 mL (sink conditions and non-sink conditions) 
of pH 6.8 phosphate buffer at a speed of 100 rpm. At each time point, 2 ml samples were 
withdrawn from the dissolution chamber and replaced with fresh dissolution media. The 
samples were filtered using 0.1 μm PVDF filters to avoid any erroneous results from un-
dissolved nano-particulates. All samples were analyzed using the HPLC method as 
described above. The samples were analyzed on zero day (initial) and after storing at 
different conditions 4C, 25C/60% RH and 40C/75% RH for one, six and twelve month/s.  
In addition, pH shift experiments were designed to mimic the in vivo conditions that the 
dosage form experience while transiting from stomach (pH 1.2) to intestine (pH 6.8) and 
understand the differences in the dissolution rate of the nanocrystalline zileuton 
formulations at different pH. The required volume of the zileuton nanosuspension was 
directly added to the USP II apparatus (paddle) with 0.1N HCl dissolution media (pH 1.2) 
(675 mL) and samples were collected at different times points until 2 h. After 2 h, pH was 
switched from 1.2 to 6.8 by addition of required volume (225 mL) of tribasic sodium 
phosphate. pH 6.8 was maintained for another 4 h and samples were withdrawn at different 
time points. The samples were filtered using 0.1 PVDF filter membrane and the drug 
concentration was quantified using RP-HPLC. Similarly, the required quantity of spray 
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dried zileuton nanoparticles were directly added to the USP apparatus II (paddle) and pH 
shift experiments were performed. All formulations were tested in sextuplets (n=6) and 
reported as the standard deviation. 
4.3.5 Storage stability testing 
All the spray-dried powder formulations were stored at three different storage conditions 
i.e. 4°C, 25°C/60% RH and 40°C/75% RH for 12 months. Samples were withdrawn at 1, 6 
and 12 month/s and analyzed for particle size distribution, zeta potential, moisture content 
and crystallinity. All samples were analyzed in triplicate and reported as the standard 
deviation. 
4.4. RESULTS & DISCUSSION 
4.4.1. Selection of stabilizer/s 
4.4.1.1 Selection of polymers and surfactants 
Different polymers and surfactants were investigated as potential stability enhancers. The 
polymers and surfactants were first screened to determine whether they caused any 
significant increase in the equilibrium solubility of the drug. These polymers and surfactants 
are present in different concentrations in the nanocrystalline formulations to stabilize the 
drug. Nanocrystalline formulations (small sized drug crystals) have significantly high 
Gibb’s free energy due to high surface area to volume ratios resulting in thermodynamically 
unstable nanocrystalline suspensions. The advantage of nanocrystalline formulations over 
their microcrystalline counterparts is their significant enhancement in dissolution 
performance. However, nanocrystalline formulations suffer from a major instability issue 
involving aggregation as well as Oswald’s ripening, which results in particle size changes 
eventually leading to a small number of very large particles causing a significant reduction 
in the dissolution rate of the formulations.  
The polymers investigated were PVP K-17, PVP K-25, PVP K-30, PVP K-90, HPMC E3, 
HPMC E5, HPMC E15, HPMC E50, HPMC K3, MC A15, EC 10, KollidonVA64, 
KollidonVA64 fine and soluplus. The surfactants investigated were Dowfax2A1, SLS, 
Kolliphor SLS fine, Poloxamer P407 and Poloxamer 188. Drug solubility was measured in 
all of the above excipient solutions. All surfactants investigated (Dowfax2A1, SLS, 
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Poloxamer P407 and Poloxamer 188) were unable to increase the drug equilibrium 
solubility. EC 10, Kolliphor SLS fine and Kollidon CLM were able to increase the drug 
equilibrium solubility (1.5-fold) compared to the no excipient (control) sample as shown in 
Figure 4.8 and Table 4.7. PVPs (K-17, K-25, K-30, K-90), HPMC K3, KollidonVA64 and 
KollidonVA64 fine were able to increase the drug equilibrium solubility (2-fold) compared 
to the no excipient (control) sample as shown in Figure 4.7 and Table 4.5. HPMCs (E3, E5, 
E15, E50) and MC A15 were able to increase the drug equilibrium solubility (2.5-fold) 
compared to the no excipient (control) sample as shown in Figure 4.7 and Table 4.5. 
Soluplus was able to increase the drug equilibrium solubility (3-fold) compared to the no 
excipient (control) sample as shown in Figure 4.7 and Table 4.5.  
The increase in the equilibrium solubility of the drug upon addition of excipient can result 
in Ostwald ripening. As a consequence, all excipients which result in significant increase in 
drug equilibrium solubility should not be selected for the next stage of formulation 
development of nanocrystalline suspensions. This eliminated the excipients: soluplus, 
HPMCs (E3, E5, E15, E50) and MC A15 from the screening studies. Furthermore, it was 
observed that there was a lot of sticking to the glass vessels (significantly affecting the 
product yield) and particle aggregation during spray drying of the formulations containing 
only surfactant excipients viz., Poloxamer P407 and Poloxamer 188, and as a result these 
stabilizers were not selected. In addition, during the wet media milling of the formulations 
containing excipients: EC 10, Kolliphor SLS fine and Kollidon CLM, it was observed that 
the nanoparticles tend to aggregate as a result of poor stabilizing effect.  
In the preliminary wet media milling experiments, the formulations containing excipients 
(PVPs, KollidonVA64 and KollidonVA64 fine) resulted in stable particle size 
nanocrystalline formulations. However, the nanocrystalline formulations prepared using 
KollidonVA64 fine resulted in unimodal particle size distribution and stable particle size 
compared to PVPs. The vinyl acetate moiety linked to the vinyl pyrrolidone chain present 
in the KollidonVA64 fine provided a strong stabilization effect to the nanoparticles, 
compared to PVPs. Consequently, KollidonVA64 fine was used as a stabilizer during wet 
media milling to prepare crystalline nanosuspensions. Post wet media milling, spray drying 
was performed to prepare powdered nanocrystalline formulations. It was observed that the 
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particle size post spray drying was in the range of 600-700 nm. Based on these observations, 
screening studies were performed for the addition of a small amount of surfactant (viz., 
Dowfax2A1 or sodium lauryl sulfate) along with KollidonVA64 fine. A combination of 
KollidonVA64 fine and Dowfax2A1 resulted in particle size <400 nm in 30 min of 
continuous milling (data not shown). It was observed that prolonging the milling time above 
30 min led to significant particle aggregation. Accordingly, a combination of KollidonVA64 
fine and Dowfax2A1 were used as stabilizers for the multiple DoE approach to optimize the 
process (wet media milling and spray drying) and formulation parameters (excipients and 
drug concentrations) for the preparation of a stable nanocrystalline zileuton.   
4.4.1.2 Selection of sugars 
Following the wet media milling process, it is required to add a sugar stabilizer to the 
nanocrystalline suspensions before spray drying in order to prevent nanoparticle 
aggregation (to maintain uniform particle size) and minimize sticking to the glass walls of 
the spray dryer (maximize the nanocrystalline powder yield). Based on the preliminary 
results, three different sugars: mannitol, sucrose and trehalose were screened. In the 
presence of sucrose, the nanoparticles tend to aggregate the most, compared to the other 
sugars. Furthermore, nano-formulations containing sucrose resulted in sticking to the glass 
walls of the spray dryer impacting the spray drying process and significantly reducing the 
total drug product yield. It has been reported that the high Tg of trehalose (106°C) results 
in less hygroscopicity, minimal/absence of internal hydrogen bonding between trehalose-
trehalose molecules and strong hydrogen bonding between trehalose-nanoparticles during 
the spray drying process [38]. During the screening studies, the nano-formulations prepared 
using trehalose and mannitol had uniform particle size, minimal moisture content and high 
drug product yield. As a result, trehalose and mannitol were selected for the multiple DoE 
studies to prepare stable nanocrystalline zileuton formulations.  
4.4.2. Design of Experiments  
Following the pre-formulation studies, five sets of DoE studies [wet media milling, spray 
drying (comparing nano-formulations containing mannitol vs. trehalose), formulation 
parameters (post wet media milling) and formulation parameters (post spray drying)], were 
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investigated to optimize and prepare stable spray-dried nanocrystalline zileuton drug 
product.  
4.4.2.1 Wet Media Milling DoE 
Based on the wet media milling DoE, it was observed that the milling critical process 
parameters (especially milling time and milling speed) have a significant influence on the 
particle size of the nanocrystalline zileuton. According to Figure 4.8(A), with increase in 
milling speed >1100 rpm, there was a decrease in the particle size <200 nm of the 
nanocrystalline zileuton suspensions. According to Figure 4.8(B), with increase in milling 
speed >1100 rpm and milling time >24 min, there was a decrease in the particle size <200 
nm of the nanocrystalline zileuton suspensions.  
A particle size <200 nm for the nanocrystalline zileuton was obtained at a milling speed 
>1000 rpm, milling time <30 min and pump speed >120 rpm (Figure 4.8C).  The surface 
plots clearly show this result with dark green shade correlating to the larger particle size 
(>250 nm) and the light green shade pattern correlates to the smaller particle size (<250 
nm). Accordingly, the DoE study has achieved uniform and homogenous particle size as 
desired.  
As can be observed in Table 4.6b, it is evident that the surface quadratic model was 
significant and the lack of fit for this model was not significant, indicating that the model 
was significant for the CQA (i.e. particle size of the nanocrystalline zileuton suspension). 
The final equation based on the three critical process parameters (milling time, milling speed 
and pump speed) and the interaction terms for the prediction of the particle size of the 
nanocrystalline zileuton suspension are provided in Table 4.6b.  
It was observed that the particle size of the zileuton macro-suspension decreased with 
increase in the milling speed and milling time, due to strong shear force and attrition force 
of the yttrium-stabilized zirconium oxide grinding beads (50) in the wet media mill 
significantly impacting upon the macroparticles and breaking them into multiple 
microparticles. These microparticles are further broken into small uniform nanoparticles 
upon several passes of the zileuton suspension in the wet media mill. A high milling speed 
indicates strong shear and attrition force of the milling beads (zirconia beads) and a high 
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milling time defines the number of passes of the zileuton macro- and micro-suspensions to 
form nanocrystalline zileuton suspensions. Following the wet media milling DoE, the 
optimized critical process parameters and CQAs predicted by the DoE model are provided 
in Table 4.6c. The predicted critical process parameters were applied to the formulations 
prepared for the validation of spray drying DoE.  
4.4.2.2 Spray drying DoE  
Following the wet media milling DoE, the statistically predicted critical process parameters 
obtained were applied to the spray drying DoE formulations. For spray drying DoE, two 
different sugar stabilizers (mannitol and trehalose, drug:sugar – 1:1, w/w) were investigated 
to prevent nanoparticle aggregation and sticking to the walls of the spray dryer glass vessel, 
resulting in uniform particle size and maximum total drug product yield at the end of the 
process.  
4.4.2.2.1 Spray drying DoE [Stabilizer:Mannitol] 
Based on the spray drying DoE (using mannitol), it was observed that the spray drying 
critical process parameters (inlet temperature, aspirator rate and feed flow rate) had a 
significant influence on the total product yield and the particle size of the nanocrystalline 
zileuton.  
According to Figure 4.9(A), with increase in the inlet temperature (>115C) and the 
aspirator rate (>85%) of the spray dryer, there was increase in the total product yield (>70% 
w/w) of the nanocrystalline zileuton (solid powder). The influence of the inlet temperature 
and the aspirator rate on the total product yield as shown by the curved green lines (against 
yellow background) on the base of the 3D surface plot is shown in the contour plot on the 
left side. The curved light blue shade on the contour and 3D surface plots indicate low total 
product yield (65% w/w) and the yellow to light orange shade on the contour and 3D surface 
plots indicate high total product yield (75% w/w). Inlet temperature is the temperature of 
the dry gas (air or inert gas) flowing through the spray dryer chamber. Aspirator rate is the 
rate at which the dry gas (air or inert gas) flowing through the spray dryer chamber. An 
optimized combination of the inlet temperature and aspirator rate is important for complete 
drying of the spray-dried particles with uniform particle size and maximum total product 
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yield. A high inlet temperature indicates increase in the rate of surface evaporation from the 
atomized droplets formed at the spray dryer nozzle. A high aspirator rate maintains a 
completely dry environment in the spray dryer, thus minimizing sticking to the walls of the 
spray dryer glass vessel and maximizing the total product yield. 
According to the Figure 4.9(B), with decrease in the feed flow rate (<20%) and increase in 
the inlet temperature (>115C) of the spray dryer, there was an increase in the total product 
yield ( 75% w/w) of the nanocrystalline zileuton (solid powder). According to the 3D 
surface plot on the right side of the Figure 4.9(B), a yellow-orange shade (high total product 
yield (75% w/w)) at the top and aqua shade (low total product yield (65% w/w)) tapering 
at the bottom of the curve was observed. The influence of the inlet temperature and the feed 
flow rate on the total product yield as shown by the curved green lines (against yellow 
background) on the base of the 3D surface plot is shown in the contour plot on the left side. 
Feed flow rate is the flow rate of the nanosuspension flowing through the spray dryer with 
the first contact being with the spray dryer nozzle following which the nanosuspension 
atomizes into multiple tiny droplets resulting in increase in surface area and increase in rate 
of surface evaporation. An optimized combination of the inlet temperature, aspirator rate 
and feed flow rate is important for complete drying of the spray-dried particles with uniform 
particle size and maximum total product yield. A high inlet temperature indicates increase 
in the rate of surface evaporation from the atomized droplets formed at the spray dryer 
nozzle. A high feed flow rate results in the formation of large droplets following atomization 
from the spray dryer nozzle. These large droplets even under the influence of high inlet 
temperature and high aspirator rate will not dry completely due to their smaller surface area 
and decreased rate of surface evaporation. Thus multiple large droplets formed at high feed 
flow rates results in incomplete drying leading to sticking to the glass walls of the spray 
dryer, minimizing total product yield and maximizing nanoparticle aggregation significantly 
impacting product quality and stability. On the contrary, low feed flow rates indicate 
formation of multiple tiny droplets following atomization from the spray dryer nozzle 
resulting in increased rate of surface evaporation, better drying with minimal sticking to the 
glass walls of the spray dryer. This results in uniform particle size and maximum total 
product yield. 
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Aspirator rates >85%, feed flow rates <20% and inlet temperatures >115C result in total 
product yield >70% w/w (Figure 4.9C). The surface plots clearly show this result with green 
shade (light to dark) correlating to high total product yield (>70% w/w) and the blue shade 
(light to dark) correlating to low total product yield (<70% w/w). Accordingly, the DoE 
study has achieved maximum total product yield as desired.  
As can be observed in Table 4.7b, it is evident that the surface reduced cubic model was 
significant and the lack of fit for this model was not significant, indicating that the model 
was significant for the CQA (i.e. total product yield of the nanocrystalline zileuton solid 
powder). The final equation based on the three critical process parameters (inlet 
temperature, aspirator rate and feed flow rate) and the interaction terms for the prediction 
of the total product yield of the nanocrystalline zileuton solid powder are provided in Table 
4.7b.  
4.4.2.2.2 Spray drying DoE [Stabilizer:Trehalose] 
Based on the spray drying DoE (using trehalose), it was observed that the spray drying 
critical process parameters (inlet temperature, aspirator rate and feed flow rate) had a 
significant influence on the total product yield and the particle size of the nanocrystalline 
zileuton.  
According to the Figure 4.10(A), a high aspirator rate (>85%) lead to increase in the total 
product yield (>65% w/w) of the nanocrystalline zileuton (solid powder). The influence of 
the inlet temperature and the aspirator rate on the total product yield as shown by the curved 
green-orange lines (against the yellow background) on the base of the 3D surface plot is 
demonstrated in the contour plot on the left side. The curved light blue – green shade on the 
contour and 3D surface plots indicate low total product yield (60% w/w) whereas the yellow 
to light orange shade on the contour and 3D surface plots indicate high total product yield 
(65-70% w/w). An optimized combination of the inlet temperature and aspirator rate is 
important for complete drying of the spray-dried particles with uniform particle size and 
maximum total product yield. Spray drying of the nanocrystalline zileuton in the presence 
of trehalose resulted in lower total product yield (65-70% w/w) compared to the spray-dried 
nanocrystalline zileuton with mannitol (75-80% w/w). However, following the spray drying 
DoE, the optimized spray-dried nanocrystalline zileuton in the presence of trehalose had a 
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uniform and smaller particle size (300-350 nm) with minimal nanoparticle aggregation 
compared to the spray-dried nanocrystalline zileuton in the presence of mannitol (450-500 
nm). One of the potential reasons for this could be recrystallization of mannitol into large 
particles along with the zileuton nanoparticles, meanwhile trehalose resulted in minimal to 
no change in the particle size of the zileuton nanoparticles during spray drying.  
According to Figure 4.10(B), with decrease in the feed flow rate (<20%) and decrease in 
the inlet temperature (<120C) of the spray dryer, there was increase in the total product 
yield ( 75% w/w) of the nanocrystalline zileuton (solid powder). According to the 3D 
surface plot on the right side of the Figure 4.10(B), a yellow-orange shade (high total 
product yield (70% w/w)) at the top and green-aqua shade (low total product yield (60% 
w/w)) tapering at the sides of the curve was observed. The influence of the inlet temperature 
and the feed flow rate on the total product yield as shown by the curved orange-green lines 
(against the yellow background) on the base of the 3D surface plot is shown in the contour 
plot on the left side. An optimized combination of the inlet temperature, aspirator rate and 
feed flow rate is important for complete drying of the spray-dried particles with uniform 
particle size and maximum total product yield. A low feed flow rate resulted in increased 
surface evaporation from the atomized droplets, maximizing the total product yield and 
producing uniform sized nanocrystalline zileuton solid powder. 
Aspirator rates >90%, feed flow rates <15% and inlet temperatures:110-115C resulted in 
total product yield >65% w/w (Figure 10C). The surface plots clearly show this result with 
dark green shade correlating to high total product yield (>65% w/w) and light green shade 
correlating to low total product yield (<65% w/w). Accordingly, the DoE study has achieved 
maximum total product yield as desired.  
As can be observed in Table 4.8b, it is evident that the surface reduced cubic model was 
significant and the lack of fit for this model was not significant, indicating that the model 
was significant for the CQA (i.e. total product yield of the nanocrystalline zileuton solid 
powder). The final equation based on the three critical process parameters (inlet 
temperature, aspirator rate and feed flow rate) and the interaction terms for the prediction 
of the total product yield of the nanocrystalline zileuton solid powder are provided in Table 
4.8b.  
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Following the spray drying DoE, the optimized critical process parameters and CQAs 
predicted by the DoE model are provided in Table 4.8c. The statistically predicted critical 
process parameters were applied for the validation of the formulation DoEs. The spray-dried 
nanocrystalline zileuton prepared using sugar stabilizer trehalose (drug:sugar-1:1, w/w) 
showed a uniform particle size distribution and maximum total product yield. Therefore, 
trehalose was used as a sugar stabilizer during spray drying for all further DoE studies 
maintaining high product quality of the nanocrystalline zileuton (solid powder).  
4.4.2.3 Formulation DoE (wet media milling) 
The statistically predicted critical process parameters based on the wet media milling DoE 
were used for the nanocrystalline zileuton formulations (nanosuspensions) DoE.   
It was observed that the formulation critical formulation parameters (drug, polymer and 
surfactant concentration) have a significant influence on the particle size of the 
nanocrystalline zileuton. According to Figure 4.11(A), with increase in drug concentration 
>0.65% w/v and at polymer concentrations between 0.4-0.7% w/v, there was decrease in 
the particle size <300 nm of the nanocrystalline zileuton suspension. According to Figure 
4.11(B), with increase in drug concentration >0.65% w/v and at surfactant concentration 
>0.045% w/v, there was decrease in particle size <300 nm of the nanocrystalline zileuton 
suspension.  
Drug concentrations >0.5% w/v, at polymer concentrations between 0.4-0.7% w/v and 
surfactant concentrations between 0.04-0.07% w/v result in particle size <300 nm (Figure 
4.11(C). Accordingly, the DoE study has achieved small and uniform particle size (<500 
nm) as desired.  
As can be observed in Table 4.9b, it is evident that the surface cubic model was significant 
and the lack of fit for this model was not significant, indicating that the model was 
significant for the CQA (i.e. particle size of the nanocrystalline zileuton suspension). The 
final equation based on the three critical formulation parameters (drug concentration, 
polymer concentration and surfactant concentration) and the interaction terms for the 
prediction of the particle size of the nanocrystalline zileuton suspension is provided in Table 
4.9b.  
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In the preparation of the nanocrystalline zileuton suspension via wet media milling, the 
surfactant (Dowfax2A1) acts as a bridge between the drug (zileuton) and the polymer 
(KollidonVA64 fine). The polymer stabilizes the drug by forming hydrogen bonds between 
the carbonyl group of the polymer and the amino group of the drug. The combination of 
excipients (polymer and surfactants) stabilizes the drug in the nanoparticulate system by 
electrosteric stabilization (electrostatic and steric stabilization). A very low concentration 
of each ingredient (drug, polymer and surfactant) results in larger particle size distribution 
due to insufficient drug-stabilizer interaction leading to destabilization of the 
nanoparticulate system. A very high concentration of each ingredient (drug, polymer and 
surfactant) leads to nanoparticle aggregation significantly affecting the product quality and 
stability. An optimized concentration of the drug and stabilizers (polymer and surfactant) is 
desired for the preparation of stable nanocrystalline zileuton suspensions during wet media 
milling.  
4.4.2.4 Formulation DoE (Spray drying) 
The statistically predicted critical process parameters based on the wet media milling DoE 
and spray drying DoE (using trehalose) were used for the formulation DoE for the 
preparation of the nanocrystalline zileuton (solid powder).  Based on the formulation DoE 
(spray drying using trehalose), it was observed that the critical formulation parameters (drug 
concentration, polymer concentration, surfactant concentration and amount of sugar) had a 
significant influence on the total product yield and the particle size of the nanocrystalline 
zileuton (solid powder).  
According to Figure 4.12(A), a high drug concentration (>0.65% w/v) and a low polymer 
concentration (<0.4% w/v) leads to an increase in the total product yield (>75% w/w) of the 
nanocrystalline zileuton (solid powder). The influence of the drug concentration and the 
polymer concentration on the total product yield as shown by the curved green-orange lines 
(against the yellow background) on the base of the 3D surface can be observed in the contour 
plot on the left side. The curved light green shade on the contour and 3D surface plots 
indicate low total product yield (65% w/w) and the yellow to light orange shade on the 
contour and 3D surface plots indicate high total product yield (75-80% w/w). According to 
the formulation DoE (spray drying), a low concentration of polymer is sufficient to stabilize 
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the drug nanoparticles. The drug concentration does not significantly influence the total 
product yield. 
According to Figure 4.12(B), with increase in the surfactant concentration (0.06% w/v) 
and increase in drug concentration (>0.65% w/v), there was increase in the total product 
yield (76% w/w) of the nanocrystalline zileuton (solid powder). The influence of the drug 
concentration and the surfactant concentration on the total product yield as shown by the 
curved orange-green lines (against the yellow background) on the base of the 3D surface 
plot can be seen in the contour plot on the left side. An optimized combination of drug, 
polymer and surfactant is desired to obtain spray-dried nanoparticles with uniform particle 
size and maximum total product yield. A high concentration of surfactant (0.06% w/v) 
provides a strong steric stabilization to the nanocrystalline drug-polymer system (which is 
stabilized electrostatically). The drug-polymer system has a tendency to aggregate, which 
upon addition of the surfactant, results in uniform and homogenous particle size due to the 
electrosteric stabilization effect. This electrosteric stabilization effect (drug-surfactant-
polymer) in combination with the optimized critical process parameters from the spray 
drying process results in completely dry nanoparticles, therefore minimizing sticking to the 
glass walls of the spray dryer, maximizing the total product yield and producing uniform 
sized nanocrystalline zileuton solid powder. 
According to Figure 4.12(C), with decrease in the amount of sugar (<1200 mg) and increase 
in drug concentration (>0.65% w/v), there was an increase in the total product yield (75% 
w/w) of the nanocrystalline zileuton (solid powder). The influence of the drug concentration 
and amount of sugar on the total product yield as shown by the curved orange-green lines 
(against the yellow background) on the base of the 3D surface plot is shown in the contour 
plot on the left side. Sugars are known to prevent nanoparticle aggregation during the drying 
process by the virtue of electrostatic repulsion. Sugars such as trehalose provide strong 
rigidity by coating the nanoparticles and thus preventing the attractive forces between the 
nanoparticles in presence of other stabilizers (surfactants and polymers) and maintaining 
sufficient repulsion to keep the nanoparticles apart [55]. An optimized ratio of the 
drug:sugar is desired to obtain stable spray-dried nanoparticles with uniform particle size 
and maximum total product yield. The low amount of sugar (<1200 mg) resulted in 
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significantly high total product yield (75% w/w), this indicates that the drug:sugar ratio 
(1:1, w/w) is sufficient to prevent nanoparticle aggregation during the spray drying process. 
A high sugar amount (>1600 mg) resulted in a decrease in total product yield (<65% w/w). 
A high amount of sugar significantly influences the particle morphology and also leads to 
increased hygroscopicity due to its hydrophilic nature (in combination with less drying of 
the nanoparticles), this leads to increased sticking of the partially dried nanoparticles to the 
glass walls of the spray dryer, significantly decreasing the total product yield.    
Polymer concentrations <0.6% w/v, surfactant concentrations >0.05% w/v and amount of 
sugar <1400 mg, resulted in total product yield between 60-70% w/w (Figure 4.12D). The 
surface plots clearly show this result with dark green shade correlating to high total product 
yield (>70% w/w) and light green shade correlating to low total product yield (<70% w/w). 
Accordingly, the DoE study has achieved maximum total product yield as desired. 
As can be observed in Table 4.10b, it is evident that the surface quadratic model was 
significant and the lack of fit for this model was not significant, indicating that the model 
was significant for the CQA (i.e. total product yield of the nanocrystalline zileuton solid 
powder). The final equation based on the four critical formulation parameters (drug 
concentration, polymer concentration, surfactant concentration and amount of sugar) and 
the interaction terms for the prediction of the total product yield of the nanocrystalline 
zileuton solid powder are provided in Table 4.10b.  
The optimized critical formulation parameters and CQAs predicted by the DoE models 
(process and formulation) are detailed in Table 4.11. The predicted critical formulation 
parameters (post wet media milling and post spray drying) were applied for the validation 
of the DoE studies.  
4.4.3. Validation of DoE studies  
The DoE studies were validated by applying the statistically predicted critical process 
parameters and critical formulation parameters to prepare sextuplets batches (n=6) of the 
spray-dried nanocrystalline zileuton formulations. The average experimental 
physicochemical properties (Table 4.12) of the sextuplet formulations were compared with 
the statistically predicted CQAs (Table 4.11). 
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4.4.4 Stability studies 
The optimized spray-dried nanocrystalline zileuton formulations prepared based on the 
statistically predicted critical process parameters and critical formulation parameters 
obtained from the DoE studies as described in the Table 4.20 were stored at three different 
stability conditions; 4C, 25C/60% RH and 40C/75% RH for one, six and twelve month/s. 
The formulations were then analyzed for particle size distribution, moisture content, drug 
loading and zeta potential. Additionally, the formulations were also analyzed using: DSC 
and PXRD (to monitor any polymorphic transformation i.e. conversion of one crystalline 
form to other); ATR-FTIR (to study the interaction between drug and polymer); PLM (to 
monitor any generation of non-crystallinity or amorphous particles); and in vitro dissolution 
testing (to investigate the effect of pH, particle size, temperature and humidity on drug 
release). 
4.4.4.1 Particle size distribution and Moisture content 
As shown in Table 4.11 and  Figure 4.13, the particle size, PDI and moisture content of the 
prepared spray-dried nanocrystalline zileuton increased following one, six and twelve 
month/s storage under: 25°C/60% RH and 40°C/75% RH. On the other hand, the optimized 
formulations stored at 4°C were determined to be stable in terms of particle size distribution, 
moisture content and zeta potential over the one year study period.  
The particle size increase for the formulations stored at 25°C/60% RH and 40°C/75% RH 
conditions (3-3.5%) is considered to be due to high humidity causing aggregation of the 
nanocrystalline zileuton particles. 
4.4.4.2 Powder X-ray diffraction 
The characteristic diffraction peaks of neat macrocrystalline zileuton drug (most stable -
anhydrous polymorphic form I) are 9.8, 15.7, 17.7, 19.7, 22.48, 22.5, 26.5, 29, and 
31.3. Figure 4.14 displays an overlay of the PXRD diffraction profiles of the neat 
macrocrystalline zileuton (raw crystalline drug), a physical mixture (zileuton, 
KollidonVA64 fine, Dowfax2A1 and trehalose) as well as the optimized spray-dried 
nanocrystalline zileuton formulation (day zero and those stored for 12 months at 4°C, 
25°C/60% RH and 40°C/75% RH). As shown in Figure 4.14, the optimized spray-dried 
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nanocrystalline zileuton formulation (day zero) showed a similar diffraction pattern as the 
neat drug but with reduced intensity. The decrease in the intensity is characteristic of the 
nanoparticles, due to their small particle size. The optimized spray-dried nanocrystalline 
zileuton formulations stored at 4°C and 25°C/60% RH for 12 months showed similar 
diffraction patterns as the day zero formulations. However, the formulations stored at 
40°C/75% RH for 12 months showed blunt diffraction peaks (compared to the sharp 
diffraction peaks for the formulations at day zero as well as the 12 months samples (at 4°C 
and 25°C/60% RH)). The increase in the particle size (as discussed above in section 4.4.1.1) 
and polymorphic transition (semi-crystallinity) as a result of the high humidity are the 
possible reasons for the blunt PXRD diffraction peaks with reduced intensity.  
4.4.4.3 Attenuated total reflectance – Fourier transform infrared spectroscopy 
According to Figure 4.15 (a and b), there is band broadening between 3000-3500 cm-1 in 
the FTIR spectra for the spray-dried nanocrystalline zileuton formulations at zero day as 
well as those stored for twelve months under all conditions (i.e. 4C, 25C/60% RH, and 
40C/75% RH). The band broadening is considered to be due to hydrogen bonding between 
the N-H moiety of zileuton and the C=O group of the polymer (KollidonVA64 fine). 
However, there is no band broadening in the case of the macrocrystalline zileuton (neat 
drug) and the physical mixture of the drug-stabilizers (drug-polymer-surfactant-sugar).   
From Figure 4.15b, two additional peaks (2970 cm-1 (C-H antisymmetric stretching 
vibrations, N-H aromatic stretching) and 2905 cm-1 (C-H symmetric stretching vibration) – 
in CH3) were observed in the nanocrystalline zileuton stored at 40°C/75% RH for 12 months 
compared to the other formulations and the neat drug as well as the physical mixture. It is 
reported that the methylene (-CH2) stretching of ethylene glycol (HO-CH2-CH2-OH) 
molecules results in a peak at 2970 cm-1 [56]. The formulations stored at high humidity 
(75% RH) have physical instability due to the high moisture content causing degradation of 
KollidonVA64 fine through converting the ethylene side chains to ethylene glycol moieties.  
The N-H stretching (present in the 1° amides) results in an absorbance peak at 3180 cm-1. 
From Figure 4.15c, a broad band (3220 – 3140 cm-1) with maximum intensity at 3180 cm-1 
in both the neat drug and the physical mixture was observed, however this peak was absent 
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in all formulations (day zero and 12 months). The peak was not present in the day zero 
nanoformulations possibly due to the labile nature of the amide group in presence of 
aqueous media during manufacturing. This peak was not present in any formulation stored 
at different stability conditions. Another possible reason behind the absence of the peak at 
3180 cm-1 could be due to the interaction (hydrogen bonding) between the drug-surfactant-
polymer complex with sugar.  
From Figure 4.15d, it was observed that there was hydrophobic interaction between the drug 
and the stabilizers in the nanocrystalline zileuton formulations (day zero and stability 
formulations (12 months)). The peaks between 1650-1550 cm-1 is mainly observed due to 
N-H bending and is stronger in amides than amines. The two sharp peaks between 1650-
1550 cm-1 is characteristic of the amide moiety in the neat drug, which is also observed in 
the physical mixture. The intensity of these peaks reduced significantly in the formulations 
(both at day zero and those stored for 12 months) due to strong interactions (hydrophobic 
(C-C) and hydrogen bonding) between the drug and the stabilizers. The highlighted area (a) 
indicate that the sharp peaks 1350 – 1150 cm-1 are present in drug and physical mixture, 
however these peaks are absent in all formulations. It has been reported that the sharp peaks 
at 1350 and 1150 cm-1 are characteristics of C-O-C stretching vibration in acrylates and 
esters [57]. Furthermore the sharp peaks between 1350 and 1150 cm-1 are also associated 
with acyl group (C-O) [58]. This sharp peaks disappears due to the strong interaction 
between the drug and the stabilizers in solid formulations. The highlighted area (b) (1150-
1050 cm-1) is associated with the formation of the alkoxy group (CH3-O-) and related C-O 
stretching vibrations in these groups during the preparation of the nanoparticles [59]. The 
neat drug and physical mixture of drug-stabilizers are devoid of these peaks, which is 
present only in the nanoparticle formulations. The polymer KollidonVA64 fine have 
number of –CH-CH2 moieties both linked to the pyrrolidone and to the vinyl functional 
groups. The carbon atom of the –CH-CH2 moieties interacts with the oxygen atom of the N-
OH moieties present in the drug (hydrophobic interaction) during the preparation of the 
nanocrystalline zileuton, thus the two peaks are observed only in the nanocrystalline 
zileuton formulations and not in the drug or the physical mixture of the drug-stabilizers. The 
highlighted area (c) (1050-950 cm-1) indicate the peak shift of one of the two peaks in the 
nanocrystalline zileuton formulations compared to those observed in the drug and the 
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physical mixture. The peak shifts from 1020 cm-1 as observed in the drug and the physical 
mixture to 980 cm-1 as observed in the nanocrystalline zileuton formulations. It has been 
reported that this peak shift is due to the C-H stretching in the monosubstituted alkene [57]. 
According to the highlighted area (d) a new peak was observed at 800 cm-1 in all 
nanoparticle formulations which was missing in the drug and physical mixture. This peak 
is a characteristics of the N-H bending in the amines and the C-H bending at the para 
position (para – carbon) of the aromatic ring. The hydrophobic interactions and the 
hydrogen bond formation between the drug and the stabilizers result in the appearance of 
the peak at 800 cm-1 only in the nanoparticles and not in the neat drug or the physical 
mixture. The hydrophobic interactions between the drug and the stabilizers result in the 
decreased intensity of the two peaks between 750-700 cm-1 in the nanocrystalline zileuton 
formulations compared to sharp peaks as observed in the neat drug and the physical mixture. 
4.4.4.4 Polarized light microscopy 
According to Figure 4.16, large rod and plate shaped crystals (sharp birefringence) was 
observed for the neat drug (macrocrystalline zileuton – 20  particle size).  This sharp 
birefringence was also observed in the physical mixture. The birefringence was evident in 
the spray-dried nanocrystalline zileuton formulations both at day zero and following 12 
months storage at 4°C. However, the large rod and plate shaped macrocrystals were 
converted to uniform sized nanocrystals during the milling process which was evident in 
the initial spray-dried nanocrystalline zileuton formulations as well as those stored for 12 
months at 4°C. In agreement with the PXRD and the particle size results it is evident that 
there is no aggregation of the spray-dried nanocrystalline zileuton formulations at 4°C and 
significant aggregation at 40C/75% RH. Additionally, it is evident that there is significantly 
more aggregation at 40C/75% RH compared to 25°C/60% RH. 
4.4.4.5 Differential Scanning Calorimetry 
According to the DSC thermograms (Figure 4.17), there was no polymorphic transition of 
the zileuton (neat drug) after processing it into nanoparticles (nanocrystalline zileuton) via 
wet media milling and spray drying. This was also evident from the PXRD (Figure 4.12) 
and the PLM (Figure 4.14) results. The melting endotherm of neat zileuton 
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(macrocrystalline drug) is observed at 153.52C. There was broadening of the melting 
endotherm peak in all nanocrystalline zileuton formulations (initial and stability 
formulations (12 months)) as observed in the DSC thermograms. The melting endotherm 
broadening in the zileuton nanoparticles at day zero and those stored at 4C for 12 months 
was observed to be 140-155C. The melting endotherm broadening in the zileuton 
nanoparticles stored at 25C/60% RH and 40C/75% RH (12 months) was observed to be 
130-155C. The melting endotherm broadening observed for all the nanoparticle 
formulations is considered to be due to the strong interactions (hydrogen bonding and 
hydrophobic) between the drug and the stabilizers. The glass transition temperature (Tg) is 
an important characteristic of the polymers and sugars. A single Tg is observed for all 
components (otherwise having different Tgs) in a true solid dispersion, indicating that the 
excipients are providing strong stabilization to the drug [60, 61]. The spray-dried 
nanocrystalline zileuton formulations showed a single Tg (~63.7°C) which correlated to the 
mixture of excipients compared to their separate Tgs (KollidonVA64 fine ~104C and 
trehalose ~107C). For the formulations stored at 40C/75% RH for 12 months, two Tgs 
(~78.7C and ~87.41C) were observed. The appearance of two Tgs is due to the presence 
of high moisture/humidity, which has a plasticization effect on the nanoparticles causing 
the nanocrystalline zileuton to isolate from the excipients, leaving the nanoparticle 
vulnerable to the physical instability (particle aggregation). All other formulations were 
stable post 12 months.  
4.4.5. In vitro dissolution testing 
The in vitro dissolution testing was performed using sextuplet formulations (n=6). In 
addition to the optimized nanocrystalline zileuton suspensions (30 min milled (216 nm)), 
two additional formulations (10 min milled (630 nm) and unmilled (20 m)) were 
investigated to determine the effect of particle size on the drug release profile (Figure 4.18a). 
The 216 nm showed the fastest dissolution rate and took only 45 min for complete drug 
release compared to 240 min and 480 min for the 630 nm and 20 µ formulations, 
respectively. The drug release or dissolution rate from the liquid crystalline zileuton 
formulations followed a particle size dependent dissolution trend. 
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For the spray-dried crystalline zileuton formulations, a similar particle size dependent trend 
in the dissolution profiles was observed (Figure 4.18b), except the rate was slower in 
comparison to the liquid crystalline formulations. The spray-dried formulations were filled 
into gelatin capsules and placed in USP apparatus I baskets. The slow dissolution rate is 
probably a result of gelatin capsule shell wetting, dissolution and erosion prior to the release 
of the spray dried powder in the dissolution media. The total time for complete drug 
dissolution from the spray dried crystalline zileuton – 276.4 nm, 738.2 nm and 22 m was 
2 h, 4 h and 8 h, respectively.  
The formulations stored at 4°C showed the fastest dissolution rate similar to the freshly 
prepared samples. The formulations stored at 40°C/75% RH showed a slower dissolution 
rate compared to the other formulations. The slow dissolution rate for the formulations 
stored at 40°C/75% RH is attributed to the increase in particle size due to nanoparticle 
aggregation as evident from the solid-state and particle size characterization techniques. The 
in vitro dissolution rate trend for the stability formulations was: freshly prepared=4°C > 
25°C/60% RH > 40°C/75% RH (post 12 months, Figure 4.18c). Complete drug release was 
achieved from the 4°C (and freshly prepared), 25°C/60% RH and  40°C/75% RH 
nanoparticle formulations in ~120 min, ~240 min and ~720 min, respectively.  
The effect of different pH conditions – stomach (pH 1.2) and intestine (pH 6.8) on the drug 
release during the transit of the nanocrystalline formulations (liquid and spray-dried) 
through the GIT was investigated using the in vitro dissolution pH shift test. The liquid 
nanocrystalline zileuton formulations showed <10 % drug release at pH 1.2 compared to the 
spray-dried formulations (<8 % drug release) in the initial 2 h (Figure 4.18d(i)). Following 
the pH switch from pH 1.2 to 6.8, the liquid nanocrystalline zileuton reached complete drug 
release in 1 h (total time: 3 h) compared to 2 h (total time: 4 h) taken by spray dried 
nanocrystalline zileuton. Following the stability studies, the pH shift experiments during in 
vitro dissolution testing were performed for the nanoparticles stored at different stability 
conditions (4°C, 40°C and 40°C/75% RH for 12 months) and compared with the day zero 
formulations. In the case of liquid nanocrystalline zileuton, the day zero and those stored at 
4C showed <10% drug release at pH 1.2 in 2 h (Figure 4.18d(ii)). Switching the pH from 
1.2 to 6.8, complete drug release was observed in 1 h (total time: 3h). However, the 
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nanoformulations stored at 40°C, showed a decrease in the drug dissolution rate and 
incomplete drug release (only 85% drug release in 4 h, total time: 6h) due to nanoparticle 
aggregation in these samples. In the case of spray dried nanocrystalline zileuton (powder 
formulations), the day zero and those stored at 4°C showed <8% drug release at pH 1.2 in 
2 h (Figure 4.18d(iii)). Switching the pH from 1.2 to 6.8, complete drug release was 
observed in 2 h (total time: 4h). The spray-dried formulations stored at 40°C/75% RH 
showed a similar trend to the liquid formulations stored at 40°C for 12 months, except the 
rate was slower.  
4.5. CONCLUSIONS 
The present research manifests the benefits of a comprehensive QbD approach for the 
systematic design and development of stable nanoparticulate drug products. Using the 
example of the spray-dried nanocrystalline zileuton, the significant CQAs were determined 
to be particle size and total product yield. The remaining CQAs were non-significant. 
Typically, a lab-scale spray dryer have total product yield of ~50% w/w, however based on 
this research, the total product yield of the nanocrystalline zileuton solid powder was ~80% 
w/w. A remarkably high total product yield was obtained following the comprehensive QbD 
approach, which is difficult to achieve in the case of individual DoE studies. Trehalose 
compared to mannitol was determined to be a better stabilizer preventing nanoparticle 
aggregation during the spray drying process which is in agreement with previous reports on 
nanoparticle aggregation. Based on the pH switch in vitro dissolution test, it was evident 
that complete drug release from the nanocrystalline zileuton formulations is achieved at 
intestinal pH (6.8). Based on the stability data, it is concluded that the spray-dried 
nanocrystalline drug products should be stored and transported at 4C to avoid any 
physicochemical instability. In addition, the manufacturing of such nanocrystalline drug 
products (lab-scale and pilot scale) requires strict temperature control (2-8C) to prevent 
nanoparticle physicochemical instability as well as any API associated instability. It is 
important to utilize orthogonal techniques (solid-state and analytical) to investigate the 
physicochemical instability (such as nanoparticle aggregation, drug degradation, 
polymorphic transition, etc.) as well as drug-stabilizer interaction because the combined 
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critical information from these techniques helps to develop robust nanoparticulate drug 
products.  
Till date, individual DoEs (either process or formulation) have been investigated for the 
development of nanocrystalline drug products. These isolated DoEs can resolve a specific 
physicochemical property (one or two) of the drug product, however, the optimized 
formulation composition or process parameters cannot be assured, since all possible process 
and formulation interactions are not investigated. The innovation in the present research is 
application of a comprehensive QbD approach for the identification, optimization, 
validation and control of the critical processes parameters and critical formulation 
parameters via multiple DoE models. The individual critical process parameters and critical 
formulation parameters as well as their interactions were analyzed for stable spray-dried 
nanocrystalline zileuton. In addition, this research investigated important CQAs (particle 
size and total product yield) to develop a precise design space.  This research can be applied 
to other BCS class II and II/IV drugs for the successful development of robust spray-dried 
nanocrystalline drug products. 
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4.6. Tables 
Table 4.1. Chemical structures of the active pharmaceutical ingredient and excipients 
Materials Chemical structures 
Zileuton 
 
KollidonVA64 fine 
 
Dowfax 2A1 
 
Trehalose 
 
Table 4.2. A DoE Design space for optimization of the wet media milling critical process 
parameters for the preparation of stable nanocrystalline zileuton. 
No. 
CPPs (wet media milling) 
Milling speed Pump speed Milling time 
rpm rpm min 
- 500-1500 80-120 15-30 
1 159 100 22.5 
2 1500 80 30 
3 1500 120 15 
4 1500 120 30 
5 1500 80 15 
6 1000 100 22.5 
7 1000 100 10 
8 1000 100 22.5 
9 1000 100 22.5 
10 1000 134 22.5 
11 1000 66 22.5 
12 1841 100 22.5 
13 500 120 15 
14 1000 100 22.5 
15 1000 100 35 
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16 500 120 30 
17 1000 100 22.5 
18 500 80 30 
19 1000 100 22.5 
20 500 80 15 
Table 4.3a. A DoE Design space for optimization of the spray drying critical process 
parameters for the preparation of stable nanocrystalline zileuton using mannitol as the sugar 
stabilizer (drug:sugar – 1:1, w/w). 
No. 
CPPs (spray drying with mannitol) 
Inlet temperature Aspirator rate Feed flow rate 
°C % % 
- 105-125 70-90 10-25 
1 115 80 18 
2 132 80 18 
3 115 80 18 
4 105 70 25 
5 115 80 18 
6 115 80 30 
7 105 90 25 
8 115 63 18 
9 105 70 10 
10 115 80 18 
11 115 80 5 
12 98 80 18 
13 125 70 25 
14 105 90 10 
15 125 90 25 
16 115 80 18 
17 115 80 18 
18 115 97 18 
19 125 90 10 
20 125 70 10 
Table 4.3b. A DoE Design space for optimization of the spray drying critical process 
parameters for the preparation of stable nanocrystalline zileuton using trehalose as the sugar 
stabilizer (drug:sugar – 1:1, w/w). 
No. 
CPPs (spray drying with trehalose) 
Inlet temperature Aspirator rate Feed flow rate 
°C % % 
- 105-125 70-90 10-25 
1 115 80 18 
2 132 80 18 
3 115 80 18 
4 105 70 25 
5 115 80 18 
6 115 80 30 
7 105 90 25 
8 115 63 18 
9 105 70 10 
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10 115 80 18 
11 115 80 5 
12 98 80 18 
13 125 70 25 
14 105 90 10 
15 125 90 25 
16 115 80 18 
17 115 80 18 
18 115 97 18 
19 125 90 10 
20 125 70 10 
Table 4.4a. A DoE Design space for the optimization of critical formulation parameters for 
the preparation of stable nanocrystalline zileuton post wet media milling. 
No. 
CFPs 
Drug concentration  Polymer concentration Surfactant concentration 
% w/v % w/v % w/v 
- 0.35-1 0.3-0.8 0.03-0.08 
1 1 0.3 0.08 
2 0.675 0.55 0.005 
3 1.325 0.55 0.055 
4 0.675 0.55 0.055 
5 1 0.3 0.08 
6 1 0.3 0.03 
7 0.675 1.05 0.055 
8 0.675 0.55 0.055 
9 0.675 0.55 0.055 
10 0.35 0.8 0.08 
11 0.675 0.55 0.055 
12 1 0.8 0.08 
13 0.675 0.55 0.055 
14 0.675 0.55 0.105 
15 0.35 0.3 0.03 
16 0.675 0.05 0.055 
17 0.35 0.8 0.08 
18 1 0.8 0.03 
19 0.35 0.8 0.03 
20 0.35 0.3 0.08 
21 0.35 0.3 0.03 
22 0.025 0.55 0.055 
23 0.675 0.55 0.055 
24 0.35 0.8 0.03 
25 1 0.3 0.03 
26 1 0.8 0.08 
27 0.35 0.3 0.08 
28 0.675 0.55 0.055 
29 0.675 0.55 0.055 
30 1 0.8 0.03 
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Table 4.4b. A DoE Design space for the optimization of critical formulation parameters for 
the preparation of stable nanocrystalline zileuton post spray drying. 
No. 
CFPs 
Drug concentration Polymer concentration 
Surfactant 
concentration 
Sugar 
amount 
% w/v % w/v % w/v mg 
- 0.35-1 0.3-0.8 0.03-0.08 850-2000 
1 1 0.8 0.03 2000 
2 0.35 0.3 0.03 2000 
3 0.35 0.3 0.08 850 
4 0.675 0.55 0.055 1425 
5 0.35 0.8 0.03 2000 
6 0.35 0.3 0.03 850 
7 1 0.3 0.03 2000 
8 1 0.8 0.08 850 
9 0.675 0.05 0.055 1425 
10 0.675 0.55 0.055 2575 
11 1 0.8 0.08 2000 
12 0.675 0.55 0.055 1425 
13 0.675 1.05 0.055 1425 
14 0.35 0.8 0.08 2000 
15 0.35 0.3 0.08 2000 
16 0.675 0.55 0.055 1425 
17 1 0.3 0.03 850 
18 1 0.3 0.08 2000 
19 0.675 0.55 0.055 275 
20 0.35 0.8 0.08 850 
21 0.675 0.55 0.105 1425 
22 0.675 0.55 0.055 1425 
23 1 0.3 0.08 850 
24 0.675 0.55 0.055 1425 
25 0.675 0.55 0.055 1425 
26 1 0.8 0.03 850 
27 0.025 0.55 0.055 1425 
28 1.325 0.55 0.055 1425 
29 0.35 0.8 0.03 850 
30 0.675 0.55 0.005 1425 
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Table 4.5. Solubility of zileuton in different excipient solutions  
Sample 
Number 
Excipient solution 
(0.2% w/v) 
Type of Stabilizer Zileuton solubility 
(µg/mL) 
Solubility 
(times X) 
1 No excipient  N/A 130.2 - 
2 Dowfax2A1 Anionic surfactant 165.2 1 
3 SLS Anionic surfactant 144.43 
4 Poloxamer P407 Nonionic surfactant 165.2 
5 Poloxamer 188 Nonionic surfactant 135.12 
6 EC 10 Nonionic polymer 187.905 1.5 
7 Kolliphor SLS fine Anionic surfactant 184.78 
8 Kollidon CLM Nonionic polymer 197.97 
9 PVP K17 Nonionic polymer 241.41 2 
10 PVP K25 Nonionic polymer 262.52 
11 PVP K30 Nonionic polymer 258.35 
12 PVP K90 Nonionic polymer 282.75 
13 HPMC K3 Nonionic polymer 258.94 
14 KollidonVA64 Nonionic polymer 254.74 
15 KollidonVA64 fine Nonionic polymer 242.55 
16 HPMC E3 Nonionic polymer 319.32 2.5 
17 HPMC E5 Nonionic polymer 327.01 
18 HPMC E15 Nonionic polymer 338.45 
19 HPMC E50 Nonionic polymer 344.9 
20 MC A15 Nonionic polymer 346.68 
21 Soluplus Nonionic polymer 391.64 3 
Table 4.6a. Results of DoE runs for optimization of the wet media milling critical process 
parameters for the preparation of stable nanocrystalline zileuton (3 CPPs x 3 CQAs). 
Wet media milling DoE 
No. 
CPPs CQAs 
Milling speed Pump speed Milling time Particle size PDI Zeta potential 
rpm rpm min 
nm units mV 
- 500-1500 80-120 15-30 
1 159 100 22.5 212.3 0.26 -78.3 
2 1500 80 30 29.16 0.322 -62.1 
3 1500 120 15 135 0.235 -66.8 
4 1500 120 30 65.7 0.156 -57.4 
5 1500 80 15 85.24 0.145 -63.6 
6 1000 100 22.5 214.5 0.187 -71.9 
7 1000 100 10 431.3 0.112 -76.3 
8 1000 100 22.5 200.4 0.237 -64.6 
9 1000 100 22.5 214.3 0.136 -57.1 
10 1000 134 22.5 130.5 0.219 -68.8 
11 1000 66 22.5 174.2 0.121 -69.3 
12 1841 100 22.5 37.13 0.228 -42.2 
13 500 120 15 306 0.136 -82.9 
14 1000 100 22.5 157.1 0.163 -72.8 
15 1000 100 35 145.9 0.17 -74.9 
16 500 120 30 182.1 0.13 -73.7 
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17 1000 100 22.5 245.4 0.459 -74.7 
18 500 80 30 274.2 0.197 -47.2 
19 1000 100 22.5 271.5 0.218 -77.6 
20 500 80 15 269 0.136 -82 
 
Table 4.6b. ANOVA table for CQA: Particle size of nanocrystalline zileuton post wet 
media milling 
Particle size  ANOVA for Response Surface Quadratic model 
Source 
Sum of 
Squares 
df 
Mean 
Square 
F Value 
p-value  
Prob > F 
Model 1.563E+005 9 17362.87 6.73 0.0032 significant 
A-Milling speed 74813.42 1 74813.42 28.99 0.0003 
R2=0.9519, Adjusted 
R2=0.9478 
B-Pump speed 130.98 1 130.98 0.051 0.8263 
C-Milling time 38388.65 1 38388.65 14.88 0.0032 
AB 2499.25 1 2499.25 0.97 0.3483 
AC 5.58 1 5.58 2.162E-003 0.9638 
BC 2531.87 1 2531.87 0.98 0.3453 
A2 19311.12 1 19311.12 7.48 0.0210 
B2 10378.25 1 10378.25 4.02 0.0727 
C2 6560.44 1 6560.44 2.54 0.1419 
Lack of Fit 18150.64 5 3630.13 2.37 0.1826 not significant 
Particle size (nm) = +217.80 – 74.01A – 3.1B – 53.02C + 17.68AB – 0.83AC – 17.79BC – 36.61A2 – 26.84B2 + 21.34C2 
 
Table 4.6c. Statistically predicted CPPs and CQAs based on the wet media milling DoE 
studies 
CPPs CQAs 
Desirability Milling speed 
(rpm) 
Milling time 
(min) 
Pump speed 
(rpm) 
Particle size 
(nm) 
PDI 
(units) 
Zeta potential 
(mV) 
1200 30 92 225 0.198 -67.99 0.898 
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Table 4.7a. Results of DoE runs for optimization of the spray drying critical process 
parameters (stabilizer: mannitol) for the preparation of stable nanocrystalline zileuton (3 
CPPs x 7 CQAs). 
Spray drying DoE (Stabilizer: Mannitol) 
No. 
CPPs CQAs 
Inlet 
temperature 
Aspirator 
rate 
Feed flow 
rate 
Outlet 
temperature 
Particle 
size 
PDI 
Zeta 
potential 
Drug 
loading 
Yield 
Moisture 
content 
°C % % 
°C nm units mV % (w/w) % (w/w) %  
- 105-125 70-90 10-25 
1 115 80 18 51 1084.00 0.098 -95.200 38.554 64.174 0.850 
2 132 80 18 60 1285.00 0.140 -73.600 33.764 66.957 0.745 
3 115 80 18 48 748.30 0.521 -11.000 33.582 61.739 0.745 
4 105 70 25 40 7259.00 0.866 -25.000 39.163 58.696 0.592 
5 115 80 18 51 222.50 0.257 -20.000 35.611 56.348 1.013 
6 115 80 30 46 169.50 0.125 -85.300 39.513 60.174 1.252 
7 105 90 25 48 165.50 0.205 -99.600 40.656 64.348 0.684 
8 115 63 18 47 180.70 0.289 -12.000 35.928 62.000 0.774 
9 105 70 10 60 167.40 0.164 -13.000 43.318 75.478 0.828 
10 115 80 18 51 1144.00 0.539 -24.000 35.656 62.696 0.980 
11 115 80 5 74 1131.00 0.373 -20.000 34.833 67.043 0.518 
12 98 80 18 37 5779.00 0.901 -36.000 37.959 60.174 0.767 
13 125 70 25 51 515.00 0.509 -42.000 41.774 54.174 0.711 
14 105 90 10 67 266.60 0.523 -37.000 37.438 84.000 0.815 
15 125 90 25 58 158.50 0.241 -11.000 41.575 60.609 0.683 
16 115 80 18 51 586.40 0.329 -15.000 36.752 74.522 1.208 
17 115 80 18 50 1071.00 0.967 -19.000 40.331 57.391 1.133 
18 115 97 18 60 172.70 0.306 -21.000 36.959 87.739 0.639 
19 125 90 10 74 356.70 0.613 -35.000 42.574 75.652 0.424 
20 125 70 10 68 191.10 0.421 -22.000 38.324 85.913 0.480 
 
Table 4.7b. ANOVA table for CQA: Total product yield of nanocrystalline zileuton (solid 
powder) post spray drying (with mannitol) 
Total product yield  ANOVA for Response Surface Reduced Cubic model 
Source 
Sum of 
Squares 
df 
Mean 
Square 
F Value 
p-value  
Prob > F 
Model 1684.42 10 168.44 5.94 0.0066 significant 
A-Inlet temperature 23.00 1 23.00 0.81 0.3913 
R2=0.9694, Adjusted 
R2=0.9622 
B-Aspirator rate 331.25 1 331.25 11.68 0.0077 
C-Feed flow rate 23.60 1 23.60 0.83 0.3855 
AB 40.50 1 40.50 1.43 0.2626 
BC 23.90 1 23.90 0.84 0.3826 
B2 310.54 1 310.54 10.95 0.0091 
ABC 47.85 1 47.85 1.69 0.2263 
A2B 133.99 1 133.99 4.72 0.0578 
A2C 231.58 1 231.58 8.17 0.0189 
AB2 25.76 1 25.76 0.91 0.3654 
Lack of Fit 43.94 4 10.98 0.26 0.8919 not significant 
Total product yield (% w/w) = +63.85 + 2.02A + 7.65B – 2.04C – 2.25AB +1.73BC +4.6B2 + 2.45ABC – 6.36A2B – 8.36A2C 
– 2.79AB2 
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Table 4.8a. Results of DoE runs for optimization of the spray drying critical process 
parameters (stabilizer:trehalose) for the preparation of stable nanocrystalline zileuton (3 
CPPs x 7 CQAs). 
Spray drying DoE (Stabilizer:Trehalose) 
No. 
CPPs CQAs 
Inlet 
temperature 
Aspirator 
rate 
Feed flow 
rate 
Outlet 
temperature 
Particle 
size 
PDI 
Zeta 
potential 
Drug 
loading 
Yield 
Moisture 
content 
°C % % 
°C nm units mV % (w/w) % (w/w) %  
- 105-125 70-90 10-25 
1 115 80 18 54 161.70 0.216 -27.00 40.00 59.57 3.36 
2 132 80 18 65 231.80 0.517 -29.00 41.25 67.57 3.21 
3 115 80 18 56 200.30 0.743 -19.00 36.27 58.61 3.47 
4 105 70 25 39 588.10 0.747 -33.00 40.31 58.96 3.45 
5 115 80 18 55 152.90 0.235 -11.00 43.06 64.96 3.42 
6 115 80 30 50 1316.00 0.779 -17.00 40.04 56.61 4.06 
7 105 90 25 50 3646.00 0.569 -19.00 43.64 51.91 3.42 
8 115 63 18 53 3069.00 0.741 -10.00 40.64 64.35 3.61 
9 105 70 10 60 3223.00 1.000 -16.00 42.23 63.65 3.93 
10 115 80 18 55 175.70 0.188 -20.00 45.30 63.30 3.78 
11 115 80 5 73 423.20 0.454 -58.60 40.02 59.39 3.07 
12 98 80 18 50 1523.00 0.351 -80.20 37.18 45.22 3.87 
13 125 70 25 50 1248.00 0.611 -23.00 44.57 60.87 3.31 
14 105 90 10 65 1054.00 0.681 -16.00 44.63 74.61 2.71 
15 125 90 25 60 964.00 0.930 -14.00 42.83 58.26 3.19 
16 115 80 18 55 117.70 0.485 -11.00 42.83 65.39 3.51 
17 115 80 18 56 148.10 0.231 -29.00 44.99 70.09 3.37 
18 115 97 18 60 284.30 0.595 -12.00 39.64 72.70 3.29 
19 125 90 10 75 1221.00 0.424 -88.40 41.24 50.00 2.79 
20 125 70 10 70 809.40 0.934 -15.00 38.22 60.00 2.98 
 
Table 4.8b. ANOVA table for CQA: Total product yield of nanocrystalline zileuton (solid 
powder) post spray drying (with trehalose) 
Total product yield  ANOVA for Response Surface Reduced Cubic model 
Source 
Sum of 
Squares 
df 
Mean 
Square 
F Value 
p-value  
Prob > F 
Model 907.60 13 69.82 4.57 0.0363 significant 
A-Inlet temperature 249.71 1 249.71 16.33 0.0068 
R2=0.9082,  
Adjusted R2=0.8993 
B-Aspirator rate 34.84 1 34.84 2.28 0.1819 
C-Feed flow rate 3.87 1 3.87 0.25 0.6328 
AB 34.12 1 34.12 2.23 0.1859 
AC 166.73 1 166.73 10.90 0.0164 
BC 14.07 1 14.07 0.92 0.3745 
A2 111.66 1 111.66 7.30 0.0355 
B2 32.65 1 32.65 2.14 0.1943 
C2 70.69 1 70.69 4.62 0.0751 
ABC 80.59 1 80.59 5.27 0.0615 
A2B 42.20 1 42.20 2.76 0.1477 
A2C 7.02 1 7.02 0.46 0.5234 
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AB2 277.07 1 277.07 18.12 0.0053 
Lack of Fit 3.36 1 3.36 0.19 0.6810 not significant 
Total product yield (% w/w) = +63.69 + 6.64A + 2.48B – 0.83C – 2.07AB + 4.57AC – 1.33BC – 2.78A2 + 1.51B2 – 2.21C2 
+3.17ABC – 3.57A2B – 1.46A2C – 9.41AB2 
 
Table 4.8c. Statistically predicted CPPs and CQAs based on the spray drying DoE studies 
Spray drying DoE (drug:sugar-1:1, w/w) Mannitol Trehalose 
CPPs 
Inlet temperature (C) 125 118 
Aspirator rate (%) 90 90 
Feed flow rate (%) 10 10 
CQAs 
Outlet temperature (C) 70 67 
Particle size (nm) 499.24 326.97 
PDI (units) 0.28 0.12 
Zeta potential (mV) -27.66 -58.18 
Drug loading (% w/w) 41.15 41.28 
Total yield (% w/w) 72.95 63.05 
Moisture content (%) 2.85 0.47 
Desirability 0.807 0.967 
 
Table 4.9a. Results of DoE runs for optimization of the critical formulation parameters 
(wet media milling) for the preparation of stable nanocrystalline zileuton (3 CFPs x 3 
CQAs). 
Formulation DoE (Wet Media Milling) 
No. 
CFPs CQAs 
Drug 
concentration  
Polymer 
concentration 
Surfactant 
concentration 
Particle size PDI Zeta potential 
% w/v % w/v % w/v 
nm units mV 
- 0.35-1 0.3-0.8 0.03-0.08 
1 1 0.3 0.08 174.1 0.266 -71.7 
2 0.675 0.55 0.005 346.5 0.336 -68.1 
3 1.325 0.55 0.055 125.8 0.224 -69.9 
4 0.675 0.55 0.055 383.3 0.263 -79.2 
5 1 0.3 0.08 182.8 0.277 -77.6 
6 1 0.3 0.03 212.6 0.316 -80.6 
7 0.675 1.05 0.055 356.8 0.499 -9.1 
8 0.675 0.55 0.055 497.5 0.315 -81 
9 0.675 0.55 0.055 397 0.213 -83.7 
10 0.35 0.8 0.08 746.1 0.885 -83.2 
11 0.675 0.55 0.055 426.6 0.313 -90.1 
12 1 0.8 0.08 230.7 0.176 -59 
13 0.675 0.55 0.055 434 0.202 -69.1 
14 0.675 0.55 0.105 526.7 0.319 -89.8 
15 0.35 0.3 0.03 732.8 0.394 -98.1 
16 0.675 0.05 0.055 286.3 0.166 -129 
17 0.35 0.8 0.08 621 0.462 -74.2 
18 1 0.8 0.03 207.6 0.181 -69 
19 0.35 0.8 0.03 703.3 0.483 -80.1 
20 0.35 0.3 0.08 748.5 0.5 -109 
21 0.35 0.3 0.03 613 0.419 -96.3 
22 0.025 0.55 0.055 1536 0.45 -112 
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23 0.675 0.55 0.055 366.3 0.282 -81.3 
24 0.35 0.8 0.03 756.2 0.478 -78.1 
25 1 0.3 0.03 108.5 0.167 -78.2 
26 1 0.8 0.08 133.3 0.225 -55.4 
27 0.35 0.3 0.08 667.1 0.434 -107 
28 0.675 0.55 0.055 230.9 0.363 -75.8 
29 0.675 0.55 0.055 234.1 0.253 -82.6 
30 1 0.8 0.03 117.3 0.278 -64.5 
 
Table 4.9b. ANOVA table for CQA: Particle size of nanocrystalline zileuton post wet 
media milling 
Particle size  ANOVA for Response Surface Cubic model 
Source 
Sum of 
Squares 
df 
Mean 
Square 
F Value 
p-value  
Prob > F 
Model 2.551E+006 22 1.160E+005 16.86 0.0004 significant 
A-Drug concentration 9.943E+005 1 9.943E+005 144.60 < 0.0001 
 
R2=0.9815,  
Adjusted R2=0.9233 
B-Polymer concentration 2485.13 1 2485.13 0.36 0.5667 
C-Surfactant concentration 16236.02 1 16236.02 2.36 0.1683 
AB 184.28 1 184.28 0.027 0.8746 
AC 594.14 1 594.14 0.086 0.7773 
BC 1578.08 1 1578.08 0.23 0.6465 
A2 2.911E+005 1 2.911E+005 42.33 0.0003 
B2 16219.91 1 16219.91 2.36 0.1685 
C2 541.88 1 541.88 0.079 0.7870 
ABC 1711.89 1 1711.89 0.25 0.6331 
A2B 883.23 1 883.23 0.13 0.7306 
A2C 9310.26 1 9310.26 1.35 0.2827 
AB2 41990.59 1 41990.59 6.11 0.0428 
Lack of Fit 8427.93 2 4213.97 0.53 0.6180 not significant 
Particle size (nm) = +392.58 – 352.55A + 17.62B + 45.05C – 3.39AB + 6.09AC – 9.93BC +103.02A2 – 24.32B2 + 4.44C2 + 10.34ABC 
– 12.87A2B – 41.78A2C + 88.73AB2 
 
Table 4.10a. Results of DoE runs for optimization of critical formulation parameters 
(spray drying) for the preparation of stable nanocrystalline zileuton (4 CFPs x 7 CQAs). 
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Formulation DoE (spray drying) 
No. 
CFPs CQAs 
Drug 
concentration 
Polymer 
concentration 
Surfactant 
concentration 
Sugar 
amount 
Outlet 
temperature 
Particle 
size 
PDI 
Zeta 
potential 
Drug 
loading 
Total 
Yield 
Moisture 
content 
% w/v % w/v % w/v mg 
°C nm units mV % % % 
- 0.35-1 0.3-0.8 0.03-0.08 850-2000 
1 1 0.8 0.03 2000 72 494.1 1 -117 11.75377 48.69 3.68 
2 0.35 0.3 0.03 2000 71 1718 0.065 -103 6.539006 63.69 3.456 
3 0.35 0.3 0.08 850 68 1756 0.291 -113 12.5826 75.40 3.214 
4 0.675 0.55 0.055 1425 68 1472 1 -109 11.98958 54.30 3.18 
5 0.35 0.8 0.03 2000 71 658.7 0.855 -106 6.510985 49.85 3.649 
6 0.35 0.3 0.03 850 71 1735 0.2 -99.1 10.98196 68.35 3.404 
7 1 0.3 0.03 2000 68 1004 0.877 -123 11.00261 59.29 3.457 
8 1 0.8 0.08 850 72 694.8 0.781 -107 21.56875 58.25 2.703 
9 0.675 0.05 0.055 1425 70 1551 0.679 -101 16.41053 82.69 2.668 
10 0.675 0.55 0.055 2575 70 1668 0.927 -114 14.89958 46.00 4.431 
11 1 0.8 0.08 2000 72 137.9 0.323 -103 9.036766 52.06 3.82 
12 0.675 0.55 0.055 1425 71 1668 0.927 -113 14.21775 65.96 3.611 
13 0.675 1.05 0.055 1425 68 1593 1 -94.1 10.57662 40.16 3.858 
14 0.35 0.8 0.08 2000 68 2880 0.956 -108 5.346451 42.95 3.729 
15 0.35 0.3 0.08 2000 76 852.2 0.233 -99.9 5.612018 58.18 3.663 
16 0.675 0.55 0.055 1425 70 1668 0.927 -50.2 11.90832 72.29 3.323 
17 1 0.3 0.03 850 68 273.3 0.663 -94.7 31.19071 83.51 2.806 
18 1 0.3 0.08 2000 70 171.9 0.177 -130 18.74133 64.15 3.433 
19 0.675 0.55 0.055 275 71 1668 0.927 -91 12.25046 65.57 2.857 
20 0.35 0.8 0.08 850 68 969.1 0.367 -80.3 9.417043 61.06 3.108 
21 0.675 0.55 0.105 1425 68 102.4 0.692 -103 15.849 70.65 3.607 
22 0.675 0.55 0.055 1425 71 1582 1 -101 16.11059 55.99 3.499 
23 1 0.3 0.08 850 72 146.1 0.414 -43.2 14.40945 85.07 2.98 
24 0.675 0.55 0.055 1425 72 898.7 0.786 -76.3 37.93154 52.89 2.728 
25 0.675 0.55 0.055 1425 67 317.9 0.642 -90.7 16.26445 54.00 3.003 
26 1 0.8 0.03 850 69 368.5 0.697 -86.9 27.06975 59.85 3.17 
27 0.025 0.55 0.055 1425 71 3440 0.735 -111 2.75378 48.84 4.421 
28 1.325 0.55 0.055 1425 71 196.9 0.455 -102 21.35168 49.52 3.146 
29 0.35 0.8 0.03 850 75 1990 0.729 -92.8 8.798703 65.44 4.334 
30 0.675 0.55 0.005 1425 72 1718 0.0656 -103 15.95752 73.25 3.166 
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Table 4.10b. ANOVA table for CQA: Total product yield of nanocrystalline zileuton 
(solid powder) post spray drying (with trehalose) 
Total product yield  ANOVA for Response Surface Quadratic model 
Source 
Sum of 
Squares 
df 
Mean 
Square 
F Value 
p-value  
Prob > F 
Model 3492.06 14 249.43 6.19 0.0006 significant 
A-Drug concentration 31.14 1 31.14 0.77 0.3931 
R2=0.9525, Adjusted 
R2=0.9149 
B-Polymer concentration 1743.67 1 1743.67 43.29 < 0.0001 
C-Surfactant concentration 1.90 1 1.90 0.047 0.8310 
D-Amount of sugar  1029.61 1 1029.61 25.56 0.0001 
AB 45.14 1 45.14 1.12 0.3065 
AC 20.07 1 20.07 0.50 0.4910 
AD 2.99 1 2.99 0.074 0.7890 
BC 19.09 1 19.09 0.47 0.5016 
BD 15.94 1 15.94 0.40 0.5387 
CD 2.90 1 2.90 0.072 0.7920 
A2 117.96 1 117.96 2.93 0.1076 
B2 26.79 1 26.79 0.67 0.4275 
C2 359.40 1 359.40 8.92 0.0092 
D2 4.88 1 4.88 0.12 0.7326 
Lack of Fit 285.94 10 28.59 0.45 0.8681 not significant 
Total product yield (% w/w) = +59.24 + 1.14A – 8.52B – 0.28C – 6.55D – 1.68AB + 1.12AC – 0.43AD – 1.09BC + 1.00BD – 0.43CD 
– 2.07A2 + 0.99B2 + 3.62C2 – 0.42D2 
 
Table 4.11. Statistically predicted CPPs, CFPs and CQAs based on the formulation DoE  
Comprehensive DoEs 
Wet media milling (CPPs) Spray drying (CPPs) Formulation (CFPs) 
Milling speed (rpm) 1200 Inlet temperature (C) 118 Drug concentration (% w/v) 1 
Milling time (min) 30 Aspirator rate (%) 90 Polymer concentration (% w/v) 0.3 
Pump speed (rpm) 92 Feed flow rate (%) 10 Surfactant concentration (% w/v) 0.06 
 Amount of sugar (mg) 850 
 
CQAs 
Outlet temperature (C) 69 
Particle size (nm) 300.03 
PDI (units) 0.126 
Zeta potential (mV) -80.84 
Drug loading (% w/w) 22.31 
Total yield (% w/w) 77.66 
Moisture content (%) 1.66 
Desirability 0.904 
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Table 4.12. Physicochemical properties of the optimized spray-dried nanocrystalline 
zileuton formulations following one, six and twelve month/s exposure under different 
storage conditions. 
Testing formulation : Optimized 
spray-dried nanocrystalline zileuton 
Particle 
size (nm) 
PDI 
(units) 
Zeta potential 
(mV) 
Moisture content 
(%) 
Drug loading (% 
w/w) 
Predicted values 300.03 0.126 -80.84 1.66 22.31 
Experimental values  
0 month Initial (n=6) 276.4 0.109 -91.4 1.09 23.8 
1 month 
4°C 273.1 0.115 -81.5 0.990 23.71 
25°C/60% RH 619.5 0.589 -103 1.17 23.25 
40°C/75% RH 996.4 0.791 -92.6 1.29 23.31 
6 months 
4°C 275.43 0.12 -79.63 0.994 23.84 
25°C/60% RH 648.91 0.723 -97.64 2.79 23.41 
40°C/75% RH 1013.19 0.817 -94.61 3.29 23.61 
12 months 
4°C 274.16 0.118 -81.2 0.989 23.82 
25°C/60% RH 694.37 0.653 -102 3.19 23.28 
40°C/75% RH 1209.43 0.923 -96.39 4.55 23.81 
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4.7. Figures 
GRAPHICAL ABSTRACT 
 
Graphical abstract: Comprehensive QbD process flow for the successful development of the 
robust nanocrystalline drug products  
 
Figure 4.1. Flow diagram comparing conventional QbT (quality by testing) approach vs. 
novel QbD (quality by design) approach. 
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Figure 4.2: (A) Biopharmaceutical classification system (I-IV); (B) Current trend in the 
BCS; (C) % of the new chemical entities distributed amongst different BCS class (I-IV); 
(D) Top 200 marketed drugs categorized amongst different BCS class (I-IV). 
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Figure 4.3: Features of nanocrystals: (1) increased dissolution rate (dc/dt) due to increased 
surface area (A); (2) increased apparent solubility (Cs) due to increased dissolution pressure 
(P) of strongly curved small nanocrystals; and (3) increased mucoadhesiveness of 
nanocrystals due to increased contact area of small versus large particles [(f(x)-function of 
x, D-diffusion coefficient, Cs-saturation solubility of drug, Cx-concentration around the 
particle/bulk concentration, h-diffusional distance, C-solubility of solid consisting of large 
particles, Pr-dissolution pressure of particle with radius r, P-dissolution pressure of an 
infinitely large particle, σ-interfacial tension of substance, V-molar volume of the particle 
material, R-gas constant, T-absolute temperature, ρ-density of the solid, r-radius, d-
diameter] 
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Figure 4.4. (A) Image of Microcer Netzsch wet media mill (B) Schematic representation 
of wet media milling process: (1) Addition of micro-suspension to feed chamber; (2) 
Transfer of micro-suspension from feed chamber to peristaltic pump; (3) Transfer of micro-
suspension from peristaltic pump to milling chamber in the presence of grinding media 
(zirconia milling beads – 0.05 mm diameter) for nano-milling; and (4) Transfer of 
nanosuspension from milling chamber to feed chamber]. 
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Figure 4.5. (A) Image of Buchi Mini Spray Dryer B-290 (B) Two fluid Nozzle 
(Atomization tool) (C) Schematic representation of Buchi Mini Spray Dryer B-290 and 
particle spray flow pattern (the vertical inverted cone (grey dotted lines) at point of 
atomization followed by red dotted lines) 
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Figure 4.6a. Risk estimation matrix for (A) process risks and (B) formulation risks 
 
Figure 4.6b. Ishikawa/Fishbone diagram for preparation of stable spray-dried 
nanocrystalline zileuton (risk assessment tool)  
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Figure 4.7. Bar chart displaying solubility of zileuton in different excipients  
 
 137 
 
 
Figure 4.8. Contour plots and 3D surface plots for CQA: particle size comparing: (A) 
effect of milling speed and pump speed on the particle size; (B) effect of milling time and 
milling speed on the particle size; and (C) comparative surface plots: milling speed vs. 
milling time (left) and milling speed vs. pump speed (right). 
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Figure 4.9. Contour plots and 3D surface plots for CQA: total product yield of spray-dried 
nanocrystalline zileuton (stabilizer: mannitol) comparing: (A) effect of inlet temperature 
and aspirator rate on the total product yield; (B) effect of inlet temperature and feed flow 
rate on the total product yield; and (C) comparative surface plots: inlet temperature vs. 
aspirator rate (left) and inlet temperature vs. feed flow rate (right) 
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Figure 4.10. Contour plots and 3D surface plots for CQA: total product yield of spray-
dried nanocrystalline zileuton (stabilizer: trehalose) comparing: (A) effect of inlet 
temperature and aspirator rate on the total product yield; (B) effect of inlet temperature and 
feed flow rate on the total product yield; and (C) comparative surface plots: inlet 
temperature vs. aspirator rate (left) and inlet temperature vs. feed flow rate (right) 
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Figure 4.11. Contour plots and 3D surface plots for CQA: particle size comparing: (A) 
effect of drug concentration and polymer concentration on the particle size; (B) effect of 
drug concentration and surfactant concentration on the particle size; and (C) comparative 
surface plots: drug concentration vs. polymer concentration (left) and drug concentration 
vs surfactant concentration (right) 
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Figure 4.12. Contour plots and 3D surface plots for CQA: total product yield of spray-
dried nanocrystalline zileuton (stabilizer:trehalose) comparing: (A) effect of drug 
concentration and polymer concentration on the total product yield; (B) effect of drug 
concentration and surfactant concentration on the total product yield; (C) effect of drug 
concentration and amount of sugar on the total product yield; and (D) comparative surface 
plots: drug concentration vs. polymer concentration (top left); drug concentration vs. 
surfactant concentration (top right) and; drug concentration vs. amount of sugar (bottom 
center) 
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Figure 4.13. Particle size distribution and moisture content of the optimized spray-dried 
nanocrystalline zileuton formulations stored for 1, 6 and 12 month/s at: (a) 4°C; (b) 
25°C/60% RH; and (c) 40°C/75% RH compared with zero month formulations. 
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Figure 4.14. PXRD diffraction profiles of the neat macrocrystalline zileuton (raw 
crystalline drug), physical mixture of the drug (zileuton), polymer (KollidonVA64 fine), 
surfactant (Dowfax2A1) and sugar (trehalose) and the optimized spray-dried 
nanocrystalline zileuton formulation (initial and formulations stored for 12 months at 4°C, 
25°C/60% RH and 40°C/75% RH) 
 
Figure 4.15a. ATR-FTIR full spectra overlay of the neat macrocrystalline zileuton (raw 
crystalline drug), physical mixture of the drug (zileuton), polymer (KollidonVA64 fine), 
surfactant (Dowfax2A1) and sugar (trehalose) and the optimized spray-dried 
nanocrystalline zileuton formulations (at day zero and those stored for 12 months at 4°C, 
25°C/60% RH and 40°C/75% RH) 
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Figure 4.15b. ATR-FTIR spectra (3000-2850 cm-1) overlay of the neat macrocrystalline 
zileuton (raw crystalline drug), physical mixture of the drug (zileuton), polymer 
(KollidonVA64 fine), surfactant (Dowfax2A1) and sugar (trehalose) and the optimized 
spray-dried nanocrystalline zileuton formulations (at day zero and those stored for 12 
months at 4°C, 25°C/60% RH and 40°C/75% RH) 
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Figure 4.15c. ATR-FTIR spectra (3220-3140 cm-1) overlay of the neat macrocrystalline 
zileuton (raw crystalline drug), physical mixture of the drug (zileuton), polymer 
(KollidonVA64 fine), surfactant (Dowfax2A1) and sugar (trehalose) and the optimized 
spray-dried nanocrystalline zileuton formulations (at day zero and those stored for 12 
months at 4°C, 25°C/60% RH and 40°C/75% RH). 
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Figure 4.15d. ATR-FTIR spectra (1700-550 cm-1) overlay of the macrocrystalline zileuton 
(neat drug), physical mixture (zileuton, KollidonVA64 fine, Dowfax2A1 and trehalose) 
and the optimized spray-dried nanocrystalline zileuton formulations (at day zero and those 
stored for 12 months at 4°C, 25°C/60% RH and 40°C/75% RH). 
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Figure 4.16. PLM images of the neat macrocrystalline zileuton (raw crystalline drug), 
physical mixture (zileuton, KollidonVA64 fine, Dowfax2A1 and trehalose) and the 
optimized spray-dried nanocrystalline zileuton formulations (day zero and those stored for 
12 months at 4°C, 25°C/60% RH and 40°C/75% RH). Note: All images are of 10X 
magnification. 
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Figure 4.17. DSC thermogram of  neat macrocrystalline zileuton (raw crystalline drug), 
and the optimized spray-dried nanocrystalline zileuton formulations (initial as well as those 
stored for 12 months at 4°C, 25°C/60% RH and 40°C/75% RH). 
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Figure 4.18a. In vitro drug release testing of different sized (30 min milled, 10 min milled, 
and unmilled) crystalline liquid suspension formulations. (USP apparatus II with paddle at 
100 rpm, pH 6.8, phosphate buffer, n = 6) 
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Figure 4.18b. In vitro drug release testing of different sized (30 min milled, 10 min milled, 
and unmilled) crystalline spray dried formulations as capsules. (USP apparatus I with 
basket at 100 rpm, pH 6.8, phosphate buffer, n = 6) 
 
Figure 4.18c. In vitro drug release testing of spray dried nanocrystalline zileuton 
comparing freshly prepared formulations with those stored at 4°C, 25°C/60% RH and 
40°C/75% RH for twelve months in capsules. (USP apparatus I with basket at 100 rpm, pH 
6.8, phosphate buffer, n=6) 
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Figure 4.18d. In vitro drug release testing with a pH shift from pH 1.2 for the initial 2 h to 
pH 6.8 for next 4 h (USP apparatus II with paddle at 100 rpm, n = 6) comparing: (i) zileuton 
nanosuspensions vs. spray dried nanocrystalline zileuton powder (at day zero); (ii) zileuton 
nanosuspension formulations stored at different stability conditions (day zero, 4°C /12 
months and 40°C/12 months); and (iii) spray dried nanocrystalline zileuton formulations 
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stored at different stability conditions (day zero, 4°C /12 months and 40°C/75% RH/12 
months).  
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Chapter 5 
Nanoamorphous Drug Products – Design and Development   
ABSTRACT  
Most of the recent drug compounds coming out of the drug discovery pipeline are labile 
(multiple polymorphs), and need to be developed into robust marketed oral drug 
formulations. There are only 22 oral macroamorphous drug products approved by FDA 
and till date no oral nanoamorphous drug products. However, there are several oral 
nanoamorphous drug formulations (including both labile and non-labile drugs) being 
researched and a few of these are in the clinical trials. Due to the labile nature of these drug 
compounds, there is a need to utilize a controlled strategy for design and development of 
robust nanoamorphous drug formulations in order to prevent any physicochemical 
instability. The present research focuses on the use of a novel integrated critical process 
parameters and critical formulation parameters (iCPP-CFPs) DoE approach for the design 
and development of stable nanoamorphous spironolactone (BCS class II compound with 
eight polymorphic forms). There are possibilities of the interconversion of these 
polymorphic forms during processing (manufacturing nanoamorphous particles) and 
during storage. In the present study, polymorphic transitions (amorphous to crystalline and 
anhydrous to hydrate) were carefully monitored via orthogonal solid-state characterization 
tools. Significant polymorphic transitions were observed in the formulations stored at 
40C/75% RH over six months, however the formulations stored at 4C were stable. The 
significant iCPP-CFPs (solvent-to-antisolvent ratio, drug concentration and inlet 
temperature of the spray dryer) were critically investigated for their influence on different 
CQAs (critical quality attributes). Solvent-to-antisolvent ratio and inlet temperature were 
identified to be the significant iCPP-CFPs. Particle size and total product yield were 
identified to be the significant CQAs. Lab-scale manufacturing of the spray dried 
nanoamorphous spironolactone resulted in a remarkably high total product yield 
(82.43.91% w/w) with a uniform and homogenous particle size (244.223.32 nm). 
Furthermore, the physicochemical attributes and the drug release criteria of the 
nanoamorphous spironolactone were compared with two marketed products 
(spironolactone tablets, USP 100 mg (Pfizer and Mylan)) and other in-house formulations. 
 162 
In addition, nanoamorphous spironolactone showed a significantly superior kinetic 
solubility/dissolution rate (10-fold) with a longer supersaturation time (~6 h) compared to 
the in-house formulations and marketed drug products.     
5.1. INTRODUCTION 
Pharmaceutical drug products are mostly administered via the oral route as this is most 
convenient and acceptable to patients [1, 2]. The use of nanoamorphous drug particles is 
an emerging strategy to allow oral administration of BCS class II and II/IV drugs (poorly 
soluble compounds) [3-5]. Amorphous nanoparticles have significantly enhanced 
solubility and bioavailability through a combination of enhanced dissolution rates (due to 
nano-size range and amorphous solid-state form) and increased supersaturation levels (due 
to amorphous solid-state form). Amorphous nanoparticles are solid dispersions in the 
colloidal size range (100 to 1000 nm) and are typically stabilized via crystallization 
inhibitors (polymers, surfactants, sugars or their combinations) [5]. The mechanisms by 
which these crystallization inhibitors stabilizes the drug in the amorphous nanoparticles 
are: (1) significant reduction in the molecular motion of the dispersed drug; (2) inhibition 
of the solution facilitated crystal growth and nucleation of the dissolved drug, maintaining 
the supersaturation level for a long period of time; and (3) improvement in the storage 
stability by inhibition of the recrystallization of amorphous drug [6].   
Nanoamorphous amphotericin and glibenclamide prepared using the stabilizers Tween 
80/poloxamer 188 and HPMC, respectively have been reported to have 13-fold and 10-fold 
enhancement in the kinetic solubility/dissolution rate compared to the macrocrystalline 
drug [7, 8]. More importantly, nanoamorphous itraconazole has been reported to have 2.5-
fold and 18-fold increase in oral bioavailability compared to macroamorphous and 
macrocrystalline formulations, respectively [3]. Nanocrystalline itraconazole showed a 
similar increase in oral bioavailability to the nanoamorphous formulation, however, there 
was a significant delay in the Cmax from the 4 h to 8 h due to the reduced solubility of the 
crystalline form. These and previous studies have used relatively stable APIs (with zero or 
a few polymorphic forms). However, most of the drugs coming out of the drug discovery 
pipeline are comparatively labile (with multiple polymorphic forms) [9]. Such labile drugs 
suffers from physical instability issues (polymorphic transition, drug crystallization and 
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nanoparticle aggregation) during processing and/or storage stability studies. When 
considering nanoamorphous formulations there are additional instability issues due to their 
small particle size (nanoparticle aggregation and increased probability of polymorphic 
transition) compared to macroamorphous counterparts. The present research focuses on 
investigating and inhibiting aggregation and polymorphic transition for nanoamorphous 
formulations of labile drugs during manufacturing and accelerated stability studies. 
Spironolactone (labile molecule with eight polymorphic forms) was used as a model BCS 
class II drug [10]. Spironolactone is a diuretic steroidal aldosterone agonist with an average 
molecular weight - 416.6 g/mol and an aqueous solubility ~ 28 g/mL [11]. 
In the present research, an integrated critical process parameter-critical formulation 
parameters (iCPP-CFPs) DoE approach was used to develop nanoamorphous 
spironolactone formulations. Sonoprecipitation followed by spray drying were utilized to 
manufacture solid nanoamorphous spironolactone. The effect of solvent-to-antisolvent 
ratio, drug concentration, surfactant concentration and inlet temperature of the spray dryer 
were evaluated. The important CQAs investigated were particle size; drug loading; zeta 
potential; and total product yield. Dowfax2A1 (anionic surfactant) and trehalose (high Tg 
sugar) were used as auxiliary stabilizers to achieve non-crystallizing, non-aggregating 
spray-dried nanoamorphous spironolactone powders. In vitro dissolution testing was 
conducted on the optimized nanoamorphous spironolactone formulations as well as storage 
stability formulations (40C/75% RH, 25C/60% RH and 4C for 6 months). The marketed 
spironolactone products (RLD – Aldactone, spironolactone USP 100 mg tablets (Pfizer) 
and generic –spironolactone USP 100 mg tablets (Mylan)) were also investigated. To the 
best of our knowledge, this is the first study to develop a nanoamorphous drug product via 
an iCPP-CFPs DoE approach using a labile drug (multiple polymorphic forms). In addition, 
the effect of temperature and humidity on the physicochemical attributes of the spray dried 
nanoamorphous spironolactone was critically evaluated via storage stability studies 
(40C/75% RH, 25C/60% RH and 4C for 6 months). The optimized nanoamorphous 
spironolactone and the marketed drug products were analyzed via an array of solid-state 
tools (PLM, PXRD, DSC, FTIR and AFM) to investigate any critical polymorphic 
transitions.  
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5.2. MATERIALS  
Crystalline spironolactone (greater than 99% purity) was purchased from Beijing 
Mesochem Technology Co. Ltd., China. Trehalose was gifted by Gattefose. Dowfax 2A1 
was gifted by Dow Chemical Company. Marketed spironolactone tablets (Aldactone, 
Spironolactone tablets, USP 100 mg (RLD) and Spironolactone Tablets, USP 100 mg 
(Generic) were purchased from G.D. Searle (Division of Pfizer Inc.) and Mylan 
Pharmaceuticals Inc., respectively. The chemical structures of the ingredients used in the 
optimized spray-dried nanoamorphous spironolactone formulation are shown in Table 5.1. 
HPLC grade solvents were purchased from Fisher Scientific. Inspire C18 column (4.6 mm 
x 100 mm, 5μm) was gifted by Dikma Technologies Inc.   
5.3. METHODS 
Based on the pre-formulation studies, it was observed that the spray drying and the freeze 
drying were the most feasible drying techniques. Furthermore, at drug-stabilizer weight 
ratios 3:1 and 1:1, w/w, it was observed that PVP K12 and HPMC E3 resulted in lowest 
interaction parameter value (towards negative) and a high negative free energy of mixing 
indicating a strong interaction (hydrogen bonding) between these stabilizers and the drug 
(Figure A, B and C). Accordingly, these polymers were considered for the formulation 
development. However, preliminary trials showed a stable formulations is obtained at a 
low concentration of surfactant (Dowfax2A1) and at 1:3, w/w drug:trehalose. Therefore, 
the iCPP-CFPs DoEs were performed using only these two excipients.  
5.3.1 Manufacturing of nanoamorphous spironolactone powder 
5.3.1.1 Spironolactone nanoemulsions via sonoprecipitation  
Spironolactone nanoemulsions were manufactured via the sonoprecipitation technique. 
Sonoprecitation is a combination of solvent-antisolvent precipitation and ultrasonication. 
Briefly, crystalline spironolactone was completely dissolved in dichloromethane (DCM) at 
different concentrations as detailed in the DoE section below (5.3.3). 1 mL drug solution 
in DCM (“solvent”) was injected (using a syringe with a 22.1G needle) in different volumes 
of distilled water containing stabilizer (anionic surfactant – Dowfax2A1) (“antisolvent”) at 
a rate of 10 mL/min under ultrasonication (probe sonication). Different surfactant 
 165 
concentrations and solvent-to-antisolvent ratios were investigated as detailed in the DoE 
section below (5.3.3). A sonic dismembrator (Fisher scientific model 550) using a probe 
tip diameter of 13 mm at a frequency of 20 kHz was used for ultrasonication. The probe 
tip was immersed a distance of 5 mm in the antisolvent solution and sonication was carried 
out for the optimized time of 1 min 40 s and at the optimized speed 3.5 units to obtain 
nano-sized precipitates. The entire process was performed at 2-8C to prevent thermal 
degradation of the drug. The resultant nanoemulsions were kept under magnetic stirring 
for 1 hour under vacuum for organic solvent removal.  
5.3.1.2 Nanoamorphous spironolactone via spray drying 
The spironolactone nanoemulsions prepared via sonoprecipitation were mixed with sugar 
stabilizer (trehalose) and spray dried to obtain nanoamorphous spironolactone powder 
(Figure 5.1). Spironolactone nanoemulsions were spray-dried using a benchtop B-290 
spray dryer (Buchi Labortechhnik AG, Flawil, Switzerland) based on the DoE detailed in 
section (3.3). The spray dryer was equilibrated using distilled water. Once the spray dryer 
was equilibrated, distilled water was changed to the nanoemulsions formulations. The 
nanoemulsion formulations were pumped using a peristaltic pump at a pump rate of 15 % 
and at a feed flow rate of 5 mL/min. The aspirator rate was 80% (air volume flow (32.5 
m3/h)). Based on the preliminary study, it was observed that the inlet temperature is a 
critical spray drying process parameter which can significantly influence different CQAs 
(particle size, particle morphology, total product yield and crystallinity) [3, 4, 12, 13]. 
Thus, the inlet temperature was one of the critical process parameters investigated as 
detailed in the DoE section below (5.3.3). Gas flow (atomizing air) was kept constant at 40 
mm Hg (air flow approximately 600 L/h) for all the formulations. Each formulation was 
spray-dried using trehalose as an excipient [drug:trehalose (1:3, w/w)] to prevent 
nanoparticle aggregation. Spray-dried powders were collected from the collection chamber 
and immediately analyzed for the CQAs (particle size, total product yield and crystallinity). 
5.3.2 Design of experiments (DoE) 
According to the preliminary investigation (data not shown), an integrated critical process 
and critical formulation parameters DoE (iCPP-CFPs) was implemented. Four different 
iCPP-CFPs were selected to analyze their effect on different CQAs of the spray dried 
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nanoamorphous spironolactone powders (particle size, polydispersity index, zeta potential, 
moisture content, drug loading and total product yield). These iCPP-CFPs were: drug 
concentration (in solvent), solvent-to-antisolvent ratio, surfactant concentration and inlet 
temperature of the spray dryer. The ranges of these factors were: drug concentration (0.1 – 
0.6 %w/v), solvent-to-antisolvent ratio (1:2 – 1:25 v/v), surfactant concentration (0.05 – 
0.5 %w/v) and inlet temperature (110 – 130 C). A response surface methodology with a 
cubic centered design was utilized to investigate these factors. The design space is provided 
in Table 5.2. Design Expert and Minitab 18.0 software were utilized for the experimental 
design and detailed analysis of the different CQAs.   
5.3.3 Characterization of the nanoamorphous spironolactone 
5.3.3.1 Particle size measurement 
Particle size measurements were performed using a Zetasizer Nano ZS90 (Malvern 
Instruments). Briefly, the spray-dried formulations were suspended in a saturated and 
filtered (0.2 μm PVDF membrane filter) solution of spironolactone in 30% glycerin 
solution to avoid any discrepancy resulting from dissolution of the nano-particles during 
measurement. The viscosity of this dispersant solution was measured via a Brookfield 
viscometer (Model DV-III) and used to calculate the particle size of the re-dispersed 
nanoamorphous spironolactone. Zeta potential of these re-dispersed formulations were 
measured in the folded capillary zeta cells using the same instrument.  All formulations 
were analyzed in triplicate and the results were reported as the mean value of these runs. 
5.3.3.2 Powder X-Ray Diffraction (PXRD) 
PXRD was utilized to determine any presence of crystallinity in the spray-dried 
formulations. X-ray diffraction patterns were obtained using an X-ray diffractometer 
(Model D5005, Bruker AXS Inc., Madison, WI) with Cu-kα radiation, a voltage of 40 kV, 
and a current of 40 mA. All the scans were performed with a scanning rate of 2°/minute 
with steps of 0.02° from 5° to 40° at 2θ ranges.  
5.3.3.3 HPLC analytical method 
The quantification of spironolactone was conducted using an Agilent-HPLC system with a 
UV detector. The absorbance wavelength was set at 254 nm. The mobile phase was a 
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mixture of distilled water and methanol at a 34:64 %v/v ratio. A C18 Inspire 5μ analytical 
column (4.6 mm × 100 mm) was used with a flow rate of 1 ml/min and the column 
temperature was maintained at 40°C using a column heater.  
5.3.3.4 Attenuated Total Reflectance - Fourier Transform Infrared Spectroscopy (ATR-
FTIR) 
IR spectroscopy was performed using a Nicolet FTIR (iS5 FTIR, Thermo Scientific) 
spectrometer with an attenuated total reflectance (ATR) accessory. Spray-dried powders 
were placed on the crystal window (Germanium) and compressed lightly using a pressure 
clamp. Spectra were recorded over a range of 400–4000 cm−1 with a resolution of 4 cm−1, 
for 128 parallel scans. Data analysis was performed on Omnic® 6.0a software (Thermo 
Nicolet Corporation).  
5.3.3.5 Polarized Light Microscopy (PLM) 
The spray-dried formulations were dispersed in the immersion oil and placed on 
microscope slides. The samples were analyzed using an Olympus BH2 polarized 
microscope with a Q-imaging camera, accessories and software. All images were obtained 
at 10X resolution. 
5.3.3.6 Differential Scanning Calorimetry (DSC) 
DSC was performed using a TA Q1000 (TA instruments, New Castle, DE) calorimeter and 
calibrated using indium and sapphire discs. Approximately 5–10 mg of spray-dried 
formulations and neat drug (control) were sealed in hermetic pans and analyzed. The 
heating rate was maintained at 5 °C/min and the temperature was increased from room 
temperature to 190 °C. Nitrogen gas was used for purging at a flow rate of 50 mL/min. The 
data were analyzed using TA universal analysis software. 
5.3.3.7 Atomic Force Microscopy (AFM) 
The spray dried nanoformulations, drug powders and tablets were mounted using double 
sided tape on a glass slide and placed under the AFM microscope. Images were captured 
using an Asylum Research MFP-3D atomic force microscope using AC Air topography 
mode. Silicon probe OMCL-AC160TS-W2 (Olympus) cantilevers with a nominal spring 
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constant of 42 N/m were used to image the surface topography of the powders and the 
tablets. Images were taken with a deflection set-point of 1 V and an integral gain between 
3 and 22, depending on the sample and the size of the image. Images up to 10-15 microns 
were collected with scan rates between 0.1 and 0.5 Hz.  All measurements were performed 
at room temperature and images were analyzed using Igor Pro 6.36 software with Asylum 
Research version 12 software. 
5.3.3.8 In vitro dissolution testing 
USP apparatus II (AT7 smart, Sotax AG Switzerland) was utilized for the in vitro 
dissolution experiments. The dissolution testing of the spray-dried powders was performed 
under non-sink conditions. All the dissolution experiments were conducted at 37°C in 900 
mL of pH 1.2 hydrochloric acid (0.1 N) at a speed of 75 rpm. At each time point, 2 mL 
samples were withdrawn from the dissolution chamber and replaced with fresh dissolution 
media. The samples were filtered using 0.1 μm PVDF filters to avoid any erroneous results 
from un-dissolved nano-particulates. All samples were analyzed using the HPLC method 
as described above. The samples were analyzed on day zero and after storing at different 
conditions 4C, 25C/60% RH and 40C/75% RH for one, three and six month/s. The 
marketed tablets were tested at the same conditions. All formulations were analyzed in 
sextuplet and the results were reported as the mean value of these runs. 
5.3.4 Stability testing 
All the spray-dried powder formulations were stored at three different storage conditions 
i.e. 4°C, 25°C/60% RH and 40°C/75% RH for 6 months. Samples were withdrawn at 1, 3 
and 6 month/s and analyzed for particle size distribution, zeta potential, moisture content, 
crystallinity and in vitro dissolution testing.  
5.4. Reference listed drug product and generic drug product  
The spray dried nanoamorphous spironolactone formulations were characterized and 
compared against two marketed spironolactone drug products: Aldactone (Spironolactone 
tablets, USP 100 mg) – Pfizer (RLD) and Spironolactone tablets, USP 100 mg – Mylan 
(Generic). All of the above analytical and solid-state characterization tools were used to 
test these marketed drug products. Furthermore, these marketed drug products were stored 
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at different accelerated stability conditions along with the spray dried nanoamorphous 
spironolactone formulations to compare the effect of temperature and humidity.  
5.5. Miscellaneous in-house spironolactone formulations 
Different in-house spironolactone formulations (macro-amorphous, macro-crystalline and 
nanocrystalline) were prepared and used as a controls for comparison against the spray 
dried nanoamorphous spironolactone formulations and marketed drug products.  
5.5.1 Macroamorphous spironolactone 
Amorphous spironolactone (micron-size amorphous) was prepared by spray drying. The 
required quantity of spironolactone and the stabilizer excipients (trehalose and 
Dowfax2A1) mixed in the same ratio as the optimized spray dried formulations were 
dissolved in methanol and spray dried. The spray dried macro-amorphous formulations 
were used as controls.   
5.5.2 Nanocrystalline spironolactone 
Spironolactone (0.4% w/v) was suspended in the aqueous stabilizer solution (i.e. 0.13% 
w/v Dowfax2A1). The prepared suspension was stirred for 30 minutes for complete 
wetting of the drug by the stabilizer solution. The suspension (80 mL) was milled using a 
Netzsch media mill (Netzsch, Exton, PA) at a fixed milling intensity of 1500 rpm in the 
continuous mode. The suspension formulation was continuously milled for 40 minutes. 
The temperature of the sample was maintained at 2-8°C using two cooling bath re-
circulators. The nano-crystalline suspension was spray-dried using trehalose as an auxiliary 
excipient [drug:trehalose (1:3, w/w)]. The nanocrystalline spironolactone formulations 
were used as controls. 
5.5.3 Macrocrystalline spironolactone 
Crystalline spironolactone (micron-sized crystalline) were prepared by serial dilution. The 
required quantity of spironolactone and the stabilizer excipients (trehalose and 
Dowfax2A1) in the same ratio as the optimized spray dried formulations were mixed via 
serial dilution. The macrocrystalline spironolactone formulations were used as controls. 
 
 170 
5.6. RESULTS & DISCUSSION 
5.6.1. Influence of iCPP-CFPs on different CQAs of spray-dried nanoamorphous 
spironolactone 
The iCPP-CFPs DoE was performed according to the CCD design space and the results are 
shown in Table 5.3. It was observed that surfactant concentration had a negligible influence 
on all CQAs.  
5.6.1.1. Particle size 
The drug concentration and inlet temperature were determined to be the critical parameters 
for the particle size. Before spray drying, the particle size of nanoamorphous 
spironolactone was <200 nm at drug concentrations and solvent-to-antisolvent ratios in the 
range of 0.2-0.5% w/v and 1:5 to 1:25 v/v, respectively (Figure 5.2a).  At drug 
concentrations above 0.5% w/v and below 0.15% w/v, the nanoparticles were significantly 
larger in size (>400 nm). After spray drying, the particle size of nanoamorphous 
spironolactone was <200 nm at drug concentrations in the range of 0.15-0.5% w/v and at 
spray dryer inlet temperatures of 115C (Figure 5.2b). At inlet temperatures above 120C, 
the particle size of spray-dried nanoamorphous spironolactone was >400 nm.  At inlet 
temperatures below 120C, the atomized droplets formed from the spray dryer are uniform 
and homogenous in terms of particle size. Moreover, at inlet temperatures below 120C, 
the particle size is maintained at <200 nm, due to the stabilizing effects of the surfactant 
(Dowfax2A1) and sugar (trehalose). As the inlet temperature increases above 120C, the 
cosolvents (DCM and water) are rapidly evaporated, causing increase in the viscosity of 
the atomized droplets, which results in nanoparticle aggregation (nanoparticles sticking to 
one another or to the glass walls of the spray dryer) leading to significant increase in 
particle size.  In addition, above 120C, the surfactant and sugar lose their stabilizing effect 
on the drug in the nanoemulsion due to rapid drying resulting in nanoparticle aggregation 
and result in increase in particle size (>400 nm). Solvent-to-antisolvent ratio and surfactant 
concentration had a negligible influence on the particle size. A plot showing predictive 
particle size (theoretically predicted from the model) and actual/observed particle size 
(experimental based on DoE) is represented in Figure 5.2c. The main effect plot, pareto 
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chart of the standardized effects and the interaction plots for particle size of 
nanoamorphous spironolactone are shown in Figure 5.2d.   
ANOVA and multiple linear regression were performed on the particle size data and a 
predictive surface reduced cubic model was generated. The final equation based on the 
three iCPP-CFPs (drug concentration, solvent-to-antisolvent ratio and inlet temperature) 
and the interaction terms for the prediction of the particle size are provided in Table 5.4. It 
is evident that the surface reduced cubic model was significant and the lack of fit for this 
model was not significant, indicating that the model was significant for the CQA.   
5.6.1.2. Total product yield 
The drug concentration, solvent-to-antisolvent ratio and inlet temperature were determined 
to be the critical parameters for the total product yield. The total product yield of 
nanoamorphous spironolactone increased from 60 to 80% w/w with increase in the drug 
concentrations from 0.1 to 0.6% w/v and increase in the solvent-to-antisolvent ratio from 
1:5 to 1:25 v/v (Figure 5.3a). At low drug concentrations (0.1-0.2% w/v), and at low 
solvent-to-antisolvent ratio (1:5 v/v), the nanoparticles formed were large in size (>400 
nm). During sonoprecipitation, these large size nanoparticles stick to the walls of the 
sonicator or the manufacturing vessel, resulting in low total product yield (60% w/w). In 
addition, a low antisolvent phase (1:5 v/v) (surfactant in distilled water) provides less 
dispersibility to the nanodroplets of the solvent phase (drug in DCM) compared to a high 
antisolvent phase (1:25 v/v). Thus, the nanodroplets are uniformly dispersed at a high 
solvent-to-antisolvent ratio (1:25 v/v), which dries rapidly upon atomization with low 
moisture content, preventing any loss of the spray-dried powder resulting in high total 
product yield (80-85% w/w).   
The total product yield of nanoamorphous spironolactone increased from 70 to 85% w/w 
with an increase in the drug concentration from 0.1 to 0.35% w/v and an increase in the 
spray drying inlet temperature from 110C to 125C (Figure 5.3b). Insufficient drying at 
low inlet temperatures (<115C) causes increase in the moisture content of the spray-dried 
powder, which causes invariable sticking of the nanoparticles to the glass walls of the spray 
dryer resulting in low yield (70% w/w).  Increase in the inlet temperature from 115C to 
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125C leads to rapid drying of the atomized droplets of the nanoemulsion resulting in 
formation of spray-dried powder with minimal moisture content avoiding sticking 
problem, thereby providing high yield (85-90% w/w). A plot showing predictive (based on 
theoretically predicted from the model) and actual/observed (experimental based on DoE) 
total product yield is represented in Figure 5.3c. Figure 5.3d shows the main effect plot, 
pareto chart of the standardized effects and the interaction plot for the total product yield 
of nanoamorphous spironolactone. 
ANOVA and multiple linear regression were performed on the results of the total product 
yield and a predictive surface reduced cubic model was generated. The final equation based 
on the three iCPP-CFPs (drug concentration, solvent-to-antisolvent ratio and inlet 
temperature) and the interaction terms for the prediction of the total product yield of the 
nanoamorphous spironolactone are provided in Table 5.5. As can be observed in Table 5.5, 
it is evident that the surface reduced cubic model was significant and the lack of fit for this 
model was not significant, indicating that the model was significant for the CQA (i.e. total 
product yield of the spray-dried nanoamorphous spironolactone).  
5.6.1.3. Zeta potential 
The drug concentration, solvent-to-antisolvent ratio and inlet temperature were determined 
to be the critical parameters for the zeta potential. The zeta potential of nanoamorphous 
spironolactone increased from -90 to -40 mV with the increase in the drug concentrations 
from 0.1 to 0.6% w/v and decrease in the solvent-to-antisolvent ratio from 1:25 to 1:5 v/v 
(Figure 5.4a). The increase in zeta potential was due to stabilizing effect of the surfactant 
molecules on the drug particles. At high solvent-to-antisolvent ratio (1:25 v/v) and at low 
drug concentrations (<0.25% w/v), the surfactant concentration is very high compared to 
the drug molecules, a low zeta potential value (-90 mV) is due to the presence excess 
surfactant molecules remaining after stabilizing the drug molecules. With the increase in 
drug concentration (towards 0.6% w/v) and decrease in solvent-to-antisolvent ratio 
(towards 1:5 v/v), these excess surfactant molecules stabilizes the drug molecules, thereby 
reducing the surfactant concentration and leading to a high zeta potential value (-40 mV).  
The zeta potential of nanoamorphous spironolactone increased from -90 to -40 mV with 
the increase in the drug concentrations from 0.1 to 0.6% w/v and increase in the spray 
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drying inlet temperatures from 110C to 130C (Figure 5.4b). At low drug concentration 
(0.1% w/v) and low inlet temperature (110C), there is incomplete coating of the drug 
nanoparticles by sugar, exposing the negatively charged surfactant on the surface of the 
drug nanoparticles, resulting in low zeta potential (-90 mV). With the gradual increase in 
the drug concentrations (0.1 to 0.6% w/v) and increase in the inlet temperatures (110C to 
130C), the atomized droplets formed at end of the two fluid nozzle of the spray dryer 
experiences rapid drying causing uniform coating of the sugar molecules to the drug-
surfactant nanoparticles minimizing the exposure of the negatively charged surfactant and 
resulting in the increase in zeta potential values (-90 to -40 mV).  A contour plot and a 3D 
surface plot shows the effect of drug concentrations, solvent-to-antisolvent ratios and inlet 
temperatures of spray dryer on zeta potential (Figure 5.4a and 5.4b). A plot showing 
predictive (based on theoretically predicted from the model) and actual/observed 
(experimental based on DoE) is represented in Figure 5.4c. Figure 5.4d shows the main 
effect plot, pareto chart of the standardized effects and interaction plot for zeta potential of 
nanoamorphous spironolactone. 
ANOVA and multiple linear regression were performed on the results of the zeta potential 
and a predictive surface reduced cubic model was generated. The final equation based on 
the three iCPP-CFPs (drug concentration, solvent-to-antisolvent ratio and inlet 
temperature) and the interaction terms for the prediction of the zeta potential of the 
nanoamorphous spironolactone are provided in Table 5.6. As can be observed in Table 5.6, 
it is evident that the surface reduced cubic model was significant and the lack of fit for this 
model was not significant, indicating that the model was significant for the CQA (i.e. zeta 
potential of the spray-dried nanoamorphous spironolactone).  
5.6.1.4. Drug loading 
The drug concentration, solvent-to-antisolvent ratio and inlet temperature were determined 
to be the critical parameters for the drug loading. The drug loading of nanoamorphous 
spironolactone decreased from 20 to 15% w/w with the increase in the drug concentrations 
from 0.1 to 0.6% w/v and increase in the solvent-to-antisolvent ratio from 1:5 to 1:25 v/v 
(Figure 5.5a). At low solvent-to-antisolvent ratio (1:5 v/v) and at low drug concentrations 
(0.1 – 0.2% w/v), the solvent phase (drug in DCM) has limited antisolvent phase (surfactant 
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in distilled water) to disperse in, as a result most of the surfactant molecules strongly 
stabilizes all drug molecules, minimizing the drug loss (either due to sticking to the walls 
of the ultrasonicator or walls of the manufacturing vessel), resulting in high drug loading 
(20% w/w). With the increase in drug concentrations (0.2 – 0.6% w/v) and increase in the 
solvent-to-antisolvent ratios (1:5 – 1:25 v/v), the solvent phase has large volumes of the 
antisolvent phase to disperse in, as a result the surfactant molecules fails to provide strong 
stability to the drug molecules, making the drug molecules vulnerable to the sticking and 
aggregation (as observed with the increase in particle size), resulting in decrease in drug 
loading (20 – 15% w/w).  
With the increase in the drug concentrations (0.1 – 0.6% w/v) and increase in the inlet 
temperatures of the spray dryer (110C - 130C), the drug loading decreases (20 – 16% 
w/w) (Figure 5.5b). At low spray dryer inlet temperatures between 110C - 125C and low 
drug concentrations (0.1 – 0.2% w/v), the dried nanoparticles formed at the point of the 
atomization from the two fluid nozzle of the spray dryer has uniform and homogenous 
particle size and limited moisture content, and due to rapid drying the sugar-surfactant 
complex provides strong stabilizing effect to the drug nanoparticles, preventing any drug 
loss (either due to drug molecules phasing out of the sugar-surfactant coating or due to 
sticking to the glass walls of the spray dryer), resulting in high drug loading (20% w/w). 
At high inlet temperatures (130C) and high drug concentrations (0.3 – 0.6% w/v), there 
is high level of rapid drying of the nanoparticles which causes the drug molecules to phase 
out of the drug nanoparticles (drug molecules coated with surfactant-sugar) due to the 
inability of the surfactant and sugar in stabilizing the drug nanoparticles at high drug 
concentrations. The drug molecules which phase out after passing through the two fluid 
nozzle atomizes into minute droplets and rapidly dry out with significant drug loss due to 
two main reasons: (1) the moisture content is very high in the dried drug particles which 
causes the drug molecules (that has phase out from the stabilizers) to stick to the glass walls 
of the spray dryer; and/or (2) the dried drug particles formed at the point of the atomization 
of the two fluid nozzle are very small in size which due to the rapid convective gas current 
in the spray dryer are subsequently carried directly to the filter compartment from which it 
is difficult to retrieve the dried particles. As a result of these two way mechanisms of drug 
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loss leading to only dried blank surfactant-sugar nanoparticles mixed with less dried drug-
surfactant-sugar nanoparticles being accumulated in the collection chamber of the spray 
dryer, there is significant decrease in the drug loading of the spray-dried formulations. A 
plot showing predictive drug loading (based on theoretically predicted from the model) and 
actual/observed drug loading (experimental based on DoE) is shown in Figure 5.5c. A 
contour plot and a 3D surface plot shows the effect of drug concentrations, solvent-to-
antisolvent ratios and inlet temperatures of spray dryer on drug loading (Figure 5.5a and 
5.5b). Figure 5.5d shows the main effect plot, pareto chart of the standardized effects and 
interaction plot for drug loading. 
ANOVA and multiple linear regression were performed on the results of the drug loading 
and a predictive surface reduced cubic model was generated. The final equation based on 
the three iCPP-CFPs (drug concentration, solvent-to-antisolvent ratio and inlet 
temperature) and the interaction terms for the prediction of the drug loading of the 
nanoamorphous spironolactone are provided in Table 5.7. As can be observed in Table 5.7, 
it is evident that the surface reduced cubic model was significant and the lack of fit for this 
model was not significant, indicating that the model was significant for the CQA (i.e. drug 
loading of the spray-dried nanoamorphous spironolactone).  
Following the iCPP-CFPs DoE studies, the optimized contour plots (Figure 5.6a and 5.6b) 
based on the DoE models were considered to predict the optimized iCPP-CFPs and CQAs 
(Table 5.8). The predicted iCPP-CFPs were applied for the validation of the DoE studies.  
5.6.2. Validation of DoE studies and Stability studies 
The iCPP-CFPs DoE studies were validated by applying the statistically predicted 
parameters to prepare sextuplets batches (n=6) of nanoamorphous spironolactone 
formulations and the average experimental physicochemical properties (Table 5.9) of the 
sextuplet formulations was compared with the statistically predicted CQAs (Table 5.8). 
The optimized nanoamorphous spironolactone formulations (experimental total product 
yield: 82.4% w/w) prepared based on the statistically predicted parameters obtained from 
the iCPP-CFPs DoE studies (described in Table 5.8) were stored at three different stability 
conditions (4C, 25C/60% RH and 40C/75% RH for one, three and six month/s). At each 
time-point, the formulations were analyzed for particle size distribution, moisture content, 
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drug loading and zeta potential. Additionally, the nanoamorphous spironolactone 
formulations were also analyzed using DSC and PXRD (to monitor any polymorphic 
transformation i.e. conversion of one crystalline form to other), AFM (to understand the 
surface topology and interaction between drug and stabilizer), ATR-FTIR (to investigate 
interaction between drug and stabilizer), PLM (to monitor any generation of non-
crystallinity or amorphous particles) and in vitro dissolution testing (to study the effect of 
particle size, solid-state form, temperature and humidity on drug release).  
5.6.3 Particle size distribution and Moisture content 
As shown in Table 5.9 and  Figure 5.7, the particle size, PDI and moisture content of the 
prepared spray-dried nanoamorphous spironolactone increased following one, three and 
six month/s storage under both conditions: 25°C/60% RH and 40°C/75% RH. The moisture 
content significantly increased for the formulations stored at 25°C/60% RH and 40°C/75% 
RH (to 3.5 and 4.25%, respectively) after six months. This can be compared to the 
formulations stored at 4°C which had the same moisture content as the initial formulations 
(1.5%). It was observed that at the high relative humidity (60% and 75%), the 
nanoamorphous (thermodynamically metastable form) converted to the crystalline form 
(thermodynamically stable) due to plasticization caused by high moisture. This physical 
instability was observed as a result of significant aggregation (increase in particle size) in 
nanoamorphous spironolactone formulations stored at 25°C/60% RH and 40°C/75% RH 
conditions (at all timepoints). On the other hand, the optimized formulations stored at 4°C 
were determined to be stable in terms of particle size distribution, moisture content and 
zeta potential over the six month storage stability.  
5.6.4 Powder X-ray diffraction 
The characteristic diffraction peaks of neat macrocrystalline spironolactone (most stable - 
polymorphic form II) were 9.5, 11.9, 12.7, 17.05, 18.7, 20.5, 23.1, 26.3, 29.6, and 
35.4 [11]. All formulations and marketed drug products showed characteristic PXRD 
diffraction peaks similar to the form II of spironolactone indicating their crystalline nature, 
except for the macro- and nanoamorphous spironolactone (Figure 5.8a). The macro- and 
nanoamorphous spironolactone displayed a halo pattern indicating their amorphous nature. 
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Additionally the marketed drug products, especially the RLD showed reduced intensity 
and less number of crystalline diffraction peaks due to the presence of multiple excipients 
in the drug products, which shadows the drug’s crystalline diffraction peaks.   
It was observed that the spray-dried nanoamorphous spironolactone formulations displayed 
a halo pattern for day zero, one and six month/s at 4C indicating a stable amorphous form 
(Figure 5.8b). However, the formulations stored at 25C/60% RH and 40C/75% RH after 
one month showed the appearance of crystalline diffraction peaks (conversion of 
amorphous to crystalline form) which sharpened and increased in intensity after six 
months. The thermodynamically metastable amorphous form plasticized in the presence of 
high humidity (60% RH and 75% RH) and converted to the stable crystalline form.  
Multiple crystalline diffraction peaks were observed at all conditions for the generic 
spironolactone drug product compared to the neat drug due to the presence of multiple 
excipients in addition to the drug (Figure 5.8c). However, most of the crystalline diffraction 
peaks relevant to the form II of the drug were clearly identified at all stability conditions 
for the generic spironolactone. Additionally, the generic drug product stored at 25C/60% 
RH and 40C/75% RH (1 and 6 month/s) showed reduced intensity diffraction peaks 
compared to that stored at 4C (1 and 6 months) and day zero. The conversion of the form 
II anhydrous to the form II hydrate in the presence of high humidity is considered to be the 
reason for the reduced intensity in the diffraction peaks for the generic drug product stored 
at 25C/60% RH and 40C/75% RH (1 and 6 month/s). 
The crystalline diffraction peaks observed for all conditions in the RLD spironolactone are 
scarce and with reduced intensity due to multiple excipients present in the drug product 
which shadows the drug’s crystalline diffraction peaks (Figure 5.8d). Additionally, the low 
intensity diffraction profiles of the RLD is due to the presence of a mixture of crystalline 
and amorphous drug forms.  
5.6.5 Attenuated total reflectance – Fourier transform infrared spectroscopy 
Spironolactone has three carbonyl groups which show characteristics absorbance in FTIR 
(carbonyl stretching bond of the lactone (C=O) – 1670 cm-1, 6-membered ring (C=O) – 
1690 cm-1 and thioacetyl (C=O) – 1765 cm-1) [14-16]. In addition, the drug also shows 
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characteristic absorbance at 1618 cm-1 due to –C=C– stretching of the α, β-unsaturated ring 
and at 2950 cm-1 due to –C=H stretching.  Any interaction (hydrogen bonding or 
hydrophobic) of the drug with the stabilizer can significantly influence these peaks (either 
shift in the wavenumber or change (increase/decrease) in the intensity) [17].   
A broad band was observed between 3000-3500 cm-1 in the FTIR spectra for the spray-
dried nanoamorphous spironolactone which was missing in the neat drug and the physical 
mixture (Figure 5.9a and 5.9b). Additionally, the generic and RLD spironolactone showed 
this broad band with two peaks at 3400 cm-1 and 3500 cm-1. The band broadening is 
considered to be due to hydrogen bonding between the: (1) –C=O moiety of the drug and 
the –OH group of the sugar; and (2) –SH moiety of the drug and the –OH group of the 
sugar. The three carbonyl (–C=O) moieties and one sulfhydryl (–SH) group of 
spironolactone form hydrogen bonding with the multiple hydroxyl (–OH) groups of the 
trehalose.  
All three carbonyl groups of the drug were significantly affected via interaction (H-
bonding) between the drug and the stabilizers (Figure 5.9c). This caused reduction in the 
absorbance intensity of the characteristic carbonyl peaks (1670, 1690 and 1765 cm-1) in the 
nanoamorphous, generic and RLD spironolactone compared to the strong intensity of these 
peaks in the neat drug and the physical mixture. The peaks at 1670 and 1690 cm-1 were 
absent in the nanoamorphous spironolactone. In addition there is significant reduction in 
peak intensity (1618 cm-1 related to –C=C– stretching) in the nanoamorphous and generic 
spironolactone compared to the rest of the samples.  
The neat drug and the physical mixture showed a medium intensity absorbance peak at 
1440 cm-1 (due to CH2 bending, CH3 bending and OH bending) which is not present in the 
nanoamorphous, generic and RLD spironolactone (Figure 5.9d). A strong intensity 
absorbance peak at 1380 cm-1 (due to C-H bending, S=O stretching, OH bending) was 
observed in the neat drug and physical mixture samples which was not observed in the 
other samples. Three strong intensity absorbance peaks (1350 cm-1 (CH3 bending, SO 
stretching, C-O stretching), 1330 cm-1 (OH bending) and 1265 cm-1(C-O stretching)) were 
observed in the neat drug and physical mixture which were reduced in intensity (1265 cm-
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1 and 1330 cm-1) or absent (1350 cm-1) in the nanoamorphous, generic and RLD 
spironolactone (Figure 5.9e).  
The absence or reduced intensity of this peaks in the nanoamorphous, generic and RLD 
spironolactone could be possibly due to strong interaction between the drug and the 
stabilizers. The nanoamorphous spironolactone is prepared via sonoprecipitation followed 
by spray drying. The generic and RLD spironolactone are also prepared by one of the 
amorphous solid dispersion manufacturing process. Amorphous solid dispersions are 
dispersions of solid amorphous drug which is in the molecularly dispersed state 
(homogenous glass solution) in the amorphous stabilizer matrix with strong interactions 
(H-bonding and hydrophobic interactions) between the drug and the stabilizers.   
In the stability formulations, the strong interaction (hydrogen bonding) between the neat 
drug and the stabilizers (Dowfax2A1 and trehalose) in the nanoamorphous formulations 
results in a broad band between 3600-3000 cm-1 (Figure 5.10a). Furthermore, the FTIR 
finger print was completely different for the neat drug and the nanoamorphous 
spironolactone formulations in the 1950-500 cm-1 region.  
An additional peak was observed at 3500 cm-1 in the nanoamorphous spironolactone stored 
at 40C/75% RH post six months which was absent in all other formulations as well as the 
neat drug (Figure 5.10b). Furthermore, there was a peak shift from 1765 cm-1 (neat drug 
and nanoamorphous spironolactone (day zero and 4C/6 months)) to 1775 cm-1 
(formulations stored at 25C/60% RH and 40C/75% RH for six months) (Figure 5.10c). 
The appearance of the new peak and the peak shift was due to the polymorphic transition 
(amorphous anhydrate form II to crystalline hydrate form II) in the nano-formulations 
stored at high humidity (60 and 75% RH) post six months.  
5.6.6 Polarized light microscopy 
It is required that spironolactone nanoemulsions should be completely amorphous before 
spray drying. All nanoemulsions were observed under PLM and no birefringence 
(crystallinity) was observed before spray drying (data not shown). After spray drying, the 
crystallinity was critically monitored for all formulations and this is discussed below.  
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All images (Figure 5.11a) showed sharp birefringence (shiny colored crystals), except the 
nanoamorphous spironolactone which lacked the birefringence (dull black particles).  The 
large rod, plate and prism shaped crystals (sharp birefringence) were observed for the neat 
drug (macrocrystalline spironolactone - 20 particle size) (Figure 5.11b). The physical 
mixture (spironolactone, Dowfax2A1 and trehalose in the same ratios as the optimized 
formulations) showed sharp birefringence. The spray-dried nanoamorphous spironolactone 
formulations (day zero and 4C/6 months) showed lack of birefringence (dull black 
particles) due to the complete amorphous nature of the formulations.  
The large rod, plate and prism shaped crystalline drug macroparticles are broken down to 
amorphous nanoparticles stabilized via the surfactant (during sonoprecipitation) which are 
further stabilized with the sugar (during spray drying). The stabilizers (surfactant-sugar 
complex) maintain the nanoamorphous nature of the formulation with specific morphology 
throughout the manufacturing process. Spray-dried nanoamorphous spironolactone 
formulations stored at 25°C/60% RH showed the appearance of limited birefringence after 
six months which is corroborated by the PXRD diffraction profiles. Furthermore, 
prominent birefringence was observed after six months in the spray-dried nanoamorphous 
spironolactone formulations stored at 40°C/75% RH. The amorphous form of the drug 
converts into the crystalline form due to plasticization effect as a result of increase in the 
relative humidity leading to nanoparticle aggregation (verified by the particle size increase 
observed in the formulations stored at high humidity (60% RH and 75% RH)) for six 
months. There is increase in the free volume of the amorphous nanoparticles due to the 
presence of high moisture/high humidity (plasticization effect of water) resulting in an 
increase in the molecular mobility [18]. This results in a decrease in the viscosity and glass 
transition temperature (Tg) of the nanoamorphous particles leading to an increased 
possibility of nucleation followed by crystallization. From the DSC analysis, it was 
observed that the nanoamorphous spironolactone showed a single uniform glass transition 
temperature at 91C (no melting endotherm) indicating a homogenous amorphous nature 
of the drug and the excipients in the solid dispersion. The high humidity during the storage 
stability (60% RH and 75% RH) results in a polymorphic transition (amorphous to 
crystalline) leading to the appearance of multiple glass transition peaks due to separation 
of the amorphous sugar-surfactant stabilizer complex from the amorphous drug.  
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5.6.7 Atomic Force Microscopy 
Based on the AFM analysis, the spray dried nanoamorphous spironolactone was 
homogenous with spherical shape and uniform particle size (200-300 nm) compared to the 
neat drug which possesses angular and prism shaped crystals (Figure 5.12). The generic 
and RLD spironolactone displayed macrocrystalline and irregular shaped crystals.  
5.6.8 In vitro dissolution testing 
The spray dried nanoamorphous powder showed superior in vitro release characteristics 
compared to the macroamorphous as well as the nanocrystalline and macrocrystalline 
spironolactone powder formulations (Figure 5.13). The nanoamorphous spironolactone 
reached maximum saturation concentration (i.e. approximately 20 μg/mL) within 
30 minutes compared to the macroamorphous spironolactone (approximately 12 m), 
which took almost 10 h to reach maximum drug concentration. The nanocrystalline and 
macrocrystalline spironolactone powder formulations took approximately 12 and 24 h, 
respectively to reach equilibrium solubility (i.e. 20 μg/mL). Following 2 h of in vitro 
dissolution testing, the nanocrystalline (784 nm), macroamorphous (12 m) and 
nanoamorphous spironolactone (251 nm) formulations showed a 2-fold, 4.5-fold and 10-
fold increase in the saturation solubility compared to the macrocrystalline spironolactone 
(20 m). The nanoamorphous spironolactone showed superior in vitro release 
characteristics (90% in 15 min) compared to the marketed products (90% in 45-60 min). 
Additionally, the generic and RLD spironolactone showed faster dissolution rates 
compared to the macrocrystalline, macroamorphous and nanocrystalline spironolactone 
(Figure 5.13).  
The nanoamorphous spironolactone formulations (day zero and those stored for six months 
at 4C) maintained the supersaturation of the drug during 6 h of in vitro dissolution testing 
(Figure 5.14). At high humidity (60% RH and 75% RH) there was a polymorphic transition 
(amorphous to crystalline) due to the plasticization effect of the moisture on the 
nanoamorphous formulations. This significantly affected the dissolution profiles of the 
nanoamorphous formulations stored for six months (25°C/60% RH and 40°C/75% RH). 
The drug release was reduced significantly to approximately 70% and 40% for the nano-
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formulations stored at 25°C/60% RH and 40°C/75% RH, respectively. There was a drop 
in the supersaturation for these nano-formulations within 45-60 min. The formulations 
stored for 25°C/60% RH and 40°C/75% RH (six months) failed to maintain the 
supersaturation which can significantly impact drug absorption. The optimized 
nanoamorphous spironolactone formulations (stored at 4C for six months) maintained the 
supersaturation for 6 h, within which the drug can be released and absorbed in the stomach 
and/or small intestine and reach the systemic circulation to provide the required therapeutic 
effect [19, 20].  
5.7. CONCLUSIONS 
This is the first study to develop a robust nanoamorphous drug formulation via an iCPP-
CFPs DoE approach using a labile drug spironolactone (multiple polymorphic forms). This 
nanoamorphous formulation was stable during both accelerated and long term stability 
conditions over a six months period. Dowfax2A1 and trehalose were determined to be the 
best excipients to provide strong stabilization of spironolactone (via hydrogen bonding and 
hydrophobic interaction). The present research shows that the use of orthogonal solid-state 
tools is extremely important since no single solid-state technique can generate all the 
necessary critical information on the physicochemical instabilities (nanoparticle 
aggregation, drug crystallization, polymorphic transition) of nanoamorphous formulations. 
Using these orthogonal research tools, two critical polymorphic transitions (anhydrous to 
hydrate and amorphous to crystalline) were identified which may occur during the 
processing and storage stability studies of labile BCS class II ad II/IV drugs. The 
nanoamorphous spironolactone prepared via an iCPP-CFPs DoE approach showed 
superior supersaturation and faster drug dissolution rate (90% in 15 min) compared to the 
marketed drug products (RLD and generic) (90% in 45-60 min). In the present research, 
80-90% w/w of the total product yield of spray-dried nanoamorphous spironolactone was 
achieved. For a lab-scale spray dryer, total product yield above 80% w/w is remarkable 
since industrial pilot level spray dryers have maximum total product yield of 50-55% w/w. 
This study will aid formulation scientists to apply novel strategies to develop 
nanoamorphous products of labile drugs compared to the conventional trial and error 
techniques utilized currently in drug product development.  
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The present research provides important information on: (1) selection of suitable 
crystallization inhibitors (stabilizing excipients); (2) selection of appropriate 
manufacturing techniques; and (3) critical process and product controls that significantly 
impact the physicochemical attributes of the nanoamorphous drug products. In addition, 
exposure of the nanoamorphous drug products to high relative humidity/ high moisture 
should be avoided to ensure complete product stability throughout the shelf life. Therefore, 
it is necessary to take precautionary handling measures for labile APIs from the first step 
to the last step of the product development. The present research can be applied to the other 
labile BCS class II and II/IV drugs.  
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5.8. Tables 
Table 5.1. Chemical structures of the active pharmaceutical ingredient and excipients 
Materials Chemical structures 
Zileuton 
 
KollidonVA64 fine 
 
Dowfax 2A1 
 
Trehalose 
 
Table 5.2. A DoE Design space for optimization of the wet media milling critical process 
parameters for the preparation of stable nanocrystalline zileuton. 
No. 
CPPs (wet media milling) 
Milling speed Pump speed Milling time 
rpm rpm min 
- 500-1500 80-120 15-30 
1 159 100 22.5 
2 1500 80 30 
3 1500 120 15 
4 1500 120 30 
5 1500 80 15 
6 1000 100 22.5 
7 1000 100 10 
8 1000 100 22.5 
9 1000 100 22.5 
10 1000 134 22.5 
11 1000 66 22.5 
12 1841 100 22.5 
13 500 120 15 
14 1000 100 22.5 
15 1000 100 35 
 185 
16 500 120 30 
17 1000 100 22.5 
18 500 80 30 
19 1000 100 22.5 
20 500 80 15 
Table 5.3a. A DoE Design space for optimization of the spray drying critical process 
parameters for the preparation of stable nanocrystalline zileuton using mannitol as the 
sugar stabilizer (drug:sugar – 1:1, w/w). 
No. 
CPPs (spray drying with mannitol) 
Inlet temperature Aspirator rate Feed flow rate 
°C % % 
- 105-125 70-90 10-25 
1 115 80 18 
2 132 80 18 
3 115 80 18 
4 105 70 25 
5 115 80 18 
6 115 80 30 
7 105 90 25 
8 115 63 18 
9 105 70 10 
10 115 80 18 
11 115 80 5 
12 98 80 18 
13 125 70 25 
14 105 90 10 
15 125 90 25 
16 115 80 18 
17 115 80 18 
18 115 97 18 
19 125 90 10 
20 125 70 10 
Table 5.3b. A DoE Design space for optimization of the spray drying critical process 
parameters for the preparation of stable nanocrystalline zileuton using trehalose as the 
sugar stabilizer (drug:sugar – 1:1, w/w). 
No. 
CPPs (spray drying with trehalose) 
Inlet temperature Aspirator rate Feed flow rate 
°C % % 
- 105-125 70-90 10-25 
1 115 80 18 
2 132 80 18 
3 115 80 18 
4 105 70 25 
5 115 80 18 
6 115 80 30 
7 105 90 25 
8 115 63 18 
9 105 70 10 
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10 115 80 18 
11 115 80 5 
12 98 80 18 
13 125 70 25 
14 105 90 10 
15 125 90 25 
16 115 80 18 
17 115 80 18 
18 115 97 18 
19 125 90 10 
20 125 70 10 
Table 5.4a. A DoE Design space for the optimization of critical formulation parameters 
for the preparation of stable nanocrystalline zileuton post wet media milling. 
No. 
CFPs 
Drug concentration  Polymer concentration Surfactant concentration 
% w/v % w/v % w/v 
- 0.35-1 0.3-0.8 0.03-0.08 
1 1 0.3 0.08 
2 0.675 0.55 0.005 
3 1.325 0.55 0.055 
4 0.675 0.55 0.055 
5 1 0.3 0.08 
6 1 0.3 0.03 
7 0.675 1.05 0.055 
8 0.675 0.55 0.055 
9 0.675 0.55 0.055 
10 0.35 0.8 0.08 
11 0.675 0.55 0.055 
12 1 0.8 0.08 
13 0.675 0.55 0.055 
14 0.675 0.55 0.105 
15 0.35 0.3 0.03 
16 0.675 0.05 0.055 
17 0.35 0.8 0.08 
18 1 0.8 0.03 
19 0.35 0.8 0.03 
20 0.35 0.3 0.08 
21 0.35 0.3 0.03 
22 0.025 0.55 0.055 
23 0.675 0.55 0.055 
24 0.35 0.8 0.03 
25 1 0.3 0.03 
26 1 0.8 0.08 
27 0.35 0.3 0.08 
28 0.675 0.55 0.055 
29 0.675 0.55 0.055 
30 1 0.8 0.03 
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Table 5.4b. A DoE Design space for the optimization of critical formulation parameters 
for the preparation of stable nanocrystalline zileuton post spray drying. 
No. 
CFPs 
Drug concentration Polymer concentration 
Surfactant 
concentration 
Sugar 
amount 
% w/v % w/v % w/v mg 
- 0.35-1 0.3-0.8 0.03-0.08 850-2000 
1 1 0.8 0.03 2000 
2 0.35 0.3 0.03 2000 
3 0.35 0.3 0.08 850 
4 0.675 0.55 0.055 1425 
5 0.35 0.8 0.03 2000 
6 0.35 0.3 0.03 850 
7 1 0.3 0.03 2000 
8 1 0.8 0.08 850 
9 0.675 0.05 0.055 1425 
10 0.675 0.55 0.055 2575 
11 1 0.8 0.08 2000 
12 0.675 0.55 0.055 1425 
13 0.675 1.05 0.055 1425 
14 0.35 0.8 0.08 2000 
15 0.35 0.3 0.08 2000 
16 0.675 0.55 0.055 1425 
17 1 0.3 0.03 850 
18 1 0.3 0.08 2000 
19 0.675 0.55 0.055 275 
20 0.35 0.8 0.08 850 
21 0.675 0.55 0.105 1425 
22 0.675 0.55 0.055 1425 
23 1 0.3 0.08 850 
24 0.675 0.55 0.055 1425 
25 0.675 0.55 0.055 1425 
26 1 0.8 0.03 850 
27 0.025 0.55 0.055 1425 
28 1.325 0.55 0.055 1425 
29 0.35 0.8 0.03 850 
30 0.675 0.55 0.005 1425 
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Table 5.5. Solubility of zileuton in different excipient solutions  
Sample 
Number 
Excipient solution 
(0.2% w/v) 
Type of Stabilizer Zileuton solubility 
(µg/mL) 
Solubility 
(times X) 
1 No excipient  N/A 130.2 - 
2 Dowfax2A1 Anionic surfactant 165.2 1 
3 SLS Anionic surfactant 144.43 
4 Poloxamer P407 Nonionic surfactant 165.2 
5 Poloxamer 188 Nonionic surfactant 135.12 
6 EC 10 Nonionic polymer 187.905 1.5 
7 Kolliphor SLS fine Anionic surfactant 184.78 
8 Kollidon CLM Nonionic polymer 197.97 
9 PVP K17 Nonionic polymer 241.41 2 
10 PVP K25 Nonionic polymer 262.52 
11 PVP K30 Nonionic polymer 258.35 
12 PVP K90 Nonionic polymer 282.75 
13 HPMC K3 Nonionic polymer 258.94 
14 KollidonVA64 Nonionic polymer 254.74 
15 KollidonVA64 fine Nonionic polymer 242.55 
16 HPMC E3 Nonionic polymer 319.32 2.5 
17 HPMC E5 Nonionic polymer 327.01 
18 HPMC E15 Nonionic polymer 338.45 
19 HPMC E50 Nonionic polymer 344.9 
20 MC A15 Nonionic polymer 346.68 
21 Soluplus Nonionic polymer 391.64 3 
 
Table 5.6a. Results of DoE runs for optimization of the wet media milling critical process 
parameters for the preparation of stable nanocrystalline zileuton (3 CPPs x 3 CQAs). 
Wet media milling DoE 
No. 
CPPs CQAs 
Milling speed Pump speed Milling time Particle size PDI Zeta potential 
rpm rpm min 
nm units mV 
- 500-1500 80-120 15-30 
1 159 100 22.5 212.3 0.26 -78.3 
2 1500 80 30 29.16 0.322 -62.1 
3 1500 120 15 135 0.235 -66.8 
4 1500 120 30 65.7 0.156 -57.4 
5 1500 80 15 85.24 0.145 -63.6 
6 1000 100 22.5 214.5 0.187 -71.9 
7 1000 100 10 431.3 0.112 -76.3 
8 1000 100 22.5 200.4 0.237 -64.6 
9 1000 100 22.5 214.3 0.136 -57.1 
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10 1000 134 22.5 130.5 0.219 -68.8 
11 1000 66 22.5 174.2 0.121 -69.3 
12 1841 100 22.5 37.13 0.228 -42.2 
13 500 120 15 306 0.136 -82.9 
14 1000 100 22.5 157.1 0.163 -72.8 
15 1000 100 35 145.9 0.17 -74.9 
16 500 120 30 182.1 0.13 -73.7 
17 1000 100 22.5 245.4 0.459 -74.7 
18 500 80 30 274.2 0.197 -47.2 
19 1000 100 22.5 271.5 0.218 -77.6 
20 500 80 15 269 0.136 -82 
 
Table 5.6b. ANOVA table for CQA: Particle size of nanocrystalline zileuton post wet 
media milling 
Particle size  ANOVA for Response Surface Quadratic model 
Source 
Sum of 
Squares 
df 
Mean 
Square 
F Value 
p-value  
Prob > F 
Model 1.563E+005 9 17362.87 6.73 0.0032 significant 
A-Milling speed 74813.42 1 74813.42 28.99 0.0003 
R2=0.9519, Adjusted 
R2=0.9478 
B-Pump speed 130.98 1 130.98 0.051 0.8263 
C-Milling time 38388.65 1 38388.65 14.88 0.0032 
AB 2499.25 1 2499.25 0.97 0.3483 
AC 5.58 1 5.58 2.162E-003 0.9638 
BC 2531.87 1 2531.87 0.98 0.3453 
A2 19311.12 1 19311.12 7.48 0.0210 
B2 10378.25 1 10378.25 4.02 0.0727 
C2 6560.44 1 6560.44 2.54 0.1419 
Lack of Fit 18150.64 5 3630.13 2.37 0.1826 not significant 
Particle size (nm) = +217.80 – 74.01A – 3.1B – 53.02C + 17.68AB – 0.83AC – 17.79BC – 36.61A2 – 26.84B2 + 21.34C2 
 
Table 5.6c. Statistically predicted CPPs and CQAs based on the wet media milling DoE 
studies 
CPPs CQAs 
Desirability Milling speed 
(rpm) 
Milling time 
(min) 
Pump speed 
(rpm) 
Particle size 
(nm) 
PDI 
(units) 
Zeta potential 
(mV) 
1200 30 92 225 0.198 -67.99 0.898 
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Table 5.7a. Results of DoE runs for optimization of the spray drying critical process 
parameters (stabilizer: mannitol) for the preparation of stable nanocrystalline zileuton (3 
CPPs x 7 CQAs). 
Spray drying DoE (Stabilizer: Mannitol) 
No. 
CPPs CQAs 
Inlet 
temperature 
Aspirator 
rate 
Feed flow 
rate 
Outlet 
temperature 
Particle 
size 
PDI 
Zeta 
potential 
Drug 
loading 
Yield 
Moisture 
content 
°C % % 
°C nm units mV % (w/w) % (w/w) %  
- 105-125 70-90 10-25 
1 115 80 18 51 1084.00 0.098 -95.200 38.554 64.174 0.850 
2 132 80 18 60 1285.00 0.140 -73.600 33.764 66.957 0.745 
3 115 80 18 48 748.30 0.521 -11.000 33.582 61.739 0.745 
4 105 70 25 40 7259.00 0.866 -25.000 39.163 58.696 0.592 
5 115 80 18 51 222.50 0.257 -20.000 35.611 56.348 1.013 
6 115 80 30 46 169.50 0.125 -85.300 39.513 60.174 1.252 
7 105 90 25 48 165.50 0.205 -99.600 40.656 64.348 0.684 
8 115 63 18 47 180.70 0.289 -12.000 35.928 62.000 0.774 
9 105 70 10 60 167.40 0.164 -13.000 43.318 75.478 0.828 
10 115 80 18 51 1144.00 0.539 -24.000 35.656 62.696 0.980 
11 115 80 5 74 1131.00 0.373 -20.000 34.833 67.043 0.518 
12 98 80 18 37 5779.00 0.901 -36.000 37.959 60.174 0.767 
13 125 70 25 51 515.00 0.509 -42.000 41.774 54.174 0.711 
14 105 90 10 67 266.60 0.523 -37.000 37.438 84.000 0.815 
15 125 90 25 58 158.50 0.241 -11.000 41.575 60.609 0.683 
16 115 80 18 51 586.40 0.329 -15.000 36.752 74.522 1.208 
17 115 80 18 50 1071.00 0.967 -19.000 40.331 57.391 1.133 
18 115 97 18 60 172.70 0.306 -21.000 36.959 87.739 0.639 
19 125 90 10 74 356.70 0.613 -35.000 42.574 75.652 0.424 
20 125 70 10 68 191.10 0.421 -22.000 38.324 85.913 0.480 
 
Table 5.7b. ANOVA table for CQA: Total product yield of nanocrystalline zileuton (solid 
powder) post spray drying (with mannitol) 
Total product yield  ANOVA for Response Surface Reduced Cubic model 
Source 
Sum of 
Squares 
df 
Mean 
Square 
F Value 
p-value  
Prob > F 
Model 1684.42 10 168.44 5.94 0.0066 significant 
A-Inlet temperature 23.00 1 23.00 0.81 0.3913 
R2=0.9694, Adjusted 
R2=0.9622 
B-Aspirator rate 331.25 1 331.25 11.68 0.0077 
C-Feed flow rate 23.60 1 23.60 0.83 0.3855 
AB 40.50 1 40.50 1.43 0.2626 
BC 23.90 1 23.90 0.84 0.3826 
B2 310.54 1 310.54 10.95 0.0091 
ABC 47.85 1 47.85 1.69 0.2263 
A2B 133.99 1 133.99 4.72 0.0578 
A2C 231.58 1 231.58 8.17 0.0189 
AB2 25.76 1 25.76 0.91 0.3654 
Lack of Fit 43.94 4 10.98 0.26 0.8919 not significant 
Total product yield (% w/w) = +63.85 + 2.02A + 7.65B – 2.04C – 2.25AB +1.73BC +4.6B2 + 2.45ABC – 6.36A2B – 8.36A2C 
– 2.79AB2 
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Table 5.8a. Results of DoE runs for optimization of the spray drying critical process 
parameters (stabilizer:trehalose) for the preparation of stable nanocrystalline zileuton (3 
CPPs x 7 CQAs). 
Spray drying DoE (Stabilizer:Trehalose) 
No. 
CPPs CQAs 
Inlet 
temperature 
Aspirator 
rate 
Feed flow 
rate 
Outlet 
temperature 
Particle 
size 
PDI 
Zeta 
potential 
Drug 
loading 
Yield 
Moisture 
content 
°C % % 
°C nm units mV % (w/w) % (w/w) %  
- 105-125 70-90 10-25 
1 115 80 18 54 161.70 0.216 -27.00 40.00 59.57 3.36 
2 132 80 18 65 231.80 0.517 -29.00 41.25 67.57 3.21 
3 115 80 18 56 200.30 0.743 -19.00 36.27 58.61 3.47 
4 105 70 25 39 588.10 0.747 -33.00 40.31 58.96 3.45 
5 115 80 18 55 152.90 0.235 -11.00 43.06 64.96 3.42 
6 115 80 30 50 1316.00 0.779 -17.00 40.04 56.61 4.06 
7 105 90 25 50 3646.00 0.569 -19.00 43.64 51.91 3.42 
8 115 63 18 53 3069.00 0.741 -10.00 40.64 64.35 3.61 
9 105 70 10 60 3223.00 1.000 -16.00 42.23 63.65 3.93 
10 115 80 18 55 175.70 0.188 -20.00 45.30 63.30 3.78 
11 115 80 5 73 423.20 0.454 -58.60 40.02 59.39 3.07 
12 98 80 18 50 1523.00 0.351 -80.20 37.18 45.22 3.87 
13 125 70 25 50 1248.00 0.611 -23.00 44.57 60.87 3.31 
14 105 90 10 65 1054.00 0.681 -16.00 44.63 74.61 2.71 
15 125 90 25 60 964.00 0.930 -14.00 42.83 58.26 3.19 
16 115 80 18 55 117.70 0.485 -11.00 42.83 65.39 3.51 
17 115 80 18 56 148.10 0.231 -29.00 44.99 70.09 3.37 
18 115 97 18 60 284.30 0.595 -12.00 39.64 72.70 3.29 
19 125 90 10 75 1221.00 0.424 -88.40 41.24 50.00 2.79 
20 125 70 10 70 809.40 0.934 -15.00 38.22 60.00 2.98 
 
Table 5.8b. ANOVA table for CQA: Total product yield of nanocrystalline zileuton (solid 
powder) post spray drying (with trehalose) 
Total product yield  ANOVA for Response Surface Reduced Cubic model 
Source 
Sum of 
Squares 
df 
Mean 
Square 
F Value 
p-value  
Prob > F 
Model 907.60 13 69.82 4.57 0.0363 significant 
A-Inlet temperature 249.71 1 249.71 16.33 0.0068 
R2=0.9082,  
Adjusted R2=0.8993 
B-Aspirator rate 34.84 1 34.84 2.28 0.1819 
C-Feed flow rate 3.87 1 3.87 0.25 0.6328 
AB 34.12 1 34.12 2.23 0.1859 
AC 166.73 1 166.73 10.90 0.0164 
BC 14.07 1 14.07 0.92 0.3745 
A2 111.66 1 111.66 7.30 0.0355 
B2 32.65 1 32.65 2.14 0.1943 
C2 70.69 1 70.69 4.62 0.0751 
ABC 80.59 1 80.59 5.27 0.0615 
A2B 42.20 1 42.20 2.76 0.1477 
A2C 7.02 1 7.02 0.46 0.5234 
AB2 277.07 1 277.07 18.12 0.0053 
 192 
Lack of Fit 3.36 1 3.36 0.19 0.6810 not significant 
Total product yield (% w/w) = +63.69 + 6.64A + 2.48B – 0.83C – 2.07AB + 4.57AC – 1.33BC – 2.78A2 + 1.51B2 – 2.21C2 
+3.17ABC – 3.57A2B – 1.46A2C – 9.41AB2 
 
Table 5.8c. Statistically predicted CPPs and CQAs based on the spray drying DoE studies 
Spray drying DoE (drug:sugar-1:1, w/w) Mannitol Trehalose 
CPPs 
Inlet temperature (C) 125 118 
Aspirator rate (%) 90 90 
Feed flow rate (%) 10 10 
CQAs 
Outlet temperature (C) 70 67 
Particle size (nm) 499.24 326.97 
PDI (units) 0.28 0.12 
Zeta potential (mV) -27.66 -58.18 
Drug loading (% w/w) 41.15 41.28 
Total yield (% w/w) 72.95 63.05 
Moisture content (%) 2.85 0.47 
Desirability 0.807 0.967 
 
Table 5.9a. Results of DoE runs for optimization of the critical formulation parameters 
(wet media milling) for the preparation of stable nanocrystalline zileuton (3 CFPs x 3 
CQAs). 
Formulation DoE (Wet Media Milling) 
No. 
CFPs CQAs 
Drug 
concentration  
Polymer 
concentration 
Surfactant 
concentration 
Particle size PDI Zeta potential 
% w/v % w/v % w/v 
nm units mV 
- 0.35-1 0.3-0.8 0.03-0.08 
1 1 0.3 0.08 174.1 0.266 -71.7 
2 0.675 0.55 0.005 346.5 0.336 -68.1 
3 1.325 0.55 0.055 125.8 0.224 -69.9 
4 0.675 0.55 0.055 383.3 0.263 -79.2 
5 1 0.3 0.08 182.8 0.277 -77.6 
6 1 0.3 0.03 212.6 0.316 -80.6 
7 0.675 1.05 0.055 356.8 0.499 -9.1 
8 0.675 0.55 0.055 497.5 0.315 -81 
9 0.675 0.55 0.055 397 0.213 -83.7 
10 0.35 0.8 0.08 746.1 0.885 -83.2 
11 0.675 0.55 0.055 426.6 0.313 -90.1 
12 1 0.8 0.08 230.7 0.176 -59 
13 0.675 0.55 0.055 434 0.202 -69.1 
14 0.675 0.55 0.105 526.7 0.319 -89.8 
15 0.35 0.3 0.03 732.8 0.394 -98.1 
16 0.675 0.05 0.055 286.3 0.166 -129 
17 0.35 0.8 0.08 621 0.462 -74.2 
18 1 0.8 0.03 207.6 0.181 -69 
19 0.35 0.8 0.03 703.3 0.483 -80.1 
20 0.35 0.3 0.08 748.5 0.5 -109 
21 0.35 0.3 0.03 613 0.419 -96.3 
22 0.025 0.55 0.055 1536 0.45 -112 
23 0.675 0.55 0.055 366.3 0.282 -81.3 
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24 0.35 0.8 0.03 756.2 0.478 -78.1 
25 1 0.3 0.03 108.5 0.167 -78.2 
26 1 0.8 0.08 133.3 0.225 -55.4 
27 0.35 0.3 0.08 667.1 0.434 -107 
28 0.675 0.55 0.055 230.9 0.363 -75.8 
29 0.675 0.55 0.055 234.1 0.253 -82.6 
30 1 0.8 0.03 117.3 0.278 -64.5 
 
Table 5.9b. ANOVA table for CQA: Particle size of nanocrystalline zileuton post wet 
media milling 
Particle size  ANOVA for Response Surface Cubic model 
Source 
Sum of 
Squares 
df 
Mean 
Square 
F Value 
p-value  
Prob > F 
Model 2.551E+006 22 1.160E+005 16.86 0.0004 significant 
A-Drug concentration 9.943E+005 1 9.943E+005 144.60 < 0.0001 
 
R2=0.9815,  
Adjusted R2=0.9233 
B-Polymer concentration 2485.13 1 2485.13 0.36 0.5667 
C-Surfactant concentration 16236.02 1 16236.02 2.36 0.1683 
AB 184.28 1 184.28 0.027 0.8746 
AC 594.14 1 594.14 0.086 0.7773 
BC 1578.08 1 1578.08 0.23 0.6465 
A2 2.911E+005 1 2.911E+005 42.33 0.0003 
B2 16219.91 1 16219.91 2.36 0.1685 
C2 541.88 1 541.88 0.079 0.7870 
ABC 1711.89 1 1711.89 0.25 0.6331 
A2B 883.23 1 883.23 0.13 0.7306 
A2C 9310.26 1 9310.26 1.35 0.2827 
AB2 41990.59 1 41990.59 6.11 0.0428 
Lack of Fit 8427.93 2 4213.97 0.53 0.6180 not significant 
Particle size (nm) = +392.58 – 352.55A + 17.62B + 45.05C – 3.39AB + 6.09AC – 9.93BC +103.02A2 – 24.32B2 + 4.44C2 + 10.34ABC 
– 12.87A2B – 41.78A2C + 88.73AB2 
 
Table 5.10a. Results of DoE runs for optimization of critical formulation parameters 
(spray drying) for the preparation of stable nanocrystalline zileuton (4 CFPs x 7 CQAs). 
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Formulation DoE (spray drying) 
No. 
CFPs CQAs 
Drug 
concentration 
Polymer 
concentration 
Surfactant 
concentration 
Sugar 
amount 
Outlet 
temperature 
Particle 
size 
PDI 
Zeta 
potential 
Drug 
loading 
Total 
Yield 
Moisture 
content 
% w/v % w/v % w/v mg 
°C nm units mV % % % 
- 0.35-1 0.3-0.8 0.03-0.08 850-2000 
1 1 0.8 0.03 2000 72 494.1 1 -117 11.75377 48.69 3.68 
2 0.35 0.3 0.03 2000 71 1718 0.065 -103 6.539006 63.69 3.456 
3 0.35 0.3 0.08 850 68 1756 0.291 -113 12.5826 75.40 3.214 
4 0.675 0.55 0.055 1425 68 1472 1 -109 11.98958 54.30 3.18 
5 0.35 0.8 0.03 2000 71 658.7 0.855 -106 6.510985 49.85 3.649 
6 0.35 0.3 0.03 850 71 1735 0.2 -99.1 10.98196 68.35 3.404 
7 1 0.3 0.03 2000 68 1004 0.877 -123 11.00261 59.29 3.457 
8 1 0.8 0.08 850 72 694.8 0.781 -107 21.56875 58.25 2.703 
9 0.675 0.05 0.055 1425 70 1551 0.679 -101 16.41053 82.69 2.668 
10 0.675 0.55 0.055 2575 70 1668 0.927 -114 14.89958 46.00 4.431 
11 1 0.8 0.08 2000 72 137.9 0.323 -103 9.036766 52.06 3.82 
12 0.675 0.55 0.055 1425 71 1668 0.927 -113 14.21775 65.96 3.611 
13 0.675 1.05 0.055 1425 68 1593 1 -94.1 10.57662 40.16 3.858 
14 0.35 0.8 0.08 2000 68 2880 0.956 -108 5.346451 42.95 3.729 
15 0.35 0.3 0.08 2000 76 852.2 0.233 -99.9 5.612018 58.18 3.663 
16 0.675 0.55 0.055 1425 70 1668 0.927 -50.2 11.90832 72.29 3.323 
17 1 0.3 0.03 850 68 273.3 0.663 -94.7 31.19071 83.51 2.806 
18 1 0.3 0.08 2000 70 171.9 0.177 -130 18.74133 64.15 3.433 
19 0.675 0.55 0.055 275 71 1668 0.927 -91 12.25046 65.57 2.857 
20 0.35 0.8 0.08 850 68 969.1 0.367 -80.3 9.417043 61.06 3.108 
21 0.675 0.55 0.105 1425 68 102.4 0.692 -103 15.849 70.65 3.607 
22 0.675 0.55 0.055 1425 71 1582 1 -101 16.11059 55.99 3.499 
23 1 0.3 0.08 850 72 146.1 0.414 -43.2 14.40945 85.07 2.98 
24 0.675 0.55 0.055 1425 72 898.7 0.786 -76.3 37.93154 52.89 2.728 
25 0.675 0.55 0.055 1425 67 317.9 0.642 -90.7 16.26445 54.00 3.003 
26 1 0.8 0.03 850 69 368.5 0.697 -86.9 27.06975 59.85 3.17 
27 0.025 0.55 0.055 1425 71 3440 0.735 -111 2.75378 48.84 4.421 
28 1.325 0.55 0.055 1425 71 196.9 0.455 -102 21.35168 49.52 3.146 
29 0.35 0.8 0.03 850 75 1990 0.729 -92.8 8.798703 65.44 4.334 
30 0.675 0.55 0.005 1425 72 1718 0.0656 -103 15.95752 73.25 3.166 
 195 
Table 5.10b. ANOVA table for CQA: Total product yield of nanocrystalline zileuton (solid 
powder) post spray drying (with trehalose) 
Total product yield  ANOVA for Response Surface Quadratic model 
Source 
Sum of 
Squares 
df 
Mean 
Square 
F Value 
p-value  
Prob > F 
Model 3492.06 14 249.43 6.19 0.0006 significant 
A-Drug concentration 31.14 1 31.14 0.77 0.3931 
R2=0.9525, Adjusted 
R2=0.9149 
B-Polymer concentration 1743.67 1 1743.67 43.29 < 0.0001 
C-Surfactant concentration 1.90 1 1.90 0.047 0.8310 
D-Amount of sugar  1029.61 1 1029.61 25.56 0.0001 
AB 45.14 1 45.14 1.12 0.3065 
AC 20.07 1 20.07 0.50 0.4910 
AD 2.99 1 2.99 0.074 0.7890 
BC 19.09 1 19.09 0.47 0.5016 
BD 15.94 1 15.94 0.40 0.5387 
CD 2.90 1 2.90 0.072 0.7920 
A2 117.96 1 117.96 2.93 0.1076 
B2 26.79 1 26.79 0.67 0.4275 
C2 359.40 1 359.40 8.92 0.0092 
D2 4.88 1 4.88 0.12 0.7326 
Lack of Fit 285.94 10 28.59 0.45 0.8681 not significant 
Total product yield (% w/w) = +59.24 + 1.14A – 8.52B – 0.28C – 6.55D – 1.68AB + 1.12AC – 0.43AD – 1.09BC + 1.00BD – 0.43CD 
– 2.07A2 + 0.99B2 + 3.62C2 – 0.42D2 
 
Table 5.11. Statistically predicted CPPs, CFPs and CQAs based on the formulation DoE  
Comprehensive DoEs 
Wet media milling (CPPs) Spray drying (CPPs) Formulation (CFPs) 
Milling speed (rpm) 1200 Inlet temperature (C) 118 Drug concentration (% w/v) 1 
Milling time (min) 30 Aspirator rate (%) 90 Polymer concentration (% w/v) 0.3 
Pump speed (rpm) 92 Feed flow rate (%) 10 Surfactant concentration (% w/v) 0.06 
 Amount of sugar (mg) 850 
 
CQAs 
Outlet temperature (C) 69 
Particle size (nm) 300.03 
PDI (units) 0.126 
Zeta potential (mV) -80.84 
Drug loading (% w/w) 22.31 
Total yield (% w/w) 77.66 
Moisture content (%) 1.66 
Desirability 0.904 
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Table 5.12. Physicochemical properties of the optimized spray-dried nanocrystalline zileuton 
formulations following one, six and twelve month/s exposure under different storage conditions. 
Testing formulation : Optimized 
spray-dried nanocrystalline zileuton 
Particle 
size (nm) 
PDI 
(units) 
Zeta potential 
(mV) 
Moisture content 
(%) 
Drug loading (% 
w/w) 
Predicted values 300.03 0.126 -80.84 1.66 22.31 
Experimental values  
0 month Initial (n=6) 276.4 0.109 -91.4 1.09 23.8 
1 month 
4°C 273.1 0.115 -81.5 0.990 23.71 
25°C/60% RH 619.5 0.589 -103 1.17 23.25 
40°C/75% RH 996.4 0.791 -92.6 1.29 23.31 
6 months 
4°C 275.43 0.12 -79.63 0.994 23.84 
25°C/60% RH 648.91 0.723 -97.64 2.79 23.41 
40°C/75% RH 1013.19 0.817 -94.61 3.29 23.61 
12 months 
4°C 274.16 0.118 -81.2 0.989 23.82 
25°C/60% RH 694.37 0.653 -102 3.19 23.28 
40°C/75% RH 1209.43 0.923 -96.39 4.55 23.81 
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5.9. Figures 
GRAPHICAL ABSTRACT 
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Figure A: Design of Experiments for drug-stabilizer interaction studies (4 manufacturing techniques, 3 drug-
stabilizer weight ratios and 3 orthogonal solid-state techniques). 
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Figure B: Interaction parameter () vs. different manufacturing techniques (left) and Free energy of mixing 
(Gm) vs. different manufacturing techniques (right) for drug:stabilizer weight ratios: (A) 3:1, w/w; (B) 1:1, 
w/w; and (C) 1:3, w/w.  
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Figure C: Interaction parameter () vs. volume fraction of stabilizer (top left – Freeze drying, top right – 
spray drying, bottom left – solvent evaporation and bottom right – serial dilution).  
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Figure 5.1: Flow diagram for the manufacturing of nano-amorphous spironolactone formulations 
 
Figure 5.2a. (A) Contour plots and (B) 3D surface plots comparing effect of solvent-to-antisolvent ratio 
and drug concentration on the particle size of nanoamorphous spironolactone.   
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Figure 5.2b. (A) Contour plots and (B) 3D surface plots comparing effect of inlet temperature of spray 
dryer and drug concentration on the particle size of nanoamorphous spironolactone.   
 
Figure 5.2c. Graph showing model predicted vs. actual values of the experiments. 
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Figure 5.2d. (A) Main effect plot (B) Pareto chart and (C) Interaction plot for mean particle size of 
nanoamorphous spironolactone.  
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Figure 5.3a. (A) Contour plots and (B) 3D surface plots comparing effect of solvent-to-antisolvent ratio 
and drug concentration on the total product yield of nanoamorphous spironolactone.   
 
Figure 5.3b. (A) Contour plots and (B) 3D surface plots comparing effect of inlet temperature of spray 
dryer and drug concentration on the total product yield of nanoamorphous spironolactone.   
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Figure 5.3c. Graph showing model predicted vs. actual values of the experiments. 
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Figure 5.3d. (A) Main effect plot (B) Pareto chart and (C) Interaction plot for mean total product yield of 
nanoamorphous spironolactone.  
 
Figure 5.4a. (A) Contour plots and (B) 3D surface plots comparing effect of solvent-to-antisolvent 
ratio and drug concentration on the zeta potential of nanoamorphous spironolactone.   
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Figure 5.4b. (A) Contour plots and (B) 3D surface plots comparing effect of inlet temperature of 
spray dryer and drug concentration on the zeta potential of nanoamorphous spironolactone.   
 
Figure 5.4c. Graph showing model predicted vs. actual values of the experiments. 
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Figure 5.4d. (A) Main effect plot (B) Pareto chart and (C) Interaction plot for mean zeta potential 
of nanoamorphous spironolactone.  
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Figure 5.5a. (A) Contour plots and (B) 3D surface plots comparing effect of solvent-to-antisolvent 
ratio and drug concentration on the drug loading of the nanoamorphous spironolactone.   
 
Figure 5.5b. (A) Contour plots and (B) 3D surface plots comparing effect of inlet temperature of 
spray dryer and drug concentration on the drug loading of the nanoamorphous spironolactone.   
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Figure 5.5c. Graph showing model predicted vs. actual values of the experiments. 
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Figure 5.5d. (A) Main effect plot (B) Pareto chart and (C) Interaction plot for mean drug loading 
of nanoamorphous spironolactone.  
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Figure 5.6a. The optimized contour plots comparing effect of drug concentration and solvent-to-antisolvent 
ratio on different CQAs: (A) Particle size; (B) Zeta potential; (C) Drug loading; and (D) Total product yield 
of nanoamorphous spironolactone. 
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Figure 5.6b. The optimized contour plots comparing effect of drug concentration and spray dryer inlet 
temperature on different CQAs: (A) Particle size; (B) Zeta potential; (C) Drug loading; and (D) Total 
product yield of nanoamorphous spironolactone. 
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Figure 5.7. Particle size distribution and moisture content of the optimized spray-dried nanoamorphous spironolactone formulations stored for 1, 3 
and 6 month/s at (a) 4°C (b) 25°C/60% RH (c) 40°C/75% RH compared with zero month formulations. 
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Figure 5.8a. PXRD diffraction profiles of the macrocrystalline spironolactone (neat crystalline drug), 
nanocrystalline spironolactone, Generic spironolactone (Mylan), RLD spironolactone (Pfizer), 
macroamorphous spironolactone and nanoamorphous spironolactone    
 
Figure 5.8b. PXRD diffraction profiles of the optimized spray-dried nanoamorphous spironolactone 
formulations (initial (0 day) and formulations stored for 1 and 6 month/s at 4°C, 25°C/60%RH and 
40°C/75%RH) 
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Figure 5.8c. PXRD diffraction profiles of the Generic spironolactone drug product (Mylan) (day zero and 
those stored for 1 and 6 month/s at 4°C, 25°C/60%RH and 40°C/75%RH) 
 
Figure 5.8d. PXRD diffraction profiles of the RLD spironolactone drug product (Pfizer) (day zero and 
those stored for 1 and 6 month/s at 4°C, 25°C/60%RH and 40°C/75%RH) 
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Figure 5.9(a). ATR-FTIR full spectra (4000-500 cm-1) overlay of the macrocrystalline spironolactone (neat 
drug), physical mixture (neat drug, surfactant (Dowfax2A1) and sugar (trehalose)), nanoamorphous 
spironolactone, RLD spironolactone (Pfizer) and Generic spironolactone (Mylan).  
 
Figure 5.9(b) - 3700-2800 cm-1, (c) - 1800-1600 cm-1 - ATR-FTIR spectra overlay of the macrocrystalline 
spironolactone (neat drug), physical mixture (neat drug, surfactant (Dowfax2A1) and sugar (trehalose)), 
nanoamorphous spironolactone, RLD spironolactone (Pfizer) and Generic spironolactone (Mylan). 
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Figure 5.9(d) - 1480-1370 cm-1, (e) – 1360-1230 cm-1 - ATR-FTIR spectra overlay of the macrocrystalline 
spironolactone (neat drug), physical mixture (neat drug, surfactant (Dowfax2A1) and sugar (trehalose)), 
nanoamorphous spironolactone, RLD spironolactone (Pfizer) and Generic spironolactone (Mylan). 
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Figure 5.10(a). ATR-FTIR full spectra (4000-500 cm-1) overlay of the macrocrystalline spironolactone 
(neat drug) and nanoamorphous spironolactone (day zero and those stored for six months at 4C, 
25C/60%RH and 40C/75%RH).  
 
Figure 5.10(b) – 3600-2800 cm-1, (c) – 1780-1640 cm-1 - ATR-FTIR overlay of the macrocrystalline 
spironolactone (neat drug) and nanoamorphous spironolactone (day zero and those stored for six months at 
4C, 25C/60%RH and 40C/75%RH).  
 
Figure 5.11a. PLM images of macrocrystalline spironolactone (neat drug), nanoamorphous spironolactone, 
Generic spironolactone (Mylan), RLD spironolactone (Pfizer). Note: All images are of 10X magnification. 
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Figure 5.11b. PLM images of the macrocrystalline spironolactone (neat drug), physical mixture 
(spironolactone, Dowfax2A1 and trehalose) and the optimized spray-dried nanoamorphous spironolactone 
formulations (day zero and those stored for 6 months at 4°C, 25°C/60% RH and 40°C/75% RH). Note: All 
images are of 10X magnification. 
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Figure 5.12. AFM images (amplitude images – left, height images – center and phase images – right) of 
the macrocrystalline spironolactone (neat drug), nanoamorphous spironolactone, Generic spironolactone 
(Mylan) and RLD spironolactone (Pfizer). 
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Figure 5.13. In vitro drug release testing of macrocrystalline spironolactone (neat drug), nanocrystalline 
spironolactone, macroamorphous spironolactone, nanoamorphous spironolactone, Generic spironolactone 
(Mylan) and RLD spironolactone (Pfizer).  
 
Figure 5.14. In vitro drug release testing of macrocrystalline spironolactone (neat drug) and the optimized 
spray-dried nanoamorphous spironolactone formulations (day zero and those stored for 6 months at 4°C, 
25°C/60% RH and 40°C/75% RH).  
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 Chapter 6 
Conclusions and Future studies 
6.1. Summary and conclusions 
The novelty of the present research is the application of a comprehensive QbD approach for the 
identification, optimization, validation and control of the critical processes parameters and critical 
formulation parameters via multiple DoE models. Till date, individual DoEs (either process or 
formulation) have been investigated for the development of nanocrystalline and nanoamorphous 
drug products. These isolated DoEs can resolve a specific physicochemical property (one or two) 
of the drug product, however, the optimized formulation composition or process parameters cannot 
be assured, since all possible process and formulation interactions are not investigated. The QbD 
approach utilized in this research are examples of how these studies can be applied to obtain precise 
design space for CQAs of nanocrystalline and nanoamorphous powders of water insoluble drugs. 
This research can be applied to other BCS class II and II/IV drugs for the successful development 
of robust spray-dried nanocrystalline and nanoamorphous drug products. 
Typically, lab-scale spray dryers have total product yield in the range of ~50-60% w/w, however 
based on this research, the total product yield of the nanocrystalline zileuton and nanoamorphous 
spironolactone solid powder was in the range of ~70-80% w/w. This remarkably high total product 
yield was obtained following the comprehensive QbD approach. Such high yield is difficult to 
achieve when using individual DoEs or in the industrial setup where there is no time for 
optimization. Trehalose compared to mannitol was determined to be a better stabilizer preventing 
nanoparticle aggregation during the spray drying process which is in agreement with previous 
reports on nanoparticle aggregation. Soluplus/PVPK-25 were determined to be better 
crystallization inhibitors for long term stabilization of the nanoamorphous formulations. Based on 
the stability data, it is concluded that the spray-dried nanocrystalline and nanoamorphous drug 
products should be stored and transported at 4C to avoid any physicochemical instability. In 
addition, the manufacturing of such nanocrystalline and nanoamorphous drug products (lab-scale 
and pilot scale) requires strict temperature control (2-8C) to prevent nanoparticle 
physicochemical instability as well as any API associated instability.  
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Furthermore, this research utilized a mechanistic approach to understand drug-stabilizer 
interactions. The interaction parameters and free energy of mixing obtained using the Flory 
Huggins principle and the melting point depression approach confirmed that the solid dispersions 
prepared via spray drying and freeze drying resulted in the strongest miscibility between drugs: 
ABT-102/spironolactone and the polymers compared to the solvent evaporation and serial dilution 
method. FTIR data showed that the C=O/O-H moieties of the polymers/sugars interacted with the 
N-H/S-H moieties of the drug via hydrogen bonding to facilitate nanoparticle stabilization. This 
study will aid pre-formulation scientists in screening stabilizers for formulation development of 
similar solid dispersion formulations compared to the conventional trial and error methods. PLM 
was a better solid state characterization tool compared to PXRD for analysis of the nanoamorphous 
formulations (ABT-102, spironolactone) stability. This study shows that nanoamorphous 
formulations prepared using sonoprecipitation followed by spray drying have an enhanced 
dissolution rate and may have enhance bioavailability compared to macro-crystalline drug. 
Nanoamorphous spironolactone prepared via the comprehensive QbD approach showed longer 
supersaturation time (~6 h) and faster drug dissolution rate (90% in 15 min) compared to the 
marketed drug products (RLD and generic spironolactone) (90% in 45-60 min).  
In addition, the present research provides important information on: (1) selection of suitable 
crystallization inhibitors (stabilizing excipients) for nanoamorphous drug products; (2) selection 
of appropriate manufacturing techniques; and (3) critical process and product controls that 
significantly impact the physicochemical attributes of the nanocrystalline and nanoamorphous 
drug products. In addition, exposure of the nanoamorphous drug products to high relative 
humidity/high moisture should be avoided to ensure complete product stability throughout the 
shelf life. Therefore, it is necessary to take precautionary handling measures for labile APIs from 
the first to the last step of the product development process.  
6.2. Future studies 
Nanoamorphous and nanocrystalline formulations were superior in their dissolution performance 
compared to the macro-sized formulations. In addition, in vivo studies should be performed to 
develop an IVIVC correlation for these solid nanoformulations.  
There are several drying techniques available which impacts the physicochemical attributes of the 
solid nanoformulations. It will be important to investigate different drying techniques such as 
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freeze drying, spray-freeze drying, vacuum drying, solvent evaporation, microwave drying, etc. to 
understand the impact of drying processing conditions on different CQAs (such as particle size, 
solid-state form, moisture content, and total product yield) of nanoamorphous and nanocrystalline 
formulations.  
The focus of the present research was to develop stable solid nanoformulations for small molecules 
(~200-400 g/mol) via a comprehensive QbD approach. Until now, only a few oral protein 
formulations are approved by FDA. With the advancement in personalized medicine and genetic 
engineering, proteins and peptides are extensively investigated due to their chemical diversity and 
non-toxicity. Stability of such biomolecules during processing is an important concern. It will be 
interesting to investigate critical process (such as spray drying, freeze drying) and formulations 
parameters (protein/peptide/stabilizer compositions) that significantly impact different CQAs 
(such as activity, size, and any structural change) for these large molecular weight compounds via 
a QbD approach. Developing robust oral protein/peptide drug products with enhanced 
bioavailability and activity will aid formulation scientists to gain important insights on their 
stability aspects. Furthermore, comprehensive QbD approach can be applied to other 
pharmaceuticals (such as microspheres, hydrogels and liposomes) to investigate critical process 
and formulation parameters involved during manufacturing of these complex dug products. 
 
 
 
 
